[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f48oN_3PynceRk-cXe1WvCQHSihzl0a0xqmsSVZtfwsU":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":86,"rows":93},"OHSU Knight Cancer Institute",[4],237,false,59,2,2077740,79,90,[14,17,20,23,25,27,29,32],{"name":15,"count":16},"Prostate Cancer",15,{"name":18,"count":19},"Leukemia",13,{"name":21,"count":22},"Breast Cancer",12,{"name":24,"count":22},"Lymphoma",{"name":26,"count":22},"Prostate Carcinoma",{"name":28,"count":22},"Malignant Solid Neoplasm",{"name":30,"count":31},"Breast Carcinoma",9,{"name":33,"count":34},"Myelodysplastic Syndromes",8,[36,41,46,51,56,61,66,71,76,81],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT02522715","Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer","2019-10-16","Cabazitaxel",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT03361436","Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery","2023-02-14","Eribulin Mesylate",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT05396859","Entrectinib in Combination With ASTX727 for the Treatment of Relapsed\u002FRefractory TP53 Mutated Acute Myeloid Leukemia","2024-06-10","Decitabine and Cedazuridine",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT02312557","Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide","2024-08-22","Enzalutamide",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT04104139","TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer","2024-09-25","Trifluridine and Tipiracil Hydrochloride",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT04539808","NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine\u002FNab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer","2024-12-08","Capecitabine",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT04251715","mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma","2025-06-30","Dexamethasone",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT05034627","Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer","2025-12-16","Calaspargase Pegol-mknl",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT06357182","Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia","2026-03-08","Azacitidine",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT04005690","Targeted Pathway Inhibition in Patients With Pancreatic Cancer","2026-06-01","Cobimetinib",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,125,150,195,394,542,608,640,714,763,803,825,923,1003,1061,1119,1159,1241,1312,1338,1374,1410,1436,1462,1488,1510,1532,1554,1576,1598,1629,1659,1682,1712,1737,1755,1773,1791,1809,1827,1845,1863,1886,1914,1939,1965,1983,2001,2019,2037,2055,2073,2098,2116,2235,2310,2356,2403,2437,2481,2532,2566,2592,2618,2645,2671,2696,2714,2732,2750,2768,2786,2804,2822,2844,2874,2896,2914,2932,2955,2981,2999,3027,3099,3141,3195,3243,3297,3331,3390,3420,3450,3508,3534,3566,3592,3625,3655,3707,3738,3760,3782,3804,3833,3855,3886,3918,3940,3970,3992,4014,4042,4064,4086,4108,4138,4165,4187,4209,4231,4253,4275,4293,4317,4335,4353,4376,4400,4418,4436,4454,4479,4497,4520,4538,4563,4581,4604,4622,4640,4658,4676,4694,4712,4730,4748,4766,4784,4802,4820,4838,4856,4874,4899,4917,4935,4953,4971,4995,5013,5031,5049,5067,5085,5103,5127,5150,5168,5193,5211,5229,5247,5265,5288,5310,5332,5354,5376,5398,5420,5438,5456,5474,5492,5510,5528,5546,5564,5582,5600,5618,5636,5654,5672,5690,5708,5726,5744,5762,5780,5798,5816,5834,5852,5870,5888,5906,5924,5953,5984,6002,6020,6038,6056,6074,6092,6110,6144,6174,6204,6243,6274,6296,6323,6345,6367,6389,6407,6425,6443,6461,6487,6511,6540,6558,6576,6594,6619,6643,6661,6685],{"intervention":95,"totalTrials":96,"cells":97},"Piflufolastat",1,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":107,"NA":123},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":100},[],{"trials":106,"activeCount":100},[],{"trials":108,"activeCount":96,"soonestReadout":114},[109],{"nctId":110,"briefTitle":111,"status":112,"phases":113,"primaryCompletion":114,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":122},"NCT05919329","Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy","RECRUITING",[91],"2028-09-01","2030-09-01","2024-06-25",80,[119,120,121],"Castration Resistant Prostate Cancer","Castration Sensitive Prostate Cancer","Prostate Adenocarcinoma",[95],{"trials":124,"activeCount":100},[],{"intervention":126,"totalTrials":96,"cells":127},"Fluciclovine PET\u002FCT",{"EARLY_PHASE1":128,"PHASE1":130,"PHASE2":132,"PHASE3":134,"PHASE4":136,"NA":148},{"trials":129,"activeCount":100},[],{"trials":131,"activeCount":100},[],{"trials":133,"activeCount":100},[],{"trials":135,"activeCount":100},[],{"trials":137,"activeCount":96,"soonestReadout":143},[138],{"nctId":139,"briefTitle":140,"status":141,"phases":142,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":146,"interventions":147},"NCT05722925","Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET","ACTIVE_NOT_RECRUITING",[91],"2026-12-01","2023-10-04",50,[15],[126],{"trials":149,"activeCount":100},[],{"intervention":151,"totalTrials":96,"cells":152},"Immune Checkpoint Inhibitor",{"EARLY_PHASE1":153,"PHASE1":155,"PHASE2":157,"PHASE3":159,"PHASE4":161,"NA":193},{"trials":154,"activeCount":100},[],{"trials":156,"activeCount":100},[],{"trials":158,"activeCount":100},[],{"trials":160,"activeCount":100},[],{"trials":162,"activeCount":96,"soonestReadout":167},[163],{"nctId":164,"briefTitle":165,"status":112,"phases":166,"primaryCompletion":167,"completion":167,"start":168,"enrollment":169,"conditions":170,"interventions":192},"NCT07405086","Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study",[91],"2028-12-31","2026-07-31",160,[171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191],"Advanced Biliary Tract Carcinoma","Advanced Head and Neck Squamous Cell Carcinoma","Advanced Hepatocellular Carcinoma","Advanced Lung Non-Small Cell Carcinoma","Advanced Malignant Solid Neoplasm","Advanced Melanoma","Advanced Renal Cell Carcinoma","Metastatic Biliary Tract Carcinoma","Metastatic Head and Neck Squamous Cell Carcinoma","Metastatic Hepatocellular Carcinoma","Metastatic Lung Non-Small Cell Carcinoma","Metastatic Malignant Solid Neoplasm","Metastatic Melanoma","Metastatic Renal Cell Carcinoma","Recurrent Head and Neck Squamous Cell Carcinoma","Stage III Hepatocellular Carcinoma AJCC v8","Stage III Lung Cancer AJCC v8","Stage III Renal Cell Cancer AJCC v8","Stage IV Hepatocellular Carcinoma AJCC v8","Stage IV Lung Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8",[151],{"trials":194,"activeCount":100},[],{"intervention":196,"totalTrials":22,"cells":197},"Cytarabine",{"EARLY_PHASE1":198,"PHASE1":200,"PHASE2":256,"PHASE3":388,"PHASE4":390,"NA":392},{"trials":199,"activeCount":100},[],{"trials":201,"activeCount":96,"soonestReadout":249},[202,229,245],{"nctId":203,"briefTitle":204,"status":205,"phases":206,"primaryCompletion":207,"completion":208,"start":209,"enrollment":210,"conditions":211,"interventions":214},"NCT02779283","Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia","COMPLETED",[88],"2018-04-19","2018-09-20","2016-01-13",7,[212,213],"Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia",[215,196,216,70,217,218,219,220,221,222,223,224,225,226,227,228],"Cyclophosphamide","Dasatinib","Doxorubicin Hydrochloride","Idarubicin","Idelalisib","Leucovorin Calcium","Methotrexate","Methylprednisolone Sodium Succinate","Ponatinib Hydrochloride","Rituximab","Ruxolitinib Phosphate","Sorafenib Tosylate","Sunitinib Malate","Vincristine Sulfate",{"nctId":230,"briefTitle":231,"status":205,"phases":232,"primaryCompletion":233,"completion":233,"start":234,"enrollment":235,"conditions":236,"interventions":239},"NCT02504359","Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma",[88],"2020-09-09","2015-07-20",11,[237,238],"Plasma Cell Leukemia","Recurrent Plasma Cell Myeloma",[240,196,241,242,243,221,244],"Carmustine","Etoposide","Ixazomib Citrate","Melphalan","Tacrolimus",{"nctId":246,"briefTitle":247,"status":112,"phases":248,"primaryCompletion":249,"completion":249,"start":250,"enrollment":251,"conditions":252,"interventions":253},"NCT04659616","Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia",[88],"2026-12-31","2021-01-14",32,[213],[196,254,255],"Daunorubicin","Pemigatinib",{"trials":257,"activeCount":387,"soonestReadout":379},[258,274,283,303,316,327,340,363,375],{"nctId":259,"briefTitle":260,"status":205,"phases":261,"primaryCompletion":262,"completion":262,"start":263,"enrollment":264,"conditions":265,"interventions":266},"NCT00074178","Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma",[89],"2006-07","2000-01",22,[24],[267,268,269,270,271,272,273],"filgrastim","pegfilgrastim","cyclophosphamide","cytarabine","dexamethasone","etoposide phosphate","methotrexate",{"nctId":275,"briefTitle":276,"status":205,"phases":277,"primaryCompletion":278,"completion":278,"start":263,"enrollment":96,"conditions":279,"interventions":280},"NCT00074191","Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma",[89],"2000-10",[24],[270,271,281,273,282],"lomustine","procarbazine hydrochloride",{"nctId":284,"briefTitle":285,"status":286,"phases":287,"primaryCompletion":288,"completion":289,"start":290,"enrollment":291,"conditions":292,"interventions":296},"NCT00074165","Treating Patients With Recurrent PCNSL With Carboplatin\u002FBBBD and Adding Rituxan To The Treatment Regimen","TERMINATED",[89],"2010-06","2010-12","2003-01",17,[293,294,24,295],"Brain and Central Nervous System Tumors","Drug\u002FAgent Toxicity by Tissue\u002FOrgan","Thrombocytopenia",[297,215,241,298,299,300,301,302,196],"Rituxan","Etoposide phosphate","Carboplatin","Sodium thiosulfate","Neupogen","Neulasta",{"nctId":304,"briefTitle":305,"status":112,"phases":306,"primaryCompletion":307,"completion":308,"start":309,"enrollment":310,"conditions":311,"interventions":313},"NCT06504459","Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML",[89],"2027-10-11","2028-05-01","2025-01-03",40,[312,213],"Acute Monocytic Leukemia",[80,314,196,315],"Cladribine","Venetoclax",{"nctId":317,"briefTitle":318,"status":286,"phases":319,"primaryCompletion":320,"completion":321,"start":322,"enrollment":323,"conditions":324,"interventions":325},"NCT00022490","Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia",[89],"2011-05","2011-07","2001-06",24,[18],[270,326],"imatinib mesylate",{"nctId":328,"briefTitle":329,"status":286,"phases":330,"primaryCompletion":331,"completion":332,"start":333,"enrollment":235,"conditions":334,"interventions":335},"NCT01005914","Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",[89],"2013-03","2014-05","2009-06",[18],[269,270,271,336,326,273,337,338,339],"doxorubicin hydrochloride","methylprednisolone","pegaspargase","vincristine sulfate",{"nctId":341,"briefTitle":342,"status":286,"phases":343,"primaryCompletion":344,"completion":345,"start":346,"enrollment":347,"conditions":348,"interventions":353},"NCT00281879","Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer",[89],"2008-02","2008-03","2006-02",200,[349,18,24,350,33,351,352],"Chronic Myeloproliferative Disorders","Multiple Myeloma and Plasma Cell Neoplasm","Myelodysplastic\u002FMyeloproliferative Neoplasms","Unusual Cancers of Childhood",[354,267,355,356,269,357,270,358,359,360,273,337,361,362],"anti-thymocyte globulin","busulfan","carmustine","cyclosporine","etoposide","fludarabine phosphate","melphalan","mycophenolate mofetil","tacrolimus",{"nctId":364,"briefTitle":365,"status":112,"phases":366,"primaryCompletion":367,"completion":368,"start":369,"enrollment":370,"conditions":371,"interventions":373},"NCT07228273","Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia",[89],"2029-06-24","2029-08-24","2025-12-12",102,[213,372],"Myelodysplastic Syndrome",[196,254,374,218,315],"Fludarabine",{"nctId":376,"briefTitle":377,"status":112,"phases":378,"primaryCompletion":379,"completion":380,"start":381,"enrollment":382,"conditions":383,"interventions":385},"NCT06895473","Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome",[89],"2027-04-30","2027-12-31","2025-06-04",26,[384],"Hematopoietic and Lymphatic System Neoplasm",[196,221,386],"Therapeutic Hydrocortisone",3,{"trials":389,"activeCount":100},[],{"trials":391,"activeCount":100},[],{"trials":393,"activeCount":100},[],{"intervention":315,"totalTrials":395,"cells":396},5,{"EARLY_PHASE1":397,"PHASE1":399,"PHASE2":526,"PHASE3":536,"PHASE4":538,"NA":540},{"trials":398,"activeCount":100},[],{"trials":400,"activeCount":9,"soonestReadout":79},[401,408,424],{"nctId":77,"briefTitle":78,"status":112,"phases":402,"primaryCompletion":79,"completion":403,"start":54,"enrollment":323,"conditions":404,"interventions":406},[88],"2026-05-29",[213,405],"Myelodysplastic Syndrome\u002FAcute Myeloid Leukemia",[80,407,315],"Iadademstat",{"nctId":409,"briefTitle":410,"status":141,"phases":411,"primaryCompletion":412,"completion":412,"start":413,"enrollment":414,"conditions":415,"interventions":421},"NCT04872790","Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia",[88],"2027-12-02","2022-09-02",20,[416,417,418,419,420],"B Acute Lymphoblastic Leukemia","B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","Mixed Phenotype Acute Leukemia","Recurrent B Acute Lymphoblastic Leukemia","Recurrent Mixed Phenotype Acute Leukemia",[216,221,422,224,315,423],"Prednisone","Blinatumomab",{"nctId":425,"briefTitle":426,"status":286,"phases":427,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":430,"interventions":479},"NCT03878524","Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial",[88],"2020-12-10","2020-04-01",[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Anatomic Stage IV Breast Cancer AJCC v8","Anemia","Ann Arbor Stage III Hodgkin Lymphoma","Ann Arbor Stage III Non-Hodgkin Lymphoma","Ann Arbor Stage IV Hodgkin Lymphoma","Ann Arbor Stage IV Non-Hodgkin Lymphoma","Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative","Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Castration-Resistant Prostate Carcinoma","Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Hematopoietic and Lymphoid System Neoplasm","Locally Advanced Pancreatic Adenocarcinoma","Metastatic Breast Carcinoma","Metastatic Pancreatic Adenocarcinoma","Myelodysplastic\u002FMyeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis","Myelodysplastic\u002FMyeloproliferative Neoplasm, Unclassifiable","Primary Myelofibrosis","Recurrent Acute Lymphoblastic Leukemia","Recurrent Acute Myeloid Leukemia","Recurrent Chronic Lymphocytic Leukemia","Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Recurrent Hematologic Malignancy","Recurrent Hodgkin Lymphoma","Recurrent Myelodysplastic Syndrome","Recurrent Myelodysplastic\u002FMyeloproliferative Neoplasm","Recurrent Myeloproliferative Neoplasm","Recurrent Non-Hodgkin Lymphoma","Recurrent Small Lymphocytic Lymphoma","Refractory Acute Lymphoblastic Leukemia","Refractory Acute Myeloid Leukemia","Refractory Chronic Lymphocytic Leukemia","Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Refractory Chronic Myelomonocytic Leukemia","Refractory Hematologic Malignancy","Refractory Hodgkin Lymphoma","Refractory Malignant Solid Neoplasm","Refractory Myelodysplastic Syndrome","Refractory Myelodysplastic\u002FMyeloproliferative Neoplasm","Refractory Non-Hodgkin Lymphoma","Refractory Plasma Cell Myeloma","Refractory Primary Myelofibrosis","Refractory Small Lymphocytic Lymphoma","Stage II Pancreatic Cancer AJCC v8","Stage III Pancreatic Cancer AJCC v8","Stage IV Pancreatic Cancer AJCC v8","Stage IV Prostate Cancer AJCC v8","Unresectable Pancreatic Adenocarcinoma",[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],"Abemaciclib","Abiraterone","Afatinib","Bevacizumab","Bicalutamide","Bortezomib","Cabozantinib","Celecoxib","Copanlisib","Dabrafenib","Dacomitinib","Darolutamide","Doxorubicin","Durvalumab","Enasidenib","Entrectinib","Erlotinib","Everolimus","Fluorouracil","Imatinib","Ipilimumab","Lenvatinib","Leucovorin","Lorlatinib","Losartan","Nab-paclitaxel","Neratinib","Nivolumab","Olaparib","Oxaliplatin","Palbociclib","Panobinostat","Pembrolizumab","Pertuzumab","Ponatinib","Regorafenib","Ruxolitinib","Sirolimus","Sorafenib","Sunitinib","Trametinib","Trastuzumab Emtansine","Tretinoin","Vemurafenib","Vismodegib","Vorinostat",{"trials":527,"activeCount":9,"soonestReadout":307},[528,532],{"nctId":304,"briefTitle":305,"status":112,"phases":529,"primaryCompletion":307,"completion":308,"start":309,"enrollment":310,"conditions":530,"interventions":531},[89],[312,213],[80,314,196,315],{"nctId":364,"briefTitle":365,"status":112,"phases":533,"primaryCompletion":367,"completion":368,"start":369,"enrollment":370,"conditions":534,"interventions":535},[89],[213,372],[196,254,374,218,315],{"trials":537,"activeCount":100},[],{"trials":539,"activeCount":100},[],{"trials":541,"activeCount":100},[],{"intervention":422,"totalTrials":395,"cells":543},{"EARLY_PHASE1":544,"PHASE1":546,"PHASE2":552,"PHASE3":602,"PHASE4":604,"NA":606},{"trials":545,"activeCount":100},[],{"trials":547,"activeCount":96,"soonestReadout":412},[548],{"nctId":409,"briefTitle":410,"status":141,"phases":549,"primaryCompletion":412,"completion":412,"start":413,"enrollment":414,"conditions":550,"interventions":551},[88],[416,417,418,419,420],[216,221,422,224,315,423],{"trials":553,"activeCount":387,"soonestReadout":39},[554,567,577,591],{"nctId":555,"briefTitle":556,"status":112,"phases":557,"primaryCompletion":143,"completion":558,"start":559,"enrollment":560,"conditions":561,"interventions":564},"NCT06249191","Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma",[88,89],"2027-04-01","2024-06-13",30,[562,563],"Diffuse Large B-Cell Lymphoma","High Grade B-Cell Lymphoma",[215,492,241,565,422,566],"Mosunetuzumab","Vincristine",{"nctId":37,"briefTitle":38,"status":141,"phases":568,"primaryCompletion":39,"completion":569,"start":570,"enrollment":571,"conditions":572,"interventions":576},[88,89],"2027-01-01","2015-08-13",37,[440,573,574,575],"Metastatic Prostate Carcinoma","Recurrent Prostate Carcinoma","Stage IV Prostate Cancer AJCC v7",[40,55,422],{"nctId":578,"briefTitle":579,"status":141,"phases":580,"primaryCompletion":581,"completion":582,"start":583,"enrollment":210,"conditions":584,"interventions":587},"NCT04267887","Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer",[89],"2028-01-01","2030-01-01","2020-05-11",[585,573,586],"Castration-Sensitive Prostate Carcinoma","Stage IVB Prostate Cancer AJCC v8",[588,589,590,422],"Abiraterone Acetate","Antiandrogen Therapy","Apalutamide",{"nctId":592,"briefTitle":593,"status":205,"phases":594,"primaryCompletion":595,"completion":595,"start":596,"enrollment":597,"conditions":598,"interventions":599},"NCT00182741","Calcitriol, Mitoxantrone, and Prednisone in Treating Patients With Metastatic Prostate Cancer",[89],"2006-08","2004-09",19,[15],[600,601],"mitoxantrone hydrochloride","prednisone",{"trials":603,"activeCount":100},[],{"trials":605,"activeCount":100},[],{"trials":607,"activeCount":100},[],{"intervention":80,"totalTrials":387,"cells":609},{"EARLY_PHASE1":610,"PHASE1":612,"PHASE2":628,"PHASE3":634,"PHASE4":636,"NA":638},{"trials":611,"activeCount":100},[],{"trials":613,"activeCount":9,"soonestReadout":79},[614,618],{"nctId":77,"briefTitle":78,"status":112,"phases":615,"primaryCompletion":79,"completion":403,"start":54,"enrollment":323,"conditions":616,"interventions":617},[88],[213,405],[80,407,315],{"nctId":619,"briefTitle":620,"status":621,"phases":622,"primaryCompletion":380,"completion":623,"start":624,"enrollment":310,"conditions":625,"interventions":626},"NCT07548983","Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation","NOT_YET_RECRUITING",[88],"2028-12-29","2026-05-20",[213],[80,215,627,516,244],"Mycophenolate Mofetil",{"trials":629,"activeCount":96,"soonestReadout":307},[630],{"nctId":304,"briefTitle":305,"status":112,"phases":631,"primaryCompletion":307,"completion":308,"start":309,"enrollment":310,"conditions":632,"interventions":633},[89],[312,213],[80,314,196,315],{"trials":635,"activeCount":100},[],{"trials":637,"activeCount":100},[],{"trials":639,"activeCount":100},[],{"intervention":509,"totalTrials":395,"cells":641},{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":650,"PHASE3":708,"PHASE4":710,"NA":712},{"trials":643,"activeCount":100},[],{"trials":645,"activeCount":100},[646],{"nctId":425,"briefTitle":426,"status":286,"phases":647,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":648,"interventions":649},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":651,"activeCount":9,"soonestReadout":64},[652,669,679,695],{"nctId":653,"briefTitle":654,"status":205,"phases":655,"primaryCompletion":345,"completion":656,"start":657,"enrollment":658,"conditions":659,"interventions":662},"NCT00381862","Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX",[89],"2008-07","2006-06",54,[660,661],"Colorectal Cancer","Nausea and Vomiting",[663,271,664,665,666,667,668],"aprepitant","fluorouracil","irinotecan hydrochloride","leucovorin calcium","oxaliplatin","palonosetron hydrochloride",{"nctId":670,"briefTitle":671,"status":286,"phases":672,"primaryCompletion":673,"completion":673,"start":345,"enrollment":674,"conditions":675,"interventions":677},"NCT00642746","Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)",[89],"2011-12",16,[676],"Metastatic Colorectal Cancer",[496,498,502,509,678],"Irinotecan",{"nctId":62,"briefTitle":63,"status":141,"phases":680,"primaryCompletion":64,"completion":681,"start":682,"enrollment":683,"conditions":684,"interventions":690},[89],"2027-01-05","2021-05-27",42,[685,686,687,688,689],"Pancreatic Adenocarcinoma","Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8","Stage I Pancreatic Cancer American Joint Committee on Cancer v8","Stage III Pancreatic Cancer American Joint Committee on Cancer v8","Stage IV Pancreatic Cancer American Joint Committee on Cancer v8",[65,498,691,220,692,509,693,694],"Irinotecan Hydrochloride","Losartan Potassium","Gemcitabine","Nab paclitaxel",{"nctId":67,"briefTitle":68,"status":141,"phases":696,"primaryCompletion":69,"completion":697,"start":698,"enrollment":395,"conditions":699,"interventions":706},[89],"2025-11-30","2021-04-28",[700,701,702,703,704,705],"Liver and Intrahepatic Bile Duct Carcinoma","Stage III Intrahepatic Cholangiocarcinoma AJCC v8","Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8","Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8","Stage IV Intrahepatic Cholangiocarcinoma AJCC v8","Unresectable Intrahepatic Cholangiocarcinoma",[70,707,678,502,509],"Floxuridine",{"trials":709,"activeCount":100},[],{"trials":711,"activeCount":100},[],{"trials":713,"activeCount":100},[],{"intervention":715,"totalTrials":387,"cells":716},"Obinutuzumab",{"EARLY_PHASE1":717,"PHASE1":719,"PHASE2":732,"PHASE3":757,"PHASE4":759,"NA":761},{"trials":718,"activeCount":100},[],{"trials":720,"activeCount":96,"soonestReadout":569},[721],{"nctId":722,"briefTitle":723,"status":112,"phases":724,"primaryCompletion":569,"completion":581,"start":725,"enrollment":726,"conditions":727,"interventions":729},"NCT05943496","Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma",[88],"2023-10-02",27,[728],"Chronic Lymphocytic Leukemia",[730,715,731],"Acalabrutinib","Tafasitamab",{"trials":733,"activeCount":96,"soonestReadout":750},[734,746],{"nctId":735,"briefTitle":736,"status":205,"phases":737,"primaryCompletion":738,"completion":738,"start":739,"enrollment":740,"conditions":741,"interventions":744},"NCT02736617","Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma",[89],"2021-06-02","2016-07-05",10,[742,743],"Recurrent Mantle Cell Lymphoma","Refractory Mantle Cell Lymphoma",[745,715],"Ibrutinib",{"nctId":747,"briefTitle":748,"status":112,"phases":749,"primaryCompletion":750,"completion":751,"start":752,"enrollment":726,"conditions":753,"interventions":755},"NCT06357676","Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial",[88,89],"2027-11-01","2029-11-01","2025-05-29",[754],"Mantle Cell Lymphoma",[756,745,715],"Glofitamab",{"trials":758,"activeCount":100},[],{"trials":760,"activeCount":100},[],{"trials":762,"activeCount":100},[],{"intervention":764,"totalTrials":9,"cells":765},"Tremelimumab",{"EARLY_PHASE1":766,"PHASE1":782,"PHASE2":784,"PHASE3":797,"PHASE4":799,"NA":801},{"trials":767,"activeCount":96,"soonestReadout":84},[768],{"nctId":82,"briefTitle":83,"status":112,"phases":769,"primaryCompletion":84,"completion":770,"start":771,"enrollment":12,"conditions":772,"interventions":778},[87],"2028-02-01","2019-08-01",[773,774,474,475,476,775,776,777],"Locally Advanced Pancreatic Ductal Adenocarcinoma","Metastatic Pancreatic Ductal Adenocarcinoma","Unresectable Pancreatic Ductal Adenocarcinoma","Borderline Resectable Pancreatic Ductal Adenocarcinoma","Resectable Pancreatic Ductal Adenocarcinoma",[85,508,779,780,781,764],"Onvansertib","Azenosertib","Saruparib",{"trials":783,"activeCount":100},[],{"trials":785,"activeCount":96,"soonestReadout":790},[786],{"nctId":787,"briefTitle":788,"status":621,"phases":789,"primaryCompletion":790,"completion":790,"start":791,"enrollment":310,"conditions":792,"interventions":795},"NCT07511504","Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma",[89],"2027-08-01","2026-04-02",[793,186,189,794],"Locally Advanced Hepatocellular Carcinoma","Unresectable Hepatocellular Carcinoma",[493,764,796],"Zanzalintinib",{"trials":798,"activeCount":100},[],{"trials":800,"activeCount":100},[],{"trials":802,"activeCount":100},[],{"intervention":254,"totalTrials":9,"cells":804},{"EARLY_PHASE1":805,"PHASE1":807,"PHASE2":813,"PHASE3":819,"PHASE4":821,"NA":823},{"trials":806,"activeCount":100},[],{"trials":808,"activeCount":96,"soonestReadout":249},[809],{"nctId":246,"briefTitle":247,"status":112,"phases":810,"primaryCompletion":249,"completion":249,"start":250,"enrollment":251,"conditions":811,"interventions":812},[88],[213],[196,254,255],{"trials":814,"activeCount":96,"soonestReadout":367},[815],{"nctId":364,"briefTitle":365,"status":112,"phases":816,"primaryCompletion":367,"completion":368,"start":369,"enrollment":370,"conditions":817,"interventions":818},[89],[213,372],[196,254,374,218,315],{"trials":820,"activeCount":100},[],{"trials":822,"activeCount":100},[],{"trials":824,"activeCount":100},[],{"intervention":273,"totalTrials":22,"cells":826},{"EARLY_PHASE1":827,"PHASE1":829,"PHASE2":843,"PHASE3":905,"PHASE4":907,"NA":909},{"trials":828,"activeCount":100},[],{"trials":830,"activeCount":96,"soonestReadout":412},[831,835,839],{"nctId":203,"briefTitle":204,"status":205,"phases":832,"primaryCompletion":207,"completion":208,"start":209,"enrollment":210,"conditions":833,"interventions":834},[88],[212,213],[215,196,216,70,217,218,219,220,221,222,223,224,225,226,227,228],{"nctId":409,"briefTitle":410,"status":141,"phases":836,"primaryCompletion":412,"completion":412,"start":413,"enrollment":414,"conditions":837,"interventions":838},[88],[416,417,418,419,420],[216,221,422,224,315,423],{"nctId":230,"briefTitle":231,"status":205,"phases":840,"primaryCompletion":233,"completion":233,"start":234,"enrollment":235,"conditions":841,"interventions":842},[88],[237,238],[240,196,241,242,243,221,244],{"trials":844,"activeCount":96,"soonestReadout":379},[845,849,863,867,880,893,897,901],{"nctId":259,"briefTitle":260,"status":205,"phases":846,"primaryCompletion":262,"completion":262,"start":263,"enrollment":264,"conditions":847,"interventions":848},[89],[24],[267,268,269,270,271,272,273],{"nctId":850,"briefTitle":851,"status":852,"phases":853,"primaryCompletion":854,"completion":855,"start":856,"enrollment":857,"conditions":858,"interventions":860},"NCT00293475","Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma","UNKNOWN",[88,89],"2022-01-31","2023-01-31","2005-10-14",81,[859],"Central Nervous System Lymphoma",[299,861,221,224,862],"Mannitol","Sodium Thiosulfate",{"nctId":275,"briefTitle":276,"status":205,"phases":864,"primaryCompletion":278,"completion":278,"start":263,"enrollment":96,"conditions":865,"interventions":866},[89],[24],[270,271,281,273,282],{"nctId":868,"briefTitle":869,"status":205,"phases":870,"primaryCompletion":871,"completion":871,"start":872,"enrollment":873,"conditions":874,"interventions":876},"NCT00245037","Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer",[88,89],"2015-08","2005-06",147,[349,18,24,350,33,351,875],"Precancerous Condition",[877,355,357,359,361,878,879,221],"therapeutic allogeneic lymphocytes","Granulocyte colony-stimulating factor","Phenytoin",{"nctId":881,"briefTitle":882,"status":883,"phases":884,"primaryCompletion":885,"completion":885,"start":885,"enrollment":100,"conditions":886,"interventions":889},"NCT00397501","BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain","WITHDRAWN",[88,89],"2013-10",[293,21,887,294,888],"Cognitive\u002FFunctional Effects","Psychosocial Effects of Cancer and Its Treatment",[890,891,273,892],"trastuzumab","carboplatin","sodium thiosulfate",{"nctId":328,"briefTitle":329,"status":286,"phases":894,"primaryCompletion":331,"completion":332,"start":333,"enrollment":235,"conditions":895,"interventions":896},[89],[18],[269,270,271,336,326,273,337,338,339],{"nctId":341,"briefTitle":342,"status":286,"phases":898,"primaryCompletion":344,"completion":345,"start":346,"enrollment":347,"conditions":899,"interventions":900},[89],[349,18,24,350,33,351,352],[354,267,355,356,269,357,270,358,359,360,273,337,361,362],{"nctId":376,"briefTitle":377,"status":112,"phases":902,"primaryCompletion":379,"completion":380,"start":381,"enrollment":382,"conditions":903,"interventions":904},[89],[384],[196,221,386],{"trials":906,"activeCount":100},[],{"trials":908,"activeCount":100},[],{"trials":910,"activeCount":100},[911],{"nctId":912,"briefTitle":913,"status":286,"phases":914,"primaryCompletion":915,"completion":915,"start":916,"enrollment":917,"conditions":918,"interventions":922},"NCT00253552","G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders",[92],"2006-05","2004-05",4,[349,919,18,24,350,33,920,921],"Graft Versus Host Disease","Myelodysplastic\u002FMyeloproliferative Diseases","Sarcoma",[267,355,269,357,358,273],{"intervention":215,"totalTrials":235,"cells":924},{"EARLY_PHASE1":925,"PHASE1":927,"PHASE2":959,"PHASE3":993,"PHASE4":995,"NA":997},{"trials":926,"activeCount":100},[],{"trials":928,"activeCount":96,"soonestReadout":380},[929,933,945,955],{"nctId":203,"briefTitle":204,"status":205,"phases":930,"primaryCompletion":207,"completion":208,"start":209,"enrollment":210,"conditions":931,"interventions":932},[88],[212,213],[215,196,216,70,217,218,219,220,221,222,223,224,225,226,227,228],{"nctId":934,"briefTitle":935,"status":286,"phases":936,"primaryCompletion":937,"completion":937,"start":938,"enrollment":9,"conditions":939,"interventions":942},"NCT00238173","Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors",[88],"2006-02-17","2004-12",[940,293,294,941],"Bone Marrow Suppression","Long-term Effects Secondary to Cancer Therapy in Children",[267,943,891,269,272,944,892],"acetylcysteine","mannitol",{"nctId":946,"briefTitle":947,"status":205,"phases":948,"primaryCompletion":949,"start":950,"enrollment":951,"conditions":952,"interventions":953},"NCT01689987","Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma",[88],"2016-04","2012-09",18,[238,471],[215,70,954,517],"Hydroxychloroquine",{"nctId":619,"briefTitle":620,"status":621,"phases":956,"primaryCompletion":380,"completion":623,"start":624,"enrollment":310,"conditions":957,"interventions":958},[88],[213],[80,215,627,516,244],{"trials":960,"activeCount":96,"soonestReadout":143},[961,965,969,973,977,989],{"nctId":259,"briefTitle":260,"status":205,"phases":962,"primaryCompletion":262,"completion":262,"start":263,"enrollment":264,"conditions":963,"interventions":964},[89],[24],[267,268,269,270,271,272,273],{"nctId":555,"briefTitle":556,"status":112,"phases":966,"primaryCompletion":143,"completion":558,"start":559,"enrollment":560,"conditions":967,"interventions":968},[88,89],[562,563],[215,492,241,565,422,566],{"nctId":284,"briefTitle":285,"status":286,"phases":970,"primaryCompletion":288,"completion":289,"start":290,"enrollment":291,"conditions":971,"interventions":972},[89],[293,294,24,295],[297,215,241,298,299,300,301,302,196],{"nctId":328,"briefTitle":329,"status":286,"phases":974,"primaryCompletion":331,"completion":332,"start":333,"enrollment":235,"conditions":975,"interventions":976},[89],[18],[269,270,271,336,326,273,337,338,339],{"nctId":978,"briefTitle":979,"status":852,"phases":980,"primaryCompletion":981,"completion":982,"start":983,"enrollment":984,"conditions":985,"interventions":987},"NCT00075387","Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors",[89],"2023-04-30","2024-04-30","2003-03-07",48,[986],"Malignant Glioma",[299,215,988,862],"Etoposide Phosphate",{"nctId":341,"briefTitle":342,"status":286,"phases":990,"primaryCompletion":344,"completion":345,"start":346,"enrollment":347,"conditions":991,"interventions":992},[89],[349,18,24,350,33,351,352],[354,267,355,356,269,357,270,358,359,360,273,337,361,362],{"trials":994,"activeCount":100},[],{"trials":996,"activeCount":100},[],{"trials":998,"activeCount":100},[999],{"nctId":912,"briefTitle":913,"status":286,"phases":1000,"primaryCompletion":915,"completion":915,"start":916,"enrollment":917,"conditions":1001,"interventions":1002},[92],[349,919,18,24,350,33,920,921],[267,355,269,357,358,273],{"intervention":55,"totalTrials":395,"cells":1004},{"EARLY_PHASE1":1005,"PHASE1":1007,"PHASE2":1013,"PHASE3":1044,"PHASE4":1046,"NA":1048},{"trials":1006,"activeCount":100},[],{"trials":1008,"activeCount":100},[1009],{"nctId":425,"briefTitle":426,"status":286,"phases":1010,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":1011,"interventions":1012},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":1014,"activeCount":9,"soonestReadout":39},[1015,1030,1034],{"nctId":1016,"briefTitle":1017,"status":205,"phases":1018,"primaryCompletion":1019,"completion":1020,"start":1021,"enrollment":1022,"conditions":1023,"interventions":1029},"NCT02099864","Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy",[89],"2019-10-01","2024-07-08","2014-02-05",36,[440,1024,1025,1026,574,1027,1028],"Metastatic Malignant Neoplasm in the Bone","Metastatic Malignant Neoplasm in the Soft Tissues","Metastatic Prostate Adenocarcinoma","Stage III Prostate Adenocarcinoma AJCC v7","Stage IV Prostate Adenocarcinoma AJCC v7",[55],{"nctId":37,"briefTitle":38,"status":141,"phases":1031,"primaryCompletion":39,"completion":569,"start":570,"enrollment":571,"conditions":1032,"interventions":1033},[88,89],[440,573,574,575],[40,55,422],{"nctId":52,"briefTitle":53,"status":141,"phases":1035,"primaryCompletion":54,"completion":1036,"start":1037,"enrollment":1038,"conditions":1039,"interventions":1043},[89],"2026-10-31","2014-11-18",58,[440,1040,1041,574,1042],"Hormone-Resistant Prostate Cancer","PSA Progression","Stage IV Prostate Adenocarcinoma Cancer AJCC v8",[55,512],{"trials":1045,"activeCount":100},[],{"trials":1047,"activeCount":100},[],{"trials":1049,"activeCount":100},[1050],{"nctId":1051,"briefTitle":1052,"status":205,"phases":1053,"primaryCompletion":1019,"completion":1054,"start":1055,"enrollment":1056,"conditions":1057,"interventions":1060},"NCT02228265","Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide",[],"2020-02-27","2013-03-12",41,[1058,440,121,1041,574,1059],"Castration Levels of Testosterone","Stage IV Prostate Cancer",[55],{"intervention":512,"totalTrials":395,"cells":1062},{"EARLY_PHASE1":1063,"PHASE1":1065,"PHASE2":1071,"PHASE3":1113,"PHASE4":1115,"NA":1117},{"trials":1064,"activeCount":100},[],{"trials":1066,"activeCount":100},[1067],{"nctId":425,"briefTitle":426,"status":286,"phases":1068,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":1069,"interventions":1070},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":1072,"activeCount":96,"soonestReadout":54},[1073,1084,1098,1102],{"nctId":1074,"briefTitle":1075,"status":286,"phases":1076,"primaryCompletion":1077,"completion":1077,"start":1078,"enrollment":9,"conditions":1079,"interventions":1082},"NCT03325166","Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases",[89],"2021-03-01","2017-11-03",[1080,1081],"Lung Carcinoma Metastatic in the Brain","Stage IV Lung Non-Small Cell Cancer AJCC v7",[1083,512],"Ferumoxytol",{"nctId":1085,"briefTitle":1086,"status":883,"phases":1087,"primaryCompletion":84,"completion":1088,"start":1089,"enrollment":100,"conditions":1090,"interventions":1096},"NCT06528210","Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer",[89],"2028-06-01","2025-04-16",[1091,1092,1093,1094,1095],"High Risk Prostate Carcinoma","Localized Prostate Adenocarcinoma","Stage I Prostate Cancer AJCC v8","Stage II Prostate Cancer AJCC v8","Stage III Prostate Cancer AJCC v8",[1097,484,512],"Gonadotropin Releasing Hormone Agonists and Antagonists",{"nctId":52,"briefTitle":53,"status":141,"phases":1099,"primaryCompletion":54,"completion":1036,"start":1037,"enrollment":1038,"conditions":1100,"interventions":1101},[89],[440,1040,1041,574,1042],[55,512],{"nctId":1103,"briefTitle":1104,"status":286,"phases":1105,"primaryCompletion":1106,"completion":1107,"start":1108,"enrollment":1109,"conditions":1110,"interventions":1112},"NCT03347617","Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma",[89],"2023-12-31","2025-06-23","2017-12-20",52,[1111],"Glioblastoma",[1083,512],{"trials":1114,"activeCount":100},[],{"trials":1116,"activeCount":100},[],{"trials":1118,"activeCount":100},[],{"intervention":498,"totalTrials":395,"cells":1120},{"EARLY_PHASE1":1121,"PHASE1":1123,"PHASE2":1129,"PHASE3":1153,"PHASE4":1155,"NA":1157},{"trials":1122,"activeCount":100},[],{"trials":1124,"activeCount":100},[1125],{"nctId":425,"briefTitle":426,"status":286,"phases":1126,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":1127,"interventions":1128},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":1130,"activeCount":96,"soonestReadout":64},[1131,1135,1145,1149],{"nctId":653,"briefTitle":654,"status":205,"phases":1132,"primaryCompletion":345,"completion":656,"start":657,"enrollment":658,"conditions":1133,"interventions":1134},[89],[660,661],[663,271,664,665,666,667,668],{"nctId":1136,"briefTitle":1137,"status":205,"phases":1138,"primaryCompletion":1139,"completion":1140,"start":1141,"enrollment":414,"conditions":1142,"interventions":1144},"NCT02427841","Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery",[89],"2019-11-12","2022-12-12","2016-01-21",[685,1143],"Resectable Pancreatic Carcinoma",[498,693,505],{"nctId":670,"briefTitle":671,"status":286,"phases":1146,"primaryCompletion":673,"completion":673,"start":345,"enrollment":674,"conditions":1147,"interventions":1148},[89],[676],[496,498,502,509,678],{"nctId":62,"briefTitle":63,"status":141,"phases":1150,"primaryCompletion":64,"completion":681,"start":682,"enrollment":683,"conditions":1151,"interventions":1152},[89],[685,686,687,688,689],[65,498,691,220,692,509,693,694],{"trials":1154,"activeCount":100},[],{"trials":1156,"activeCount":100},[],{"trials":1158,"activeCount":100},[],{"intervention":693,"totalTrials":395,"cells":1160},{"EARLY_PHASE1":1161,"PHASE1":1163,"PHASE2":1165,"PHASE3":1235,"PHASE4":1237,"NA":1239},{"trials":1162,"activeCount":100},[],{"trials":1164,"activeCount":100},[],{"trials":1166,"activeCount":96,"soonestReadout":64},[1167,1171,1175,1197,1206],{"nctId":1136,"briefTitle":1137,"status":205,"phases":1168,"primaryCompletion":1139,"completion":1140,"start":1141,"enrollment":414,"conditions":1169,"interventions":1170},[89],[685,1143],[498,693,505],{"nctId":62,"briefTitle":63,"status":141,"phases":1172,"primaryCompletion":64,"completion":681,"start":682,"enrollment":683,"conditions":1173,"interventions":1174},[89],[685,686,687,688,689],[65,498,691,220,692,509,693,694],{"nctId":1176,"briefTitle":1177,"status":286,"phases":1178,"primaryCompletion":1179,"completion":1179,"start":1180,"enrollment":1181,"conditions":1182,"interventions":1191},"NCT06630325","A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer",[89],"2026-03-11","2025-06-24",6,[1183,175,1184,1185,1186,1187,1188,432,1189,475,1095,1190,476,477],"Advanced Breast Carcinoma","Advanced Ovarian Carcinoma","Advanced Pancreatic Carcinoma","Advanced Prostate Carcinoma","Advanced Sarcoma","Anatomic Stage III Breast Cancer AJCC v8","Stage III Ovarian Cancer AJCC v8","Stage IV Ovarian Cancer AJCC v8",[480,1192,693,1193,1194,1195,1196],"Exemestane","Letrozole","Osimertinib","Pemetrexed","Tamoxifen",{"nctId":1198,"briefTitle":1199,"status":883,"phases":1200,"primaryCompletion":1201,"completion":1202,"start":1203,"enrollment":100,"conditions":1204,"interventions":1205},"NCT06398587","Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma",[89],"2026-05-04","2027-06-07","2024-08-01",[773,774,474,475,476,478],[779,693,505],{"nctId":1207,"briefTitle":1208,"status":205,"phases":1209,"primaryCompletion":1210,"completion":1210,"start":1211,"enrollment":658,"conditions":1212,"interventions":1231},"NCT01532687","Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma",[89],"2019-10-31","2012-03-13",[1213,1214,1215,1216,1217,1218,1219,1220,1221,1222,1223,1224,1225,1226,1227,1228,921,1229,1230],"Adult Alveolar Soft Part Sarcoma","Adult Angiosarcoma","Adult Desmoplastic Small Round Cell Tumor","Adult Epithelioid Hemangioendothelioma","Adult Epithelioid Sarcoma","Adult Extraskeletal Myxoid Chondrosarcoma","Adult Extraskeletal Osteosarcoma","Adult Fibrosarcoma","Adult Leiomyosarcoma","Adult Liposarcoma","Adult Malignant Peripheral Nerve Sheath Tumor","Adult Rhabdomyosarcoma","Adult Synovial Sarcoma","Adult Undifferentiated Pleomorphic Sarcoma","Malignant Adult Hemangiopericytoma","Recurrent Adult Soft Tissue Sarcoma","Stage III Adult Soft Tissue Sarcoma AJCC v7","Stage IV Adult Soft Tissue Sarcoma AJCC v7",[693,1232,1233,1234],"Gemcitabine Hydrochloride","Pazopanib","Pazopanib Hydrochloride",{"trials":1236,"activeCount":100},[],{"trials":1238,"activeCount":100},[],{"trials":1240,"activeCount":100},[],{"intervention":1242,"totalTrials":917,"cells":1243},"Paclitaxel",{"EARLY_PHASE1":1244,"PHASE1":1266,"PHASE2":1292,"PHASE3":1306,"PHASE4":1308,"NA":1310},{"trials":1245,"activeCount":100},[1246],{"nctId":1247,"briefTitle":1248,"status":883,"phases":1249,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":100,"conditions":1252,"interventions":1255},"NCT05238831","SMMART Adaptive Clinical Treatment (ACT) Trial",[87],"2026-05-31","2023-01-30",[1183,175,1184,1185,1186,1187,1188,432,1228,1253,1254,574,474,1189,475,1190,476],"Recurrent Breast Carcinoma","Recurrent Ovarian Carcinoma",[1256,1257,1258,1259,483,65,299,85,495,1260,1261,1262,678,1193,505,1263,508,1242,510,513,1264,521,523,1265,524],"Alectinib","Alpelisib","Anastrozole","Atezolizumab","Eribulin","Fulvestrant","Hyaluronidase-zzxf\u002FPertuzumab\u002FTrastuzumab","Niraparib","Trastuzumab","Vinorelbine",{"trials":1267,"activeCount":100},[1268,1280],{"nctId":1269,"briefTitle":1270,"status":883,"phases":1271,"primaryCompletion":1272,"completion":1272,"start":288,"enrollment":100,"conditions":1273,"interventions":1277},"NCT01138137","N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer",[88],"2014-12",[1274,1275,1276],"Ovarian Carcinoma, Stage 3 or 4","Epithelial Ovarian Carcinoma","Primary Peritoneal Carcinoma",[1242,1278,1279],"N-acetylcysteine","Cisplatin",{"nctId":1281,"briefTitle":1282,"status":205,"phases":1283,"primaryCompletion":1284,"completion":1284,"start":1285,"enrollment":1286,"conditions":1287,"interventions":1290},"NCT02503358","Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer",[88],"2020-07-16","2016-07-21",23,[1288,1289],"Stage IIIB Non-Small Cell Lung Cancer AJCC v7","Stage IV Non-Small Cell Lung Cancer AJCC v7",[1242,1291],"Selumetinib",{"trials":1293,"activeCount":96,"soonestReadout":558},[1294],{"nctId":1295,"briefTitle":1296,"status":112,"phases":1297,"primaryCompletion":558,"completion":1298,"start":1299,"enrollment":1300,"conditions":1301,"interventions":1303},"NCT06320405","Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors",[88,89],"2029-04-01","2024-05-21",38,[175,182,1302,467],"Recurrent Malignant Solid Neoplasm",[1304,1242,1305],"Axatilimab","Retifanlimab",{"trials":1307,"activeCount":100},[],{"trials":1309,"activeCount":100},[],{"trials":1311,"activeCount":100},[],{"intervention":220,"totalTrials":387,"cells":1313},{"EARLY_PHASE1":1314,"PHASE1":1316,"PHASE2":1322,"PHASE3":1332,"PHASE4":1334,"NA":1336},{"trials":1315,"activeCount":100},[],{"trials":1317,"activeCount":100},[1318],{"nctId":203,"briefTitle":204,"status":205,"phases":1319,"primaryCompletion":207,"completion":208,"start":209,"enrollment":210,"conditions":1320,"interventions":1321},[88],[212,213],[215,196,216,70,217,218,219,220,221,222,223,224,225,226,227,228],{"trials":1323,"activeCount":96,"soonestReadout":64},[1324,1328],{"nctId":653,"briefTitle":654,"status":205,"phases":1325,"primaryCompletion":345,"completion":656,"start":657,"enrollment":658,"conditions":1326,"interventions":1327},[89],[660,661],[663,271,664,665,666,667,668],{"nctId":62,"briefTitle":63,"status":141,"phases":1329,"primaryCompletion":64,"completion":681,"start":682,"enrollment":683,"conditions":1330,"interventions":1331},[89],[685,686,687,688,689],[65,498,691,220,692,509,693,694],{"trials":1333,"activeCount":100},[],{"trials":1335,"activeCount":100},[],{"trials":1337,"activeCount":100},[],{"intervention":374,"totalTrials":387,"cells":1339},{"EARLY_PHASE1":1340,"PHASE1":1342,"PHASE2":1344,"PHASE3":1368,"PHASE4":1370,"NA":1372},{"trials":1341,"activeCount":100},[],{"trials":1343,"activeCount":100},[],{"trials":1345,"activeCount":96,"soonestReadout":367},[1346,1356,1360],{"nctId":1347,"briefTitle":1348,"status":205,"phases":1349,"primaryCompletion":1350,"completion":1350,"start":872,"enrollment":1351,"conditions":1352,"interventions":1353},"NCT00253513","Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome",[88,89],"2009-10",60,[18,33],[1354,1355],"fludarabine","treosulfan",{"nctId":364,"briefTitle":365,"status":112,"phases":1357,"primaryCompletion":367,"completion":368,"start":369,"enrollment":370,"conditions":1358,"interventions":1359},[89],[213,372],[196,254,374,218,315],{"nctId":1361,"briefTitle":1362,"status":286,"phases":1363,"primaryCompletion":345,"completion":345,"start":1364,"enrollment":96,"conditions":1365,"interventions":1366},"NCT00416884","Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML",[89],"2003-05",[18],[1367,374],"Campath",{"trials":1369,"activeCount":100},[],{"trials":1371,"activeCount":100},[],{"trials":1373,"activeCount":100},[],{"intervention":493,"totalTrials":387,"cells":1375},{"EARLY_PHASE1":1376,"PHASE1":1378,"PHASE2":1398,"PHASE3":1404,"PHASE4":1406,"NA":1408},{"trials":1377,"activeCount":100},[],{"trials":1379,"activeCount":100},[1380,1394],{"nctId":1381,"briefTitle":1382,"status":205,"phases":1383,"primaryCompletion":1384,"completion":1385,"start":1386,"enrollment":387,"conditions":1387,"interventions":1393},"NCT03544125","Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer",[88],"2018-08-07","2020-11-18","2018-05-03",[432,1388,1389,1390,1391,1392],"Estrogen Receptor Negative","HER2\u002FNeu Negative","Progesterone Receptor Negative","Prognostic Stage IV Breast Cancer AJCC v8","Triple-Negative Breast Carcinoma",[493,508],{"nctId":425,"briefTitle":426,"status":286,"phases":1395,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":1396,"interventions":1397},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":1399,"activeCount":96,"soonestReadout":790},[1400],{"nctId":787,"briefTitle":788,"status":621,"phases":1401,"primaryCompletion":790,"completion":790,"start":791,"enrollment":310,"conditions":1402,"interventions":1403},[89],[793,186,189,794],[493,764,796],{"trials":1405,"activeCount":100},[],{"trials":1407,"activeCount":100},[],{"trials":1409,"activeCount":100},[],{"intervention":502,"totalTrials":387,"cells":1411},{"EARLY_PHASE1":1412,"PHASE1":1414,"PHASE2":1420,"PHASE3":1430,"PHASE4":1432,"NA":1434},{"trials":1413,"activeCount":100},[],{"trials":1415,"activeCount":100},[1416],{"nctId":425,"briefTitle":426,"status":286,"phases":1417,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":1418,"interventions":1419},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":1421,"activeCount":96,"soonestReadout":69},[1422,1426],{"nctId":670,"briefTitle":671,"status":286,"phases":1423,"primaryCompletion":673,"completion":673,"start":345,"enrollment":674,"conditions":1424,"interventions":1425},[89],[676],[496,498,502,509,678],{"nctId":67,"briefTitle":68,"status":141,"phases":1427,"primaryCompletion":69,"completion":697,"start":698,"enrollment":395,"conditions":1428,"interventions":1429},[89],[700,701,702,703,704,705],[70,707,678,502,509],{"trials":1431,"activeCount":100},[],{"trials":1433,"activeCount":100},[],{"trials":1435,"activeCount":100},[],{"intervention":678,"totalTrials":387,"cells":1437},{"EARLY_PHASE1":1438,"PHASE1":1444,"PHASE2":1446,"PHASE3":1456,"PHASE4":1458,"NA":1460},{"trials":1439,"activeCount":100},[1440],{"nctId":1247,"briefTitle":1248,"status":883,"phases":1441,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":100,"conditions":1442,"interventions":1443},[87],[1183,175,1184,1185,1186,1187,1188,432,1228,1253,1254,574,474,1189,475,1190,476],[1256,1257,1258,1259,483,65,299,85,495,1260,1261,1262,678,1193,505,1263,508,1242,510,513,1264,521,523,1265,524],{"trials":1445,"activeCount":100},[],{"trials":1447,"activeCount":96,"soonestReadout":69},[1448,1452],{"nctId":670,"briefTitle":671,"status":286,"phases":1449,"primaryCompletion":673,"completion":673,"start":345,"enrollment":674,"conditions":1450,"interventions":1451},[89],[676],[496,498,502,509,678],{"nctId":67,"briefTitle":68,"status":141,"phases":1453,"primaryCompletion":69,"completion":697,"start":698,"enrollment":395,"conditions":1454,"interventions":1455},[89],[700,701,702,703,704,705],[70,707,678,502,509],{"trials":1457,"activeCount":100},[],{"trials":1459,"activeCount":100},[],{"trials":1461,"activeCount":100},[],{"intervention":65,"totalTrials":387,"cells":1463},{"EARLY_PHASE1":1464,"PHASE1":1470,"PHASE2":1476,"PHASE3":1482,"PHASE4":1484,"NA":1486},{"trials":1465,"activeCount":100},[1466],{"nctId":1247,"briefTitle":1248,"status":883,"phases":1467,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":100,"conditions":1468,"interventions":1469},[87],[1183,175,1184,1185,1186,1187,1188,432,1228,1253,1254,574,474,1189,475,1190,476],[1256,1257,1258,1259,483,65,299,85,495,1260,1261,1262,678,1193,505,1263,508,1242,510,513,1264,521,523,1265,524],{"trials":1471,"activeCount":100},[1472],{"nctId":425,"briefTitle":426,"status":286,"phases":1473,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":1474,"interventions":1475},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":1477,"activeCount":96,"soonestReadout":64},[1478],{"nctId":62,"briefTitle":63,"status":141,"phases":1479,"primaryCompletion":64,"completion":681,"start":682,"enrollment":683,"conditions":1480,"interventions":1481},[89],[685,686,687,688,689],[65,498,691,220,692,509,693,694],{"trials":1483,"activeCount":100},[],{"trials":1485,"activeCount":100},[],{"trials":1487,"activeCount":100},[],{"intervention":218,"totalTrials":9,"cells":1489},{"EARLY_PHASE1":1490,"PHASE1":1492,"PHASE2":1498,"PHASE3":1504,"PHASE4":1506,"NA":1508},{"trials":1491,"activeCount":100},[],{"trials":1493,"activeCount":100},[1494],{"nctId":203,"briefTitle":204,"status":205,"phases":1495,"primaryCompletion":207,"completion":208,"start":209,"enrollment":210,"conditions":1496,"interventions":1497},[88],[212,213],[215,196,216,70,217,218,219,220,221,222,223,224,225,226,227,228],{"trials":1499,"activeCount":96,"soonestReadout":367},[1500],{"nctId":364,"briefTitle":365,"status":112,"phases":1501,"primaryCompletion":367,"completion":368,"start":369,"enrollment":370,"conditions":1502,"interventions":1503},[89],[213,372],[196,254,374,218,315],{"trials":1505,"activeCount":100},[],{"trials":1507,"activeCount":100},[],{"trials":1509,"activeCount":100},[],{"intervention":665,"totalTrials":9,"cells":1511},{"EARLY_PHASE1":1512,"PHASE1":1514,"PHASE2":1516,"PHASE3":1526,"PHASE4":1528,"NA":1530},{"trials":1513,"activeCount":100},[],{"trials":1515,"activeCount":100},[],{"trials":1517,"activeCount":96,"soonestReadout":64},[1518,1522],{"nctId":653,"briefTitle":654,"status":205,"phases":1519,"primaryCompletion":345,"completion":656,"start":657,"enrollment":658,"conditions":1520,"interventions":1521},[89],[660,661],[663,271,664,665,666,667,668],{"nctId":62,"briefTitle":63,"status":141,"phases":1523,"primaryCompletion":64,"completion":681,"start":682,"enrollment":683,"conditions":1524,"interventions":1525},[89],[685,686,687,688,689],[65,498,691,220,692,509,693,694],{"trials":1527,"activeCount":100},[],{"trials":1529,"activeCount":100},[],{"trials":1531,"activeCount":100},[],{"intervention":492,"totalTrials":9,"cells":1533},{"EARLY_PHASE1":1534,"PHASE1":1536,"PHASE2":1542,"PHASE3":1548,"PHASE4":1550,"NA":1552},{"trials":1535,"activeCount":100},[],{"trials":1537,"activeCount":100},[1538],{"nctId":425,"briefTitle":426,"status":286,"phases":1539,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":1540,"interventions":1541},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":1543,"activeCount":96,"soonestReadout":143},[1544],{"nctId":555,"briefTitle":556,"status":112,"phases":1545,"primaryCompletion":143,"completion":558,"start":559,"enrollment":560,"conditions":1546,"interventions":1547},[88,89],[562,563],[215,492,241,565,422,566],{"trials":1549,"activeCount":100},[],{"trials":1551,"activeCount":100},[],{"trials":1553,"activeCount":100},[],{"intervention":745,"totalTrials":9,"cells":1555},{"EARLY_PHASE1":1556,"PHASE1":1558,"PHASE2":1560,"PHASE3":1570,"PHASE4":1572,"NA":1574},{"trials":1557,"activeCount":100},[],{"trials":1559,"activeCount":100},[],{"trials":1561,"activeCount":96,"soonestReadout":750},[1562,1566],{"nctId":735,"briefTitle":736,"status":205,"phases":1563,"primaryCompletion":738,"completion":738,"start":739,"enrollment":740,"conditions":1564,"interventions":1565},[89],[742,743],[745,715],{"nctId":747,"briefTitle":748,"status":112,"phases":1567,"primaryCompletion":750,"completion":751,"start":752,"enrollment":726,"conditions":1568,"interventions":1569},[88,89],[754],[756,745,715],{"trials":1571,"activeCount":100},[],{"trials":1573,"activeCount":100},[],{"trials":1575,"activeCount":100},[],{"intervention":40,"totalTrials":9,"cells":1577},{"EARLY_PHASE1":1578,"PHASE1":1580,"PHASE2":1586,"PHASE3":1592,"PHASE4":1594,"NA":1596},{"trials":1579,"activeCount":100},[],{"trials":1581,"activeCount":100},[1582],{"nctId":425,"briefTitle":426,"status":286,"phases":1583,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":1584,"interventions":1585},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":1587,"activeCount":96,"soonestReadout":39},[1588],{"nctId":37,"briefTitle":38,"status":141,"phases":1589,"primaryCompletion":39,"completion":569,"start":570,"enrollment":571,"conditions":1590,"interventions":1591},[88,89],[440,573,574,575],[40,55,422],{"trials":1593,"activeCount":100},[],{"trials":1595,"activeCount":100},[],{"trials":1597,"activeCount":100},[],{"intervention":314,"totalTrials":9,"cells":1599},{"EARLY_PHASE1":1600,"PHASE1":1602,"PHASE2":1604,"PHASE3":1623,"PHASE4":1625,"NA":1627},{"trials":1601,"activeCount":100},[],{"trials":1603,"activeCount":100},[],{"trials":1605,"activeCount":96,"soonestReadout":307},[1606,1619],{"nctId":1607,"briefTitle":1608,"status":205,"phases":1609,"primaryCompletion":1610,"completion":1611,"start":1612,"enrollment":1613,"conditions":1614,"interventions":1618},"NCT00764517","Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma",[89],"2015-01","2017-03","2008-08",57,[1615,451,1616,1617],"Recurrent B-Cell Non-Hodgkin Lymphoma","Recurrent Indolent Adult Non-Hodgkin Lymphoma","Refractory B-Cell Non-Hodgkin Lymphoma",[314,224,525],{"nctId":304,"briefTitle":305,"status":112,"phases":1620,"primaryCompletion":307,"completion":308,"start":309,"enrollment":310,"conditions":1621,"interventions":1622},[89],[312,213],[80,314,196,315],{"trials":1624,"activeCount":100},[],{"trials":1626,"activeCount":100},[],{"trials":1628,"activeCount":100},[],{"intervention":588,"totalTrials":9,"cells":1630},{"EARLY_PHASE1":1631,"PHASE1":1633,"PHASE2":1647,"PHASE3":1653,"PHASE4":1655,"NA":1657},{"trials":1632,"activeCount":100},[],{"trials":1634,"activeCount":100},[1635],{"nctId":1636,"briefTitle":1637,"status":286,"phases":1638,"primaryCompletion":1639,"start":1640,"enrollment":387,"conditions":1641,"interventions":1645},"NCT01913015","Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer",[88],"2014-06","2013-07",[1642,1643,1644,1059],"Adenocarcinoma of the Prostate","Hormone-resistant Prostate Cancer","Recurrent Prostate Cancer",[1646],"abiraterone acetate",{"trials":1648,"activeCount":96,"soonestReadout":581},[1649],{"nctId":578,"briefTitle":579,"status":141,"phases":1650,"primaryCompletion":581,"completion":582,"start":583,"enrollment":210,"conditions":1651,"interventions":1652},[89],[585,573,586],[588,589,590,422],{"trials":1654,"activeCount":100},[],{"trials":1656,"activeCount":100},[],{"trials":1658,"activeCount":100},[],{"intervention":1660,"totalTrials":96,"cells":1661},"Ulipristal Acetate",{"EARLY_PHASE1":1662,"PHASE1":1664,"PHASE2":1666,"PHASE3":1676,"PHASE4":1678,"NA":1680},{"trials":1663,"activeCount":100},[],{"trials":1665,"activeCount":100},[],{"trials":1667,"activeCount":96,"soonestReadout":380},[1668],{"nctId":1669,"briefTitle":1670,"status":621,"phases":1671,"primaryCompletion":380,"completion":380,"start":791,"enrollment":382,"conditions":1672,"interventions":1675},"NCT07434128","Mammogram Pretreatment With Ulipristal Acetate",[89],[1673,1674],"Mammography Screening","Breast Density",[1660],{"trials":1677,"activeCount":100},[],{"trials":1679,"activeCount":100},[],{"trials":1681,"activeCount":100},[],{"intervention":1683,"totalTrials":96,"cells":1684},"Olanzapine",{"EARLY_PHASE1":1685,"PHASE1":1687,"PHASE2":1689,"PHASE3":1706,"PHASE4":1708,"NA":1710},{"trials":1686,"activeCount":100},[],{"trials":1688,"activeCount":100},[],{"trials":1690,"activeCount":96,"soonestReadout":249},[1691],{"nctId":1692,"briefTitle":1693,"status":112,"phases":1694,"primaryCompletion":249,"completion":249,"start":1695,"enrollment":1696,"conditions":1697,"interventions":1705},"NCT05705492","Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer",[89],"2024-07-17",66,[175,171,1698,1699,1700,1701,1702,1703,1704,793],"Advanced Esophageal Carcinoma","Metastatic Esophageal Carcinoma","Locally Advanced Colorectal Carcinoma","Locally Advanced Esophageal Carcinoma","Locally Advanced Gastric Carcinoma","Metastatic Colorectal Carcinoma (mCRC)","Advanced Lung Carcinoma",[1683],{"trials":1707,"activeCount":100},[],{"trials":1709,"activeCount":100},[],{"trials":1711,"activeCount":100},[],{"intervention":1713,"totalTrials":96,"cells":1714},"Amiodarone Hydrochloride",{"EARLY_PHASE1":1715,"PHASE1":1717,"PHASE2":1719,"PHASE3":1731,"PHASE4":1733,"NA":1735},{"trials":1716,"activeCount":100},[],{"trials":1718,"activeCount":100},[],{"trials":1720,"activeCount":96,"soonestReadout":1725},[1721],{"nctId":1722,"briefTitle":1723,"status":112,"phases":1724,"primaryCompletion":1725,"completion":1725,"start":1726,"enrollment":12,"conditions":1727,"interventions":1730},"NCT06067438","Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer",[89],"2027-08-30","2024-06-21",[1728,1729],"Atrial Fibrillation","Esophageal Carcinoma",[1713],{"trials":1732,"activeCount":100},[],{"trials":1734,"activeCount":100},[],{"trials":1736,"activeCount":100},[],{"intervention":1304,"totalTrials":96,"cells":1738},{"EARLY_PHASE1":1739,"PHASE1":1741,"PHASE2":1743,"PHASE3":1749,"PHASE4":1751,"NA":1753},{"trials":1740,"activeCount":100},[],{"trials":1742,"activeCount":100},[],{"trials":1744,"activeCount":96,"soonestReadout":558},[1745],{"nctId":1295,"briefTitle":1296,"status":112,"phases":1746,"primaryCompletion":558,"completion":1298,"start":1299,"enrollment":1300,"conditions":1747,"interventions":1748},[88,89],[175,182,1302,467],[1304,1242,1305],{"trials":1750,"activeCount":100},[],{"trials":1752,"activeCount":100},[],{"trials":1754,"activeCount":100},[],{"intervention":1305,"totalTrials":96,"cells":1756},{"EARLY_PHASE1":1757,"PHASE1":1759,"PHASE2":1761,"PHASE3":1767,"PHASE4":1769,"NA":1771},{"trials":1758,"activeCount":100},[],{"trials":1760,"activeCount":100},[],{"trials":1762,"activeCount":96,"soonestReadout":558},[1763],{"nctId":1295,"briefTitle":1296,"status":112,"phases":1764,"primaryCompletion":558,"completion":1298,"start":1299,"enrollment":1300,"conditions":1765,"interventions":1766},[88,89],[175,182,1302,467],[1304,1242,1305],{"trials":1768,"activeCount":100},[],{"trials":1770,"activeCount":100},[],{"trials":1772,"activeCount":100},[],{"intervention":796,"totalTrials":96,"cells":1774},{"EARLY_PHASE1":1775,"PHASE1":1777,"PHASE2":1779,"PHASE3":1785,"PHASE4":1787,"NA":1789},{"trials":1776,"activeCount":100},[],{"trials":1778,"activeCount":100},[],{"trials":1780,"activeCount":96,"soonestReadout":790},[1781],{"nctId":787,"briefTitle":788,"status":621,"phases":1782,"primaryCompletion":790,"completion":790,"start":791,"enrollment":310,"conditions":1783,"interventions":1784},[89],[793,186,189,794],[493,764,796],{"trials":1786,"activeCount":100},[],{"trials":1788,"activeCount":100},[],{"trials":1790,"activeCount":100},[],{"intervention":565,"totalTrials":96,"cells":1792},{"EARLY_PHASE1":1793,"PHASE1":1795,"PHASE2":1797,"PHASE3":1803,"PHASE4":1805,"NA":1807},{"trials":1794,"activeCount":100},[],{"trials":1796,"activeCount":100},[],{"trials":1798,"activeCount":96,"soonestReadout":143},[1799],{"nctId":555,"briefTitle":556,"status":112,"phases":1800,"primaryCompletion":143,"completion":558,"start":559,"enrollment":560,"conditions":1801,"interventions":1802},[88,89],[562,563],[215,492,241,565,422,566],{"trials":1804,"activeCount":100},[],{"trials":1806,"activeCount":100},[],{"trials":1808,"activeCount":100},[],{"intervention":566,"totalTrials":96,"cells":1810},{"EARLY_PHASE1":1811,"PHASE1":1813,"PHASE2":1815,"PHASE3":1821,"PHASE4":1823,"NA":1825},{"trials":1812,"activeCount":100},[],{"trials":1814,"activeCount":100},[],{"trials":1816,"activeCount":96,"soonestReadout":143},[1817],{"nctId":555,"briefTitle":556,"status":112,"phases":1818,"primaryCompletion":143,"completion":558,"start":559,"enrollment":560,"conditions":1819,"interventions":1820},[88,89],[562,563],[215,492,241,565,422,566],{"trials":1822,"activeCount":100},[],{"trials":1824,"activeCount":100},[],{"trials":1826,"activeCount":100},[],{"intervention":692,"totalTrials":96,"cells":1828},{"EARLY_PHASE1":1829,"PHASE1":1831,"PHASE2":1833,"PHASE3":1839,"PHASE4":1841,"NA":1843},{"trials":1830,"activeCount":100},[],{"trials":1832,"activeCount":100},[],{"trials":1834,"activeCount":96,"soonestReadout":64},[1835],{"nctId":62,"briefTitle":63,"status":141,"phases":1836,"primaryCompletion":64,"completion":681,"start":682,"enrollment":683,"conditions":1837,"interventions":1838},[89],[685,686,687,688,689],[65,498,691,220,692,509,693,694],{"trials":1840,"activeCount":100},[],{"trials":1842,"activeCount":100},[],{"trials":1844,"activeCount":100},[],{"intervention":694,"totalTrials":96,"cells":1846},{"EARLY_PHASE1":1847,"PHASE1":1849,"PHASE2":1851,"PHASE3":1857,"PHASE4":1859,"NA":1861},{"trials":1848,"activeCount":100},[],{"trials":1850,"activeCount":100},[],{"trials":1852,"activeCount":96,"soonestReadout":64},[1853],{"nctId":62,"briefTitle":63,"status":141,"phases":1854,"primaryCompletion":64,"completion":681,"start":682,"enrollment":683,"conditions":1855,"interventions":1856},[89],[685,686,687,688,689],[65,498,691,220,692,509,693,694],{"trials":1858,"activeCount":100},[],{"trials":1860,"activeCount":100},[],{"trials":1862,"activeCount":100},[],{"intervention":1864,"totalTrials":96,"cells":1865},"Lutetium Lu 177 Dotatate",{"EARLY_PHASE1":1866,"PHASE1":1868,"PHASE2":1870,"PHASE3":1880,"PHASE4":1882,"NA":1884},{"trials":1867,"activeCount":100},[],{"trials":1869,"activeCount":100},[],{"trials":1871,"activeCount":96,"soonestReadout":1876},[1872],{"nctId":1873,"briefTitle":1874,"status":621,"phases":1875,"primaryCompletion":1876,"completion":1876,"start":1877,"enrollment":740,"conditions":1878,"interventions":1879},"NCT04529044","177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer",[89],"2026-12-20","2025-12-01",[432,444,1253],[1864],{"trials":1881,"activeCount":100},[],{"trials":1883,"activeCount":100},[],{"trials":1885,"activeCount":100},[],{"intervention":1887,"totalTrials":96,"cells":1888},"Atorvastatin",{"EARLY_PHASE1":1889,"PHASE1":1891,"PHASE2":1893,"PHASE3":1908,"PHASE4":1910,"NA":1912},{"trials":1890,"activeCount":100},[],{"trials":1892,"activeCount":100},[],{"trials":1894,"activeCount":96,"soonestReadout":1899},[1895],{"nctId":1896,"briefTitle":1897,"status":141,"phases":1898,"primaryCompletion":1899,"completion":1900,"start":1901,"enrollment":1902,"conditions":1903,"interventions":1907},"NCT06157099","Atorvastatin for Preventing Disease Metastasis in Patients With Resected High-Risk Stage IIA, IIB, or IIIA Melanoma",[89],"2028-03-01","2029-09-01","2024-09-01",150,[1904,1905,1906],"Pathologic Stage IIIA Cutaneous Melanoma AJCC v8","Pathologic Stage IIA Cutaneous Melanoma AJCC v8","Pathologic Stage IIB Cutaneous Melanoma AJCC v8",[1887],{"trials":1909,"activeCount":100},[],{"trials":1911,"activeCount":100},[],{"trials":1913,"activeCount":100},[],{"intervention":1915,"totalTrials":96,"cells":1916},"¹⁸F-Fluoromisonidazole",{"EARLY_PHASE1":1917,"PHASE1":1919,"PHASE2":1921,"PHASE3":1933,"PHASE4":1935,"NA":1937},{"trials":1918,"activeCount":100},[],{"trials":1920,"activeCount":100},[],{"trials":1922,"activeCount":96,"soonestReadout":1927},[1923],{"nctId":1924,"briefTitle":1925,"status":112,"phases":1926,"primaryCompletion":1927,"completion":1928,"start":1929,"enrollment":145,"conditions":1930,"interventions":1932},"NCT03649880","Feasibility of FMISO in Brain Tumors",[89],"2029-01-31","2030-01-31","2019-06-01",[1931],"Malignant Brain Neoplasm",[1915],{"trials":1934,"activeCount":100},[],{"trials":1936,"activeCount":100},[],{"trials":1938,"activeCount":100},[],{"intervention":1940,"totalTrials":96,"cells":1941},"Carfilzomib",{"EARLY_PHASE1":1942,"PHASE1":1944,"PHASE2":1946,"PHASE3":1959,"PHASE4":1961,"NA":1963},{"trials":1943,"activeCount":100},[],{"trials":1945,"activeCount":100},[],{"trials":1947,"activeCount":96,"soonestReadout":1952},[1948],{"nctId":1949,"briefTitle":1950,"status":141,"phases":1951,"primaryCompletion":1952,"completion":1953,"start":1954,"enrollment":395,"conditions":1955,"interventions":1956},"NCT04850599","Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma",[89],"2026-10-15","2029-02-21","2022-06-14",[238,471],[1940,1957,1958],"Isatuximab","Pomalidomide",{"trials":1960,"activeCount":100},[],{"trials":1962,"activeCount":100},[],{"trials":1964,"activeCount":100},[],{"intervention":1957,"totalTrials":96,"cells":1966},{"EARLY_PHASE1":1967,"PHASE1":1969,"PHASE2":1971,"PHASE3":1977,"PHASE4":1979,"NA":1981},{"trials":1968,"activeCount":100},[],{"trials":1970,"activeCount":100},[],{"trials":1972,"activeCount":96,"soonestReadout":1952},[1973],{"nctId":1949,"briefTitle":1950,"status":141,"phases":1974,"primaryCompletion":1952,"completion":1953,"start":1954,"enrollment":395,"conditions":1975,"interventions":1976},[89],[238,471],[1940,1957,1958],{"trials":1978,"activeCount":100},[],{"trials":1980,"activeCount":100},[],{"trials":1982,"activeCount":100},[],{"intervention":1958,"totalTrials":96,"cells":1984},{"EARLY_PHASE1":1985,"PHASE1":1987,"PHASE2":1989,"PHASE3":1995,"PHASE4":1997,"NA":1999},{"trials":1986,"activeCount":100},[],{"trials":1988,"activeCount":100},[],{"trials":1990,"activeCount":96,"soonestReadout":1952},[1991],{"nctId":1949,"briefTitle":1950,"status":141,"phases":1992,"primaryCompletion":1952,"completion":1953,"start":1954,"enrollment":395,"conditions":1993,"interventions":1994},[89],[238,471],[1940,1957,1958],{"trials":1996,"activeCount":100},[],{"trials":1998,"activeCount":100},[],{"trials":2000,"activeCount":100},[],{"intervention":589,"totalTrials":96,"cells":2002},{"EARLY_PHASE1":2003,"PHASE1":2005,"PHASE2":2007,"PHASE3":2013,"PHASE4":2015,"NA":2017},{"trials":2004,"activeCount":100},[],{"trials":2006,"activeCount":100},[],{"trials":2008,"activeCount":96,"soonestReadout":581},[2009],{"nctId":578,"briefTitle":579,"status":141,"phases":2010,"primaryCompletion":581,"completion":582,"start":583,"enrollment":210,"conditions":2011,"interventions":2012},[89],[585,573,586],[588,589,590,422],{"trials":2014,"activeCount":100},[],{"trials":2016,"activeCount":100},[],{"trials":2018,"activeCount":100},[],{"intervention":590,"totalTrials":96,"cells":2020},{"EARLY_PHASE1":2021,"PHASE1":2023,"PHASE2":2025,"PHASE3":2031,"PHASE4":2033,"NA":2035},{"trials":2022,"activeCount":100},[],{"trials":2024,"activeCount":100},[],{"trials":2026,"activeCount":96,"soonestReadout":581},[2027],{"nctId":578,"briefTitle":579,"status":141,"phases":2028,"primaryCompletion":581,"completion":582,"start":583,"enrollment":210,"conditions":2029,"interventions":2030},[89],[585,573,586],[588,589,590,422],{"trials":2032,"activeCount":100},[],{"trials":2034,"activeCount":100},[],{"trials":2036,"activeCount":100},[],{"intervention":707,"totalTrials":96,"cells":2038},{"EARLY_PHASE1":2039,"PHASE1":2041,"PHASE2":2043,"PHASE3":2049,"PHASE4":2051,"NA":2053},{"trials":2040,"activeCount":100},[],{"trials":2042,"activeCount":100},[],{"trials":2044,"activeCount":96,"soonestReadout":69},[2045],{"nctId":67,"briefTitle":68,"status":141,"phases":2046,"primaryCompletion":69,"completion":697,"start":698,"enrollment":395,"conditions":2047,"interventions":2048},[89],[700,701,702,703,704,705],[70,707,678,502,509],{"trials":2050,"activeCount":100},[],{"trials":2052,"activeCount":100},[],{"trials":2054,"activeCount":100},[],{"intervention":756,"totalTrials":96,"cells":2056},{"EARLY_PHASE1":2057,"PHASE1":2059,"PHASE2":2061,"PHASE3":2067,"PHASE4":2069,"NA":2071},{"trials":2058,"activeCount":100},[],{"trials":2060,"activeCount":100},[],{"trials":2062,"activeCount":96,"soonestReadout":750},[2063],{"nctId":747,"briefTitle":748,"status":112,"phases":2064,"primaryCompletion":750,"completion":751,"start":752,"enrollment":726,"conditions":2065,"interventions":2066},[88,89],[754],[756,745,715],{"trials":2068,"activeCount":100},[],{"trials":2070,"activeCount":100},[],{"trials":2072,"activeCount":100},[],{"intervention":2074,"totalTrials":96,"cells":2075},"Gruticibart",{"EARLY_PHASE1":2076,"PHASE1":2078,"PHASE2":2080,"PHASE3":2092,"PHASE4":2094,"NA":2096},{"trials":2077,"activeCount":100},[],{"trials":2079,"activeCount":100},[],{"trials":2081,"activeCount":96,"soonestReadout":2086},[2082],{"nctId":2083,"briefTitle":2084,"status":621,"phases":2085,"primaryCompletion":2086,"completion":2087,"start":2088,"enrollment":12,"conditions":2089,"interventions":2091},"NCT07498517","Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT",[89],"2029-02-02","2029-10-02","2026-02-28",[2090],"Thrombosis",[2074],{"trials":2093,"activeCount":100},[],{"trials":2095,"activeCount":100},[],{"trials":2097,"activeCount":100},[],{"intervention":386,"totalTrials":96,"cells":2099},{"EARLY_PHASE1":2100,"PHASE1":2102,"PHASE2":2104,"PHASE3":2110,"PHASE4":2112,"NA":2114},{"trials":2101,"activeCount":100},[],{"trials":2103,"activeCount":100},[],{"trials":2105,"activeCount":96,"soonestReadout":379},[2106],{"nctId":376,"briefTitle":377,"status":112,"phases":2107,"primaryCompletion":379,"completion":380,"start":381,"enrollment":382,"conditions":2108,"interventions":2109},[89],[384],[196,221,386],{"trials":2111,"activeCount":100},[],{"trials":2113,"activeCount":100},[],{"trials":2115,"activeCount":100},[],{"intervention":1083,"totalTrials":235,"cells":2117},{"EARLY_PHASE1":2118,"PHASE1":2145,"PHASE2":2156,"PHASE3":2198,"PHASE4":2200,"NA":2202},{"trials":2119,"activeCount":100},[2120,2133],{"nctId":2121,"briefTitle":2122,"status":286,"phases":2123,"primaryCompletion":2124,"completion":2124,"start":2125,"enrollment":9,"conditions":2126,"interventions":2132},"NCT03280277","Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Locally Advanced Rectal Cancer",[87],"2021-08-26","2018-04-27",[2127,2128,2129,2130,2131],"Locally Advanced Rectal Carcinoma","Stage III Rectal Cancer AJCC v7","Stage IIIA Rectal Cancer AJCC v7","Stage IIIB Rectal Cancer AJCC v7","Stage IIIC Rectal Cancer AJCC v7",[1083],{"nctId":2134,"briefTitle":2135,"status":883,"phases":2136,"primaryCompletion":2137,"completion":2137,"start":2125,"enrollment":100,"conditions":2138,"interventions":2144},"NCT02857218","Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Stage IIB-IIIC Esophageal Cancer",[87],"2021-08-19",[2139,2140,2141,2142,2143],"Stage IIB Esophageal Cancer AJCC v7","Stage III Esophageal Cancer AJCC v7","Stage IIIA Esophageal Cancer AJCC v7","Stage IIIB Esophageal Cancer AJCC v7","Stage IIIC Esophageal Cancer AJCC v7",[1083],{"trials":2146,"activeCount":100},[2147],{"nctId":2148,"briefTitle":2149,"status":286,"phases":2150,"primaryCompletion":2151,"completion":2151,"start":2152,"enrollment":1181,"conditions":2153,"interventions":2155},"NCT00769093","Assessing Dynamic Magnetic Resonance (MR) Imaging in Patients With Recurrent High Grade Glioma Receiving Chemotherapy",[88],"2014-07","2008-10",[2154],"Brain Neoplasms",[1083],{"trials":2157,"activeCount":96,"soonestReadout":2187},[2158,2162,2174,2183,2194],{"nctId":1074,"briefTitle":1075,"status":286,"phases":2159,"primaryCompletion":1077,"completion":1077,"start":1078,"enrollment":9,"conditions":2160,"interventions":2161},[89],[1080,1081],[1083,512],{"nctId":2163,"briefTitle":2164,"status":286,"phases":2165,"primaryCompletion":2166,"completion":2167,"start":2168,"enrollment":310,"conditions":2169,"interventions":2172},"NCT00659126","Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors",[89],"2019-12-31","2020-12-31","2006-11-16",[2170,2171],"Metastatic Malignant Neoplasm in the Brain","Primary Brain Neoplasm",[1083,2173],"Gadolinium",{"nctId":2175,"briefTitle":2176,"status":883,"phases":2177,"primaryCompletion":2178,"completion":2178,"start":2179,"enrollment":100,"conditions":2180,"interventions":2182},"NCT03234309","Ferumoxytol in Magnetic Resonance Imaging of Pediatric Patients With Brain Tumors",[89],"2021-08-30","2017-10-20",[2181],"Brain Neoplasm",[1083],{"nctId":2184,"briefTitle":2185,"status":112,"phases":2186,"primaryCompletion":2187,"completion":2188,"start":2189,"enrollment":1902,"conditions":2190,"interventions":2193},"NCT03270059","Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System",[89],"2027-12-15","2028-12-15","2017-10-06",[2191,2192,2170],"Central Nervous System Neoplasm","Cranial Nerve Disorder",[1083,2173],{"nctId":1103,"briefTitle":1104,"status":286,"phases":2195,"primaryCompletion":1106,"completion":1107,"start":1108,"enrollment":1109,"conditions":2196,"interventions":2197},[89],[1111],[1083,512],{"trials":2199,"activeCount":100},[],{"trials":2201,"activeCount":100},[],{"trials":2203,"activeCount":100},[2204,2214,2225],{"nctId":2205,"briefTitle":2206,"status":205,"phases":2207,"primaryCompletion":2208,"completion":2208,"start":2209,"enrollment":2210,"conditions":2211,"interventions":2212},"NCT02359097","Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma",[92],"2021-03-12","2015-01-06",29,[1111],[1083,2213],"Gadoteridol",{"nctId":2215,"briefTitle":2216,"status":286,"phases":2217,"primaryCompletion":2218,"completion":2218,"start":2219,"enrollment":2220,"conditions":2221,"interventions":2224},"NCT02070705","DCE MRI in Patients With Pancreatic Cancer",[92],"2024-08-07","2014-01-31",77,[2222,685,2223],"Familial Pancreatic Cancer","Pancreatic Intraductal Papillary-Mucinous Neoplasm",[1083],{"nctId":2226,"briefTitle":2227,"status":205,"phases":2228,"primaryCompletion":2229,"completion":2230,"start":2231,"enrollment":2232,"conditions":2233,"interventions":2234},"NCT00103038","Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases",[92],"2016-05-10","2016-06-10","2004-06-04",155,[859,986,2170],[1083,2173],{"intervention":271,"totalTrials":740,"cells":2236},{"EARLY_PHASE1":2237,"PHASE1":2239,"PHASE2":2249,"PHASE3":2280,"PHASE4":2282,"NA":2284},{"trials":2238,"activeCount":100},[],{"trials":2240,"activeCount":100},[2241,2245],{"nctId":203,"briefTitle":204,"status":205,"phases":2242,"primaryCompletion":207,"completion":208,"start":209,"enrollment":210,"conditions":2243,"interventions":2244},[88],[212,213],[215,196,216,70,217,218,219,220,221,222,223,224,225,226,227,228],{"nctId":946,"briefTitle":947,"status":205,"phases":2246,"primaryCompletion":949,"start":950,"enrollment":951,"conditions":2247,"interventions":2248},[88],[238,471],[215,70,954,517],{"trials":2250,"activeCount":96,"soonestReadout":69},[2251,2255,2259,2263,2272,2276],{"nctId":259,"briefTitle":260,"status":205,"phases":2252,"primaryCompletion":262,"completion":262,"start":263,"enrollment":264,"conditions":2253,"interventions":2254},[89],[24],[267,268,269,270,271,272,273],{"nctId":653,"briefTitle":654,"status":205,"phases":2256,"primaryCompletion":345,"completion":656,"start":657,"enrollment":658,"conditions":2257,"interventions":2258},[89],[660,661],[663,271,664,665,666,667,668],{"nctId":275,"briefTitle":276,"status":205,"phases":2260,"primaryCompletion":278,"completion":278,"start":263,"enrollment":96,"conditions":2261,"interventions":2262},[89],[24],[270,271,281,273,282],{"nctId":2264,"briefTitle":2265,"status":286,"phases":2266,"primaryCompletion":346,"completion":346,"start":2267,"enrollment":9,"conditions":2268,"interventions":2269},"NCT00227682","Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma",[89],"2004-06",[350],[2270,271,2271],"arsenic trioxide","thalidomide",{"nctId":328,"briefTitle":329,"status":286,"phases":2273,"primaryCompletion":331,"completion":332,"start":333,"enrollment":235,"conditions":2274,"interventions":2275},[89],[18],[269,270,271,336,326,273,337,338,339],{"nctId":67,"briefTitle":68,"status":141,"phases":2277,"primaryCompletion":69,"completion":697,"start":698,"enrollment":395,"conditions":2278,"interventions":2279},[89],[700,701,702,703,704,705],[70,707,678,502,509],{"trials":2281,"activeCount":100},[],{"trials":2283,"activeCount":100},[],{"trials":2285,"activeCount":100},[2286,2295],{"nctId":2287,"briefTitle":2288,"status":205,"phases":2289,"primaryCompletion":2290,"completion":2290,"start":916,"enrollment":310,"conditions":2291,"interventions":2293},"NCT00248547","Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant",[92],"2009-01",[2292],"Cancer",[663,271,2294],"ondansetron",{"nctId":2296,"briefTitle":2297,"status":205,"phases":2298,"primaryCompletion":2299,"completion":2300,"start":2301,"enrollment":2302,"conditions":2303,"interventions":2309},"NCT01748942","Dexamethasone in Reducing Oral Pain and Dry Mouth After Surgery in Patients With Oropharyngeal Cancer",[92],"2016-07","2017-03-29","2012-12",76,[2304,2305,2306,2307,2308],"Dysphagia","Pain","Stage I Oropharyngeal Squamous Cell Carcinoma","Stage II Oropharyngeal Squamous Cell Carcinoma","Stage III Oropharyngeal Squamous Cell Carcinoma",[70,70],{"intervention":241,"totalTrials":1181,"cells":2311},{"EARLY_PHASE1":2312,"PHASE1":2314,"PHASE2":2320,"PHASE3":2346,"PHASE4":2348,"NA":2350},{"trials":2313,"activeCount":100},[],{"trials":2315,"activeCount":100},[2316],{"nctId":230,"briefTitle":231,"status":205,"phases":2317,"primaryCompletion":233,"completion":233,"start":234,"enrollment":235,"conditions":2318,"interventions":2319},[88],[237,238],[240,196,241,242,243,221,244],{"trials":2321,"activeCount":96,"soonestReadout":143},[2322,2334,2338,2342],{"nctId":2323,"briefTitle":2324,"status":205,"phases":2325,"primaryCompletion":2208,"completion":2208,"start":2326,"enrollment":2327,"conditions":2328,"interventions":2333},"NCT00303849","Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors",[88,89],"2005-09-15",33,[2329,2330,2331,2332],"Anaplastic Oligoastrocytoma","Anaplastic Oligodendroglioma","Mixed Glioma","Oligoastrocytoma",[299,241,988,861,243,862],{"nctId":555,"briefTitle":556,"status":112,"phases":2335,"primaryCompletion":143,"completion":558,"start":559,"enrollment":560,"conditions":2336,"interventions":2337},[88,89],[562,563],[215,492,241,565,422,566],{"nctId":284,"briefTitle":285,"status":286,"phases":2339,"primaryCompletion":288,"completion":289,"start":290,"enrollment":291,"conditions":2340,"interventions":2341},[89],[293,294,24,295],[297,215,241,298,299,300,301,302,196],{"nctId":341,"briefTitle":342,"status":286,"phases":2343,"primaryCompletion":344,"completion":345,"start":346,"enrollment":347,"conditions":2344,"interventions":2345},[89],[349,18,24,350,33,351,352],[354,267,355,356,269,357,270,358,359,360,273,337,361,362],{"trials":2347,"activeCount":100},[],{"trials":2349,"activeCount":100},[],{"trials":2351,"activeCount":100},[2352],{"nctId":912,"briefTitle":913,"status":286,"phases":2353,"primaryCompletion":915,"completion":915,"start":916,"enrollment":917,"conditions":2354,"interventions":2355},[92],[349,919,18,24,350,33,920,921],[267,355,269,357,358,273],{"intervention":2173,"totalTrials":395,"cells":2357},{"EARLY_PHASE1":2358,"PHASE1":2373,"PHASE2":2375,"PHASE3":2385,"PHASE4":2387,"NA":2389},{"trials":2359,"activeCount":100},[2360],{"nctId":2361,"briefTitle":2362,"status":205,"phases":2363,"primaryCompletion":2364,"completion":2365,"start":2366,"enrollment":2367,"conditions":2368,"interventions":2371},"NCT00978562","DSC-MRI With Ferumoxytol and DCE-MRI With Gadolinium in Imaging Vascular Properties in Younger Patients With Brain Tumors",[87],"2015-12","2018-12","2009-08",14,[2369,2370],"Childhood Brain Neoplasm","Recurrent Childhood Brain Neoplasm",[2372,2173],"Ferumoxytol Non-Stoichiometric Magnetite",{"trials":2374,"activeCount":100},[],{"trials":2376,"activeCount":96,"soonestReadout":2187},[2377,2381],{"nctId":2163,"briefTitle":2164,"status":286,"phases":2378,"primaryCompletion":2166,"completion":2167,"start":2168,"enrollment":310,"conditions":2379,"interventions":2380},[89],[2170,2171],[1083,2173],{"nctId":2184,"briefTitle":2185,"status":112,"phases":2382,"primaryCompletion":2187,"completion":2188,"start":2189,"enrollment":1902,"conditions":2383,"interventions":2384},[89],[2191,2192,2170],[1083,2173],{"trials":2386,"activeCount":100},[],{"trials":2388,"activeCount":100},[],{"trials":2390,"activeCount":100},[2391,2399],{"nctId":2392,"briefTitle":2393,"status":205,"phases":2394,"primaryCompletion":1639,"completion":1639,"start":2395,"enrollment":2367,"conditions":2396,"interventions":2398},"NCT00660543","MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy",[92],"2006-12",[2397],"Adult Brain Glioblastoma",[2173,2372],{"nctId":2226,"briefTitle":2227,"status":205,"phases":2400,"primaryCompletion":2229,"completion":2230,"start":2231,"enrollment":2232,"conditions":2401,"interventions":2402},[92],[859,986,2170],[1083,2173],{"intervention":85,"totalTrials":917,"cells":2404},{"EARLY_PHASE1":2405,"PHASE1":2415,"PHASE2":2429,"PHASE3":2431,"PHASE4":2433,"NA":2435},{"trials":2406,"activeCount":96,"soonestReadout":84},[2407,2411],{"nctId":1247,"briefTitle":1248,"status":883,"phases":2408,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":100,"conditions":2409,"interventions":2410},[87],[1183,175,1184,1185,1186,1187,1188,432,1228,1253,1254,574,474,1189,475,1190,476],[1256,1257,1258,1259,483,65,299,85,495,1260,1261,1262,678,1193,505,1263,508,1242,510,513,1264,521,523,1265,524],{"nctId":82,"briefTitle":83,"status":112,"phases":2412,"primaryCompletion":84,"completion":770,"start":771,"enrollment":12,"conditions":2413,"interventions":2414},[87],[773,774,474,475,476,775,776,777],[85,508,779,780,781,764],{"trials":2416,"activeCount":96,"soonestReadout":74},[2417,2425],{"nctId":72,"briefTitle":73,"status":141,"phases":2418,"primaryCompletion":74,"completion":2419,"start":2420,"enrollment":16,"conditions":2421,"interventions":2424},[88],"2026-10-01","2022-08-09",[443,445,474,2422,2423,475,476],"Stage IIA Pancreatic Cancer AJCC v8","Stage IIB Pancreatic Cancer AJCC v8",[75,85],{"nctId":425,"briefTitle":426,"status":286,"phases":2426,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":2427,"interventions":2428},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":2430,"activeCount":100},[],{"trials":2432,"activeCount":100},[],{"trials":2434,"activeCount":100},[],{"trials":2436,"activeCount":100},[],{"intervention":224,"totalTrials":395,"cells":2438},{"EARLY_PHASE1":2439,"PHASE1":2441,"PHASE2":2451,"PHASE3":2475,"PHASE4":2477,"NA":2479},{"trials":2440,"activeCount":100},[],{"trials":2442,"activeCount":96,"soonestReadout":412},[2443,2447],{"nctId":203,"briefTitle":204,"status":205,"phases":2444,"primaryCompletion":207,"completion":208,"start":209,"enrollment":210,"conditions":2445,"interventions":2446},[88],[212,213],[215,196,216,70,217,218,219,220,221,222,223,224,225,226,227,228],{"nctId":409,"briefTitle":410,"status":141,"phases":2448,"primaryCompletion":412,"completion":412,"start":413,"enrollment":414,"conditions":2449,"interventions":2450},[88],[416,417,418,419,420],[216,221,422,224,315,423],{"trials":2452,"activeCount":100},[2453,2457,2471],{"nctId":850,"briefTitle":851,"status":852,"phases":2454,"primaryCompletion":854,"completion":855,"start":856,"enrollment":857,"conditions":2455,"interventions":2456},[88,89],[859],[299,861,221,224,862],{"nctId":2458,"briefTitle":2459,"status":286,"phases":2460,"primaryCompletion":2290,"completion":2461,"start":2462,"enrollment":9,"conditions":2463,"interventions":2464},"NCT00691652","Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma",[88,89],"2009-04","2008-05",[24],[2465,2466,2467,2468,2469,2470],"rituximab","clofarabine","DNA methylation analysis","gene expression analysis","microarray analysis","polymerase chain reaction",{"nctId":1607,"briefTitle":1608,"status":205,"phases":2472,"primaryCompletion":1610,"completion":1611,"start":1612,"enrollment":1613,"conditions":2473,"interventions":2474},[89],[1615,451,1616,1617],[314,224,525],{"trials":2476,"activeCount":100},[],{"trials":2478,"activeCount":100},[],{"trials":2480,"activeCount":100},[],{"intervention":216,"totalTrials":395,"cells":2482},{"EARLY_PHASE1":2483,"PHASE1":2485,"PHASE2":2499,"PHASE3":2526,"PHASE4":2528,"NA":2530},{"trials":2484,"activeCount":100},[],{"trials":2486,"activeCount":96,"soonestReadout":412},[2487,2491,2495],{"nctId":203,"briefTitle":204,"status":205,"phases":2488,"primaryCompletion":207,"completion":208,"start":209,"enrollment":210,"conditions":2489,"interventions":2490},[88],[212,213],[215,196,216,70,217,218,219,220,221,222,223,224,225,226,227,228],{"nctId":409,"briefTitle":410,"status":141,"phases":2492,"primaryCompletion":412,"completion":412,"start":413,"enrollment":414,"conditions":2493,"interventions":2494},[88],[416,417,418,419,420],[216,221,422,224,315,423],{"nctId":425,"briefTitle":426,"status":286,"phases":2496,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":2497,"interventions":2498},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":2500,"activeCount":100},[2501,2514],{"nctId":2502,"briefTitle":2503,"status":205,"phases":2504,"primaryCompletion":2505,"completion":2506,"start":2507,"enrollment":597,"conditions":2508,"interventions":2513},"NCT01441882","Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia",[89],"2016-07-12","2018-01-01","2011-10",[462,2509,2510,2511,2512],"Stage I Chronic Lymphocytic Leukemia","Stage II Chronic Lymphocytic Leukemia","Stage III Chronic Lymphocytic Leukemia","Stage IV Chronic Lymphocytic Leukemia",[216],{"nctId":2515,"briefTitle":2516,"status":286,"phases":2517,"primaryCompletion":2518,"completion":2519,"start":2520,"enrollment":22,"conditions":2521,"interventions":2524},"NCT01620216","Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia",[89],"2017-04-25","2017-04-30","2012-05-11",[2522,2523,449,450,460,461],"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome","Chronic Myelomonocytic Leukemia",[216,219,2525,514,223,516,518,226,519,227],"Pacritinib",{"trials":2527,"activeCount":100},[],{"trials":2529,"activeCount":100},[],{"trials":2531,"activeCount":100},[],{"intervention":361,"totalTrials":917,"cells":2533},{"EARLY_PHASE1":2534,"PHASE1":2536,"PHASE2":2542,"PHASE3":2560,"PHASE4":2562,"NA":2564},{"trials":2535,"activeCount":100},[],{"trials":2537,"activeCount":96,"soonestReadout":380},[2538],{"nctId":619,"briefTitle":620,"status":621,"phases":2539,"primaryCompletion":380,"completion":623,"start":624,"enrollment":310,"conditions":2540,"interventions":2541},[88],[213],[80,215,627,516,244],{"trials":2543,"activeCount":100},[2544,2552,2556],{"nctId":2545,"briefTitle":2546,"status":286,"phases":2547,"primaryCompletion":2548,"completion":2548,"start":872,"enrollment":96,"conditions":2549,"interventions":2551},"NCT00243009","Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Metastatic Kidney Cancer That Cannot Be Removed By Surgery",[89],"2006-04",[2550],"Kidney Cancer",[357,359,361],{"nctId":868,"briefTitle":869,"status":205,"phases":2553,"primaryCompletion":871,"completion":871,"start":872,"enrollment":873,"conditions":2554,"interventions":2555},[88,89],[349,18,24,350,33,351,875],[877,355,357,359,361,878,879,221],{"nctId":341,"briefTitle":342,"status":286,"phases":2557,"primaryCompletion":344,"completion":345,"start":346,"enrollment":347,"conditions":2558,"interventions":2559},[89],[349,18,24,350,33,351,352],[354,267,355,356,269,357,270,358,359,360,273,337,361,362],{"trials":2561,"activeCount":100},[],{"trials":2563,"activeCount":100},[],{"trials":2565,"activeCount":100},[],{"intervention":244,"totalTrials":387,"cells":2567},{"EARLY_PHASE1":2568,"PHASE1":2570,"PHASE2":2580,"PHASE3":2586,"PHASE4":2588,"NA":2590},{"trials":2569,"activeCount":100},[],{"trials":2571,"activeCount":96,"soonestReadout":380},[2572,2576],{"nctId":230,"briefTitle":231,"status":205,"phases":2573,"primaryCompletion":233,"completion":233,"start":234,"enrollment":235,"conditions":2574,"interventions":2575},[88],[237,238],[240,196,241,242,243,221,244],{"nctId":619,"briefTitle":620,"status":621,"phases":2577,"primaryCompletion":380,"completion":623,"start":624,"enrollment":310,"conditions":2578,"interventions":2579},[88],[213],[80,215,627,516,244],{"trials":2581,"activeCount":100},[2582],{"nctId":341,"briefTitle":342,"status":286,"phases":2583,"primaryCompletion":344,"completion":345,"start":346,"enrollment":347,"conditions":2584,"interventions":2585},[89],[349,18,24,350,33,351,352],[354,267,355,356,269,357,270,358,359,360,273,337,361,362],{"trials":2587,"activeCount":100},[],{"trials":2589,"activeCount":100},[],{"trials":2591,"activeCount":100},[],{"intervention":516,"totalTrials":387,"cells":2593},{"EARLY_PHASE1":2594,"PHASE1":2596,"PHASE2":2606,"PHASE3":2612,"PHASE4":2614,"NA":2616},{"trials":2595,"activeCount":100},[],{"trials":2597,"activeCount":96,"soonestReadout":380},[2598,2602],{"nctId":425,"briefTitle":426,"status":286,"phases":2599,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":2600,"interventions":2601},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"nctId":619,"briefTitle":620,"status":621,"phases":2603,"primaryCompletion":380,"completion":623,"start":624,"enrollment":310,"conditions":2604,"interventions":2605},[88],[213],[80,215,627,516,244],{"trials":2607,"activeCount":100},[2608],{"nctId":2515,"briefTitle":2516,"status":286,"phases":2609,"primaryCompletion":2518,"completion":2519,"start":2520,"enrollment":22,"conditions":2610,"interventions":2611},[89],[2522,2523,449,450,460,461],[216,219,2525,514,223,516,518,226,519,227],{"trials":2613,"activeCount":100},[],{"trials":2615,"activeCount":100},[],{"trials":2617,"activeCount":100},[],{"intervention":495,"totalTrials":387,"cells":2619},{"EARLY_PHASE1":2620,"PHASE1":2626,"PHASE2":2637,"PHASE3":2639,"PHASE4":2641,"NA":2643},{"trials":2621,"activeCount":100},[2622],{"nctId":1247,"briefTitle":1248,"status":883,"phases":2623,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":100,"conditions":2624,"interventions":2625},[87],[1183,175,1184,1185,1186,1187,1188,432,1228,1253,1254,574,474,1189,475,1190,476],[1256,1257,1258,1259,483,65,299,85,495,1260,1261,1262,678,1193,505,1263,508,1242,510,513,1264,521,523,1265,524],{"trials":2627,"activeCount":96,"soonestReadout":49},[2628,2633],{"nctId":47,"briefTitle":48,"status":141,"phases":2629,"primaryCompletion":49,"completion":249,"start":2630,"enrollment":19,"conditions":2631,"interventions":2632},[88],"2022-10-28",[213,450,461],[50,495],{"nctId":425,"briefTitle":426,"status":286,"phases":2634,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":2635,"interventions":2636},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":2638,"activeCount":100},[],{"trials":2640,"activeCount":100},[],{"trials":2642,"activeCount":100},[],{"trials":2644,"activeCount":100},[],{"intervention":60,"totalTrials":96,"cells":2646},{"EARLY_PHASE1":2647,"PHASE1":2649,"PHASE2":2663,"PHASE3":2665,"PHASE4":2667,"NA":2669},{"trials":2648,"activeCount":100},[],{"trials":2650,"activeCount":96,"soonestReadout":59},[2651],{"nctId":57,"briefTitle":58,"status":141,"phases":2652,"primaryCompletion":59,"completion":1250,"start":2653,"enrollment":597,"conditions":2654,"interventions":2662},[88],"2019-12-11",[2655,2656,2657,2658,2659,2660,2661],"Rectal Adenocarcinoma","Stage IIA Rectal Cancer AJCC v8","Stage IIB Rectal Cancer AJCC v8","Stage III Rectal Cancer AJCC v8","Stage IIIA Rectal Cancer AJCC v8","Stage IIIB Rectal Cancer AJCC v8","Stage IIIC Rectal Cancer AJCC v8",[60],{"trials":2664,"activeCount":100},[],{"trials":2666,"activeCount":100},[],{"trials":2668,"activeCount":100},[],{"trials":2670,"activeCount":100},[],{"intervention":45,"totalTrials":96,"cells":2672},{"EARLY_PHASE1":2673,"PHASE1":2675,"PHASE2":2688,"PHASE3":2690,"PHASE4":2692,"NA":2694},{"trials":2674,"activeCount":100},[],{"trials":2676,"activeCount":96,"soonestReadout":44},[2677],{"nctId":42,"briefTitle":43,"status":141,"phases":2678,"primaryCompletion":44,"completion":2679,"start":2680,"enrollment":16,"conditions":2681,"interventions":2687},[88],"2033-04-14","2018-03-19",[2682,2683,2684,2685,28,2686],"Liposarcoma","Malignant Abdominal Neoplasm","Malignant Retroperitoneal Neoplasm","Malignant Scrotal Neoplasm","Malignant Spermatic Cord Neoplasm",[45],{"trials":2689,"activeCount":100},[],{"trials":2691,"activeCount":100},[],{"trials":2693,"activeCount":100},[],{"trials":2695,"activeCount":100},[],{"intervention":407,"totalTrials":96,"cells":2697},{"EARLY_PHASE1":2698,"PHASE1":2700,"PHASE2":2706,"PHASE3":2708,"PHASE4":2710,"NA":2712},{"trials":2699,"activeCount":100},[],{"trials":2701,"activeCount":96,"soonestReadout":79},[2702],{"nctId":77,"briefTitle":78,"status":112,"phases":2703,"primaryCompletion":79,"completion":403,"start":54,"enrollment":323,"conditions":2704,"interventions":2705},[88],[213,405],[80,407,315],{"trials":2707,"activeCount":100},[],{"trials":2709,"activeCount":100},[],{"trials":2711,"activeCount":100},[],{"trials":2713,"activeCount":100},[],{"intervention":423,"totalTrials":96,"cells":2715},{"EARLY_PHASE1":2716,"PHASE1":2718,"PHASE2":2724,"PHASE3":2726,"PHASE4":2728,"NA":2730},{"trials":2717,"activeCount":100},[],{"trials":2719,"activeCount":96,"soonestReadout":412},[2720],{"nctId":409,"briefTitle":410,"status":141,"phases":2721,"primaryCompletion":412,"completion":412,"start":413,"enrollment":414,"conditions":2722,"interventions":2723},[88],[416,417,418,419,420],[216,221,422,224,315,423],{"trials":2725,"activeCount":100},[],{"trials":2727,"activeCount":100},[],{"trials":2729,"activeCount":100},[],{"trials":2731,"activeCount":100},[],{"intervention":730,"totalTrials":96,"cells":2733},{"EARLY_PHASE1":2734,"PHASE1":2736,"PHASE2":2742,"PHASE3":2744,"PHASE4":2746,"NA":2748},{"trials":2735,"activeCount":100},[],{"trials":2737,"activeCount":96,"soonestReadout":569},[2738],{"nctId":722,"briefTitle":723,"status":112,"phases":2739,"primaryCompletion":569,"completion":581,"start":725,"enrollment":726,"conditions":2740,"interventions":2741},[88],[728],[730,715,731],{"trials":2743,"activeCount":100},[],{"trials":2745,"activeCount":100},[],{"trials":2747,"activeCount":100},[],{"trials":2749,"activeCount":100},[],{"intervention":731,"totalTrials":96,"cells":2751},{"EARLY_PHASE1":2752,"PHASE1":2754,"PHASE2":2760,"PHASE3":2762,"PHASE4":2764,"NA":2766},{"trials":2753,"activeCount":100},[],{"trials":2755,"activeCount":96,"soonestReadout":569},[2756],{"nctId":722,"briefTitle":723,"status":112,"phases":2757,"primaryCompletion":569,"completion":581,"start":725,"enrollment":726,"conditions":2758,"interventions":2759},[88],[728],[730,715,731],{"trials":2761,"activeCount":100},[],{"trials":2763,"activeCount":100},[],{"trials":2765,"activeCount":100},[],{"trials":2767,"activeCount":100},[],{"intervention":50,"totalTrials":96,"cells":2769},{"EARLY_PHASE1":2770,"PHASE1":2772,"PHASE2":2778,"PHASE3":2780,"PHASE4":2782,"NA":2784},{"trials":2771,"activeCount":100},[],{"trials":2773,"activeCount":96,"soonestReadout":49},[2774],{"nctId":47,"briefTitle":48,"status":141,"phases":2775,"primaryCompletion":49,"completion":249,"start":2630,"enrollment":19,"conditions":2776,"interventions":2777},[88],[213,450,461],[50,495],{"trials":2779,"activeCount":100},[],{"trials":2781,"activeCount":100},[],{"trials":2783,"activeCount":100},[],{"trials":2785,"activeCount":100},[],{"intervention":75,"totalTrials":96,"cells":2787},{"EARLY_PHASE1":2788,"PHASE1":2790,"PHASE2":2796,"PHASE3":2798,"PHASE4":2800,"NA":2802},{"trials":2789,"activeCount":100},[],{"trials":2791,"activeCount":96,"soonestReadout":74},[2792],{"nctId":72,"briefTitle":73,"status":141,"phases":2793,"primaryCompletion":74,"completion":2419,"start":2420,"enrollment":16,"conditions":2794,"interventions":2795},[88],[443,445,474,2422,2423,475,476],[75,85],{"trials":2797,"activeCount":100},[],{"trials":2799,"activeCount":100},[],{"trials":2801,"activeCount":100},[],{"trials":2803,"activeCount":100},[],{"intervention":255,"totalTrials":96,"cells":2805},{"EARLY_PHASE1":2806,"PHASE1":2808,"PHASE2":2814,"PHASE3":2816,"PHASE4":2818,"NA":2820},{"trials":2807,"activeCount":100},[],{"trials":2809,"activeCount":96,"soonestReadout":249},[2810],{"nctId":246,"briefTitle":247,"status":112,"phases":2811,"primaryCompletion":249,"completion":249,"start":250,"enrollment":251,"conditions":2812,"interventions":2813},[88],[213],[196,254,255],{"trials":2815,"activeCount":100},[],{"trials":2817,"activeCount":100},[],{"trials":2819,"activeCount":100},[],{"trials":2821,"activeCount":100},[],{"intervention":779,"totalTrials":9,"cells":2823},{"EARLY_PHASE1":2824,"PHASE1":2830,"PHASE2":2832,"PHASE3":2838,"PHASE4":2840,"NA":2842},{"trials":2825,"activeCount":96,"soonestReadout":84},[2826],{"nctId":82,"briefTitle":83,"status":112,"phases":2827,"primaryCompletion":84,"completion":770,"start":771,"enrollment":12,"conditions":2828,"interventions":2829},[87],[773,774,474,475,476,775,776,777],[85,508,779,780,781,764],{"trials":2831,"activeCount":100},[],{"trials":2833,"activeCount":100},[2834],{"nctId":1198,"briefTitle":1199,"status":883,"phases":2835,"primaryCompletion":1201,"completion":1202,"start":1203,"enrollment":100,"conditions":2836,"interventions":2837},[89],[773,774,474,475,476,478],[779,693,505],{"trials":2839,"activeCount":100},[],{"trials":2841,"activeCount":100},[],{"trials":2843,"activeCount":100},[],{"intervention":508,"totalTrials":917,"cells":2845},{"EARLY_PHASE1":2846,"PHASE1":2856,"PHASE2":2866,"PHASE3":2868,"PHASE4":2870,"NA":2872},{"trials":2847,"activeCount":96,"soonestReadout":84},[2848,2852],{"nctId":1247,"briefTitle":1248,"status":883,"phases":2849,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":100,"conditions":2850,"interventions":2851},[87],[1183,175,1184,1185,1186,1187,1188,432,1228,1253,1254,574,474,1189,475,1190,476],[1256,1257,1258,1259,483,65,299,85,495,1260,1261,1262,678,1193,505,1263,508,1242,510,513,1264,521,523,1265,524],{"nctId":82,"briefTitle":83,"status":112,"phases":2853,"primaryCompletion":84,"completion":770,"start":771,"enrollment":12,"conditions":2854,"interventions":2855},[87],[773,774,474,475,476,775,776,777],[85,508,779,780,781,764],{"trials":2857,"activeCount":100},[2858,2862],{"nctId":1381,"briefTitle":1382,"status":205,"phases":2859,"primaryCompletion":1384,"completion":1385,"start":1386,"enrollment":387,"conditions":2860,"interventions":2861},[88],[432,1388,1389,1390,1391,1392],[493,508],{"nctId":425,"briefTitle":426,"status":286,"phases":2863,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":2864,"interventions":2865},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":2867,"activeCount":100},[],{"trials":2869,"activeCount":100},[],{"trials":2871,"activeCount":100},[],{"trials":2873,"activeCount":100},[],{"intervention":2875,"totalTrials":96,"cells":2876},"Myc Inhibitor OMO-103",{"EARLY_PHASE1":2877,"PHASE1":2886,"PHASE2":2888,"PHASE3":2890,"PHASE4":2892,"NA":2894},{"trials":2878,"activeCount":96,"soonestReadout":380},[2879],{"nctId":2880,"briefTitle":2881,"status":112,"phases":2882,"primaryCompletion":380,"completion":380,"start":2883,"enrollment":22,"conditions":2884,"interventions":2885},"NCT07089940","OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma",[87],"2026-01-27",[773,774,474,475,476],[2875],{"trials":2887,"activeCount":100},[],{"trials":2889,"activeCount":100},[],{"trials":2891,"activeCount":100},[],{"trials":2893,"activeCount":100},[],{"trials":2895,"activeCount":100},[],{"intervention":780,"totalTrials":96,"cells":2897},{"EARLY_PHASE1":2898,"PHASE1":2904,"PHASE2":2906,"PHASE3":2908,"PHASE4":2910,"NA":2912},{"trials":2899,"activeCount":96,"soonestReadout":84},[2900],{"nctId":82,"briefTitle":83,"status":112,"phases":2901,"primaryCompletion":84,"completion":770,"start":771,"enrollment":12,"conditions":2902,"interventions":2903},[87],[773,774,474,475,476,775,776,777],[85,508,779,780,781,764],{"trials":2905,"activeCount":100},[],{"trials":2907,"activeCount":100},[],{"trials":2909,"activeCount":100},[],{"trials":2911,"activeCount":100},[],{"trials":2913,"activeCount":100},[],{"intervention":781,"totalTrials":96,"cells":2915},{"EARLY_PHASE1":2916,"PHASE1":2922,"PHASE2":2924,"PHASE3":2926,"PHASE4":2928,"NA":2930},{"trials":2917,"activeCount":96,"soonestReadout":84},[2918],{"nctId":82,"briefTitle":83,"status":112,"phases":2919,"primaryCompletion":84,"completion":770,"start":771,"enrollment":12,"conditions":2920,"interventions":2921},[87],[773,774,474,475,476,775,776,777],[85,508,779,780,781,764],{"trials":2923,"activeCount":100},[],{"trials":2925,"activeCount":100},[],{"trials":2927,"activeCount":100},[],{"trials":2929,"activeCount":100},[],{"trials":2931,"activeCount":100},[],{"intervention":2933,"totalTrials":96,"cells":2934},"Glucarpidase",{"EARLY_PHASE1":2935,"PHASE1":2945,"PHASE2":2947,"PHASE3":2949,"PHASE4":2951,"NA":2953},{"trials":2936,"activeCount":96,"soonestReadout":249},[2937],{"nctId":2938,"briefTitle":2939,"status":141,"phases":2940,"primaryCompletion":249,"completion":249,"start":2941,"enrollment":22,"conditions":2942,"interventions":2944},"NCT03960177","Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma",[87],"2019-03-27",[2943],"Osteosarcoma",[2933],{"trials":2946,"activeCount":100},[],{"trials":2948,"activeCount":100},[],{"trials":2950,"activeCount":100},[],{"trials":2952,"activeCount":100},[],{"trials":2954,"activeCount":100},[],{"intervention":2956,"totalTrials":96,"cells":2957},"Topical liquid lidocaine",{"EARLY_PHASE1":2958,"PHASE1":2960,"PHASE2":2962,"PHASE3":2964,"PHASE4":2977,"NA":2979},{"trials":2959,"activeCount":100},[],{"trials":2961,"activeCount":100},[],{"trials":2963,"activeCount":100},[],{"trials":2965,"activeCount":100},[2966],{"nctId":2967,"briefTitle":2968,"status":205,"phases":2969,"primaryCompletion":2970,"completion":2970,"start":673,"enrollment":145,"conditions":2971,"interventions":2975},"NCT01539317","Therapy to Prevent Sexual Pain in Breast Cancer Survivors",[90],"2013-11",[2972,2973,21,2974],"Vulvodynia","Dyspareunia","Menopause",[2956,2976],"Topical saline",{"trials":2978,"activeCount":100},[],{"trials":2980,"activeCount":100},[],{"intervention":2976,"totalTrials":96,"cells":2982},{"EARLY_PHASE1":2983,"PHASE1":2985,"PHASE2":2987,"PHASE3":2989,"PHASE4":2995,"NA":2997},{"trials":2984,"activeCount":100},[],{"trials":2986,"activeCount":100},[],{"trials":2988,"activeCount":100},[],{"trials":2990,"activeCount":100},[2991],{"nctId":2967,"briefTitle":2968,"status":205,"phases":2992,"primaryCompletion":2970,"completion":2970,"start":673,"enrollment":145,"conditions":2993,"interventions":2994},[90],[2972,2973,21,2974],[2956,2976],{"trials":2996,"activeCount":100},[],{"trials":2998,"activeCount":100},[],{"intervention":3000,"totalTrials":96,"cells":3001},"moxifloxacin hydrochloride",{"EARLY_PHASE1":3002,"PHASE1":3004,"PHASE2":3006,"PHASE3":3008,"PHASE4":3023,"NA":3025},{"trials":3003,"activeCount":100},[],{"trials":3005,"activeCount":100},[],{"trials":3007,"activeCount":100},[],{"trials":3009,"activeCount":100},[3010],{"nctId":3011,"briefTitle":3012,"status":286,"phases":3013,"primaryCompletion":3014,"completion":2301,"start":915,"enrollment":3015,"conditions":3016,"interventions":3022},"NCT00324324","Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant",[90],"2007-04",240,[21,349,3017,3018,18,24,350,33,351,3019,3020,3021],"Gestational Trophoblastic Tumor","Infection","Neuroblastoma","Ovarian Cancer","Testicular Germ Cell Tumor",[3000],{"trials":3024,"activeCount":100},[],{"trials":3026,"activeCount":100},[],{"intervention":299,"totalTrials":740,"cells":3028},{"EARLY_PHASE1":3029,"PHASE1":3035,"PHASE2":3045,"PHASE3":3093,"PHASE4":3095,"NA":3097},{"trials":3030,"activeCount":100},[3031],{"nctId":1247,"briefTitle":1248,"status":883,"phases":3032,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":100,"conditions":3033,"interventions":3034},[87],[1183,175,1184,1185,1186,1187,1188,432,1228,1253,1254,574,474,1189,475,1190,476],[1256,1257,1258,1259,483,65,299,85,495,1260,1261,1262,678,1193,505,1263,508,1242,510,513,1264,521,523,1265,524],{"trials":3036,"activeCount":100},[3037,3041],{"nctId":934,"briefTitle":935,"status":286,"phases":3038,"primaryCompletion":937,"completion":937,"start":938,"enrollment":9,"conditions":3039,"interventions":3040},[88],[940,293,294,941],[267,943,891,269,272,944,892],{"nctId":425,"briefTitle":426,"status":286,"phases":3042,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":3043,"interventions":3044},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":3046,"activeCount":100},[3047,3051,3070,3074,3081,3085,3089],{"nctId":850,"briefTitle":851,"status":852,"phases":3048,"primaryCompletion":854,"completion":855,"start":856,"enrollment":857,"conditions":3049,"interventions":3050},[88,89],[859],[299,861,221,224,862],{"nctId":3052,"briefTitle":3053,"status":852,"phases":3054,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":291,"conditions":3058,"interventions":3069},"NCT00983398","Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors",[88,89],"2021-12-31","2022-12-31","2009-07-09",[3059,3060,3061,3062,3063,3064,3065,3066,3067,3068],"Central Nervous System Embryonal Neoplasm","Embryonal Tumor With Multilayered Rosettes, C19MC-Altered","Germ Cell Tumor","Medulloblastoma","Medulloepithelioma","Primitive Neuroectodermal Tumor","Recurrent Childhood Central Nervous System Embryonal Neoplasm","Recurrent Malignant Germ Cell Tumor","Recurrent Medulloblastoma","Recurrent Primitive Neuroectodermal Tumor",[299,861,243,862],{"nctId":2323,"briefTitle":2324,"status":205,"phases":3071,"primaryCompletion":2208,"completion":2208,"start":2326,"enrollment":2327,"conditions":3072,"interventions":3073},[88,89],[2329,2330,2331,2332],[299,241,988,861,243,862],{"nctId":3075,"briefTitle":3076,"status":205,"phases":3077,"primaryCompletion":262,"completion":262,"start":3078,"enrollment":597,"conditions":3079,"interventions":3080},"NCT00017576","Calcitriol and Carboplatin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy",[89],"2000-12",[15],[891],{"nctId":284,"briefTitle":285,"status":286,"phases":3082,"primaryCompletion":288,"completion":289,"start":290,"enrollment":291,"conditions":3083,"interventions":3084},[89],[293,294,24,295],[297,215,241,298,299,300,301,302,196],{"nctId":881,"briefTitle":882,"status":883,"phases":3086,"primaryCompletion":885,"completion":885,"start":885,"enrollment":100,"conditions":3087,"interventions":3088},[88,89],[293,21,887,294,888],[890,891,273,892],{"nctId":978,"briefTitle":979,"status":852,"phases":3090,"primaryCompletion":981,"completion":982,"start":983,"enrollment":984,"conditions":3091,"interventions":3092},[89],[986],[299,215,988,862],{"trials":3094,"activeCount":100},[],{"trials":3096,"activeCount":100},[],{"trials":3098,"activeCount":100},[],{"intervention":862,"totalTrials":210,"cells":3100},{"EARLY_PHASE1":3101,"PHASE1":3103,"PHASE2":3109,"PHASE3":3135,"PHASE4":3137,"NA":3139},{"trials":3102,"activeCount":100},[],{"trials":3104,"activeCount":100},[3105],{"nctId":934,"briefTitle":935,"status":286,"phases":3106,"primaryCompletion":937,"completion":937,"start":938,"enrollment":9,"conditions":3107,"interventions":3108},[88],[940,293,294,941],[267,943,891,269,272,944,892],{"trials":3110,"activeCount":100},[3111,3115,3119,3123,3127,3131],{"nctId":850,"briefTitle":851,"status":852,"phases":3112,"primaryCompletion":854,"completion":855,"start":856,"enrollment":857,"conditions":3113,"interventions":3114},[88,89],[859],[299,861,221,224,862],{"nctId":3052,"briefTitle":3053,"status":852,"phases":3116,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":291,"conditions":3117,"interventions":3118},[88,89],[3059,3060,3061,3062,3063,3064,3065,3066,3067,3068],[299,861,243,862],{"nctId":2323,"briefTitle":2324,"status":205,"phases":3120,"primaryCompletion":2208,"completion":2208,"start":2326,"enrollment":2327,"conditions":3121,"interventions":3122},[88,89],[2329,2330,2331,2332],[299,241,988,861,243,862],{"nctId":284,"briefTitle":285,"status":286,"phases":3124,"primaryCompletion":288,"completion":289,"start":290,"enrollment":291,"conditions":3125,"interventions":3126},[89],[293,294,24,295],[297,215,241,298,299,300,301,302,196],{"nctId":881,"briefTitle":882,"status":883,"phases":3128,"primaryCompletion":885,"completion":885,"start":885,"enrollment":100,"conditions":3129,"interventions":3130},[88,89],[293,21,887,294,888],[890,891,273,892],{"nctId":978,"briefTitle":979,"status":852,"phases":3132,"primaryCompletion":981,"completion":982,"start":983,"enrollment":984,"conditions":3133,"interventions":3134},[89],[986],[299,215,988,862],{"trials":3136,"activeCount":100},[],{"trials":3138,"activeCount":100},[],{"trials":3140,"activeCount":100},[],{"intervention":326,"totalTrials":1181,"cells":3142},{"EARLY_PHASE1":3143,"PHASE1":3145,"PHASE2":3147,"PHASE3":3189,"PHASE4":3191,"NA":3193},{"trials":3144,"activeCount":100},[],{"trials":3146,"activeCount":100},[],{"trials":3148,"activeCount":100},[3149,3157,3164,3168,3172,3181],{"nctId":3150,"briefTitle":3151,"status":205,"phases":3152,"primaryCompletion":3153,"completion":3153,"start":3154,"enrollment":1286,"conditions":3155,"interventions":3156},"NCT00331409","Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer",[89],"2010-01","2006-01",[2550],[497,326],{"nctId":3158,"briefTitle":3159,"status":205,"phases":3160,"primaryCompletion":872,"completion":872,"start":3161,"enrollment":674,"conditions":3162,"interventions":3163},"NCT00053248","Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia",[88,89],"2002-10",[18],[2270,326],{"nctId":317,"briefTitle":318,"status":286,"phases":3165,"primaryCompletion":320,"completion":321,"start":322,"enrollment":323,"conditions":3166,"interventions":3167},[89],[18],[270,326],{"nctId":328,"briefTitle":329,"status":286,"phases":3169,"primaryCompletion":331,"completion":332,"start":333,"enrollment":235,"conditions":3170,"interventions":3171},[89],[18],[269,270,271,336,326,273,337,338,339],{"nctId":3173,"briefTitle":3174,"status":286,"phases":3175,"primaryCompletion":320,"completion":320,"start":3176,"enrollment":3177,"conditions":3178,"interventions":3179},"NCT00015847","Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia",[89],"2001-04",25,[18],[3180,326],"recombinant interferon alfa",{"nctId":3182,"briefTitle":3183,"status":286,"phases":3184,"primaryCompletion":3185,"completion":2507,"start":3186,"enrollment":740,"conditions":3187,"interventions":3188},"NCT00245128","Imatinib Mesylate in Treating Patients With Myelofibrosis",[89],"2007-03","2005-08",[349],[326],{"trials":3190,"activeCount":100},[],{"trials":3192,"activeCount":100},[],{"trials":3194,"activeCount":100},[],{"intervention":243,"totalTrials":1181,"cells":3196},{"EARLY_PHASE1":3197,"PHASE1":3199,"PHASE2":3215,"PHASE3":3237,"PHASE4":3239,"NA":3241},{"trials":3198,"activeCount":100},[],{"trials":3200,"activeCount":100},[3201,3211],{"nctId":3202,"briefTitle":3203,"status":286,"phases":3204,"primaryCompletion":2364,"completion":3205,"start":3206,"enrollment":3207,"conditions":3208,"interventions":3210},"NCT00253721","Melphalan With BBBD in Treating Patients With Brain Malignancies",[88],"2016-12","1998-05",21,[293,24,3209],"Metastatic Cancer",[243],{"nctId":230,"briefTitle":231,"status":205,"phases":3212,"primaryCompletion":233,"completion":233,"start":234,"enrollment":235,"conditions":3213,"interventions":3214},[88],[237,238],[240,196,241,242,243,221,244],{"trials":3216,"activeCount":100},[3217,3221,3225,3233],{"nctId":3052,"briefTitle":3053,"status":852,"phases":3218,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":291,"conditions":3219,"interventions":3220},[88,89],[3059,3060,3061,3062,3063,3064,3065,3066,3067,3068],[299,861,243,862],{"nctId":2323,"briefTitle":2324,"status":205,"phases":3222,"primaryCompletion":2208,"completion":2208,"start":2326,"enrollment":2327,"conditions":3223,"interventions":3224},[88,89],[2329,2330,2331,2332],[299,241,988,861,243,862],{"nctId":3226,"briefTitle":3227,"status":205,"phases":3228,"primaryCompletion":871,"completion":3205,"start":3229,"enrollment":571,"conditions":3230,"interventions":3231},"NCT00238433","Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma",[89],"2005-03",[24],[267,355,360,3232],"thiotepa",{"nctId":341,"briefTitle":342,"status":286,"phases":3234,"primaryCompletion":344,"completion":345,"start":346,"enrollment":347,"conditions":3235,"interventions":3236},[89],[349,18,24,350,33,351,352],[354,267,355,356,269,357,270,358,359,360,273,337,361,362],{"trials":3238,"activeCount":100},[],{"trials":3240,"activeCount":100},[],{"trials":3242,"activeCount":100},[],{"intervention":226,"totalTrials":395,"cells":3244},{"EARLY_PHASE1":3245,"PHASE1":3247,"PHASE2":3264,"PHASE3":3291,"PHASE4":3293,"NA":3295},{"trials":3246,"activeCount":100},[],{"trials":3248,"activeCount":100},[3249,3253],{"nctId":203,"briefTitle":204,"status":205,"phases":3250,"primaryCompletion":207,"completion":208,"start":209,"enrollment":210,"conditions":3251,"interventions":3252},[88],[212,213],[215,196,216,70,217,218,219,220,221,222,223,224,225,226,227,228],{"nctId":3254,"briefTitle":3255,"status":205,"phases":3256,"primaryCompletion":950,"completion":3257,"start":3258,"enrollment":951,"conditions":3259,"interventions":3260},"NCT00822848","Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma",[88],"2013-04-30","2009-02",[921],[3261,3262,3263],"epirubicin hydrochloride","ifosfamide","sorafenib tosylate",{"trials":3265,"activeCount":100},[3266,3275,3287],{"nctId":3267,"briefTitle":3268,"status":286,"phases":3269,"primaryCompletion":3270,"completion":3271,"start":656,"enrollment":22,"conditions":3272,"interventions":3273},"NCT00722072","Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy",[89],"2010-07","2012-07",[21],[3274,3263],"fulvestrant",{"nctId":3276,"briefTitle":3277,"status":205,"phases":3278,"primaryCompletion":3279,"completion":2167,"start":3280,"enrollment":414,"conditions":3281,"interventions":3284},"NCT02050919","Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma",[89],"2018-05-07","2013-12-03",[3282,3283,1229,1230],"Pleomorphic Rhabdomyosarcoma","Stage IIB Adult Soft Tissue Sarcoma AJCC v7",[3285,3286,226],"Epirubicin Hydrochloride","Ifosfamide",{"nctId":2515,"briefTitle":2516,"status":286,"phases":3288,"primaryCompletion":2518,"completion":2519,"start":2520,"enrollment":22,"conditions":3289,"interventions":3290},[89],[2522,2523,449,450,460,461],[216,219,2525,514,223,516,518,226,519,227],{"trials":3292,"activeCount":100},[],{"trials":3294,"activeCount":100},[],{"trials":3296,"activeCount":100},[],{"intervention":272,"totalTrials":395,"cells":3298},{"EARLY_PHASE1":3299,"PHASE1":3301,"PHASE2":3307,"PHASE3":3325,"PHASE4":3327,"NA":3329},{"trials":3300,"activeCount":100},[],{"trials":3302,"activeCount":100},[3303],{"nctId":934,"briefTitle":935,"status":286,"phases":3304,"primaryCompletion":937,"completion":937,"start":938,"enrollment":9,"conditions":3305,"interventions":3306},[88],[940,293,294,941],[267,943,891,269,272,944,892],{"trials":3308,"activeCount":100},[3309,3313,3317,3321],{"nctId":259,"briefTitle":260,"status":205,"phases":3310,"primaryCompletion":262,"completion":262,"start":263,"enrollment":264,"conditions":3311,"interventions":3312},[89],[24],[267,268,269,270,271,272,273],{"nctId":2323,"briefTitle":2324,"status":205,"phases":3314,"primaryCompletion":2208,"completion":2208,"start":2326,"enrollment":2327,"conditions":3315,"interventions":3316},[88,89],[2329,2330,2331,2332],[299,241,988,861,243,862],{"nctId":284,"briefTitle":285,"status":286,"phases":3318,"primaryCompletion":288,"completion":289,"start":290,"enrollment":291,"conditions":3319,"interventions":3320},[89],[293,294,24,295],[297,215,241,298,299,300,301,302,196],{"nctId":978,"briefTitle":979,"status":852,"phases":3322,"primaryCompletion":981,"completion":982,"start":983,"enrollment":984,"conditions":3323,"interventions":3324},[89],[986],[299,215,988,862],{"trials":3326,"activeCount":100},[],{"trials":3328,"activeCount":100},[],{"trials":3330,"activeCount":100},[],{"intervention":3332,"totalTrials":395,"cells":3333},"docetaxel",{"EARLY_PHASE1":3334,"PHASE1":3336,"PHASE2":3338,"PHASE3":3384,"PHASE4":3386,"NA":3388},{"trials":3335,"activeCount":100},[],{"trials":3337,"activeCount":100},[],{"trials":3339,"activeCount":100},[3340,3348,3356,3364,3372],{"nctId":3341,"briefTitle":3342,"status":286,"phases":3343,"primaryCompletion":3344,"completion":3344,"start":3345,"enrollment":387,"conditions":3346,"interventions":3347},"NCT00482274","Docetaxel in Treating Patients With Relapsed Prostate Cancer",[89],"2009-07","2007-05",[15],[3332],{"nctId":3349,"briefTitle":3350,"status":205,"phases":3351,"primaryCompletion":3352,"completion":3352,"start":3353,"enrollment":3177,"conditions":3354,"interventions":3355},"NCT00003781","Docetaxel in Treating Patients With Stage IV Prostate Cancer",[89],"2003-06","1998-12",[2305,15],[3332],{"nctId":3357,"briefTitle":3358,"status":205,"phases":3359,"primaryCompletion":595,"completion":595,"start":3360,"enrollment":3177,"conditions":3361,"interventions":3363},"NCT00238199","Calcitriol and Docetaxel in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer",[89],"2002-06",[3362],"Pancreatic Cancer",[3332],{"nctId":3365,"briefTitle":3366,"status":205,"phases":3367,"primaryCompletion":3368,"start":3369,"enrollment":1613,"conditions":3370,"interventions":3371},"NCT00017563","Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer",[89],"2010-05","2000-09",[15],[3332,600],{"nctId":3373,"briefTitle":3374,"status":286,"phases":3375,"primaryCompletion":3376,"completion":3377,"start":3378,"enrollment":235,"conditions":3379,"interventions":3381},"NCT01253642","Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel",[89],"2016-09-15","2017-09-15","2010-07-12",[1040,3380,121,574],"Metastatic Prostatic Adenocarcinoma",[3382,3383],"Docetaxel","Phenelzine Sulfate",{"trials":3385,"activeCount":100},[],{"trials":3387,"activeCount":100},[],{"trials":3389,"activeCount":100},[],{"intervention":861,"totalTrials":917,"cells":3391},{"EARLY_PHASE1":3392,"PHASE1":3394,"PHASE2":3400,"PHASE3":3414,"PHASE4":3416,"NA":3418},{"trials":3393,"activeCount":100},[],{"trials":3395,"activeCount":100},[3396],{"nctId":934,"briefTitle":935,"status":286,"phases":3397,"primaryCompletion":937,"completion":937,"start":938,"enrollment":9,"conditions":3398,"interventions":3399},[88],[940,293,294,941],[267,943,891,269,272,944,892],{"trials":3401,"activeCount":100},[3402,3406,3410],{"nctId":850,"briefTitle":851,"status":852,"phases":3403,"primaryCompletion":854,"completion":855,"start":856,"enrollment":857,"conditions":3404,"interventions":3405},[88,89],[859],[299,861,221,224,862],{"nctId":3052,"briefTitle":3053,"status":852,"phases":3407,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":291,"conditions":3408,"interventions":3409},[88,89],[3059,3060,3061,3062,3063,3064,3065,3066,3067,3068],[299,861,243,862],{"nctId":2323,"briefTitle":2324,"status":205,"phases":3411,"primaryCompletion":2208,"completion":2208,"start":2326,"enrollment":2327,"conditions":3412,"interventions":3413},[88,89],[2329,2330,2331,2332],[299,241,988,861,243,862],{"trials":3415,"activeCount":100},[],{"trials":3417,"activeCount":100},[],{"trials":3419,"activeCount":100},[],{"intervention":505,"totalTrials":917,"cells":3421},{"EARLY_PHASE1":3422,"PHASE1":3428,"PHASE2":3434,"PHASE3":3444,"PHASE4":3446,"NA":3448},{"trials":3423,"activeCount":100},[3424],{"nctId":1247,"briefTitle":1248,"status":883,"phases":3425,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":100,"conditions":3426,"interventions":3427},[87],[1183,175,1184,1185,1186,1187,1188,432,1228,1253,1254,574,474,1189,475,1190,476],[1256,1257,1258,1259,483,65,299,85,495,1260,1261,1262,678,1193,505,1263,508,1242,510,513,1264,521,523,1265,524],{"trials":3429,"activeCount":100},[3430],{"nctId":425,"briefTitle":426,"status":286,"phases":3431,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":3432,"interventions":3433},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":3435,"activeCount":100},[3436,3440],{"nctId":1136,"briefTitle":1137,"status":205,"phases":3437,"primaryCompletion":1139,"completion":1140,"start":1141,"enrollment":414,"conditions":3438,"interventions":3439},[89],[685,1143],[498,693,505],{"nctId":1198,"briefTitle":1199,"status":883,"phases":3441,"primaryCompletion":1201,"completion":1202,"start":1203,"enrollment":100,"conditions":3442,"interventions":3443},[89],[773,774,474,475,476,478],[779,693,505],{"trials":3445,"activeCount":100},[],{"trials":3447,"activeCount":100},[],{"trials":3449,"activeCount":100},[],{"intervention":217,"totalTrials":387,"cells":3451},{"EARLY_PHASE1":3452,"PHASE1":3454,"PHASE2":3496,"PHASE3":3502,"PHASE4":3504,"NA":3506},{"trials":3453,"activeCount":100},[],{"trials":3455,"activeCount":100},[3456,3460],{"nctId":203,"briefTitle":204,"status":205,"phases":3457,"primaryCompletion":207,"completion":208,"start":209,"enrollment":210,"conditions":3458,"interventions":3459},[88],[212,213],[215,196,216,70,217,218,219,220,221,222,223,224,225,226,227,228],{"nctId":3461,"briefTitle":3462,"status":205,"phases":3463,"primaryCompletion":3464,"completion":3465,"start":3466,"enrollment":674,"conditions":3467,"interventions":3494},"NCT03009201","Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery",[88],"2019-10-08","2023-06-30","2017-03-10",[3468,3469,3470,3471,3472,3473,3474,3475,3476,3477,3478,3479,3480,3481,3482,3483,3484,3282,3485,3486,3487,3488,3489,3490,3491,3492,3493],"Advanced Soft Tissue Sarcoma","Locally Advanced Angiosarcoma","Locally Advanced Leiomyosarcoma","Locally Advanced Liposarcoma","Locally Advanced Malignant Peripheral Nerve Sheath Tumor","Locally Advanced Myxofibrosarcoma","Locally Advanced Undifferentiated Pleomorphic Sarcoma","Metastatic Angiosarcoma","Metastatic Epithelioid Sarcoma","Metastatic Fibrosarcoma","Metastatic Liposarcoma","Metastatic Malignant Peripheral Nerve Sheath Tumor","Metastatic Myxofibrosarcoma","Metastatic Soft Tissue Sarcoma","Metastatic Synovial Sarcoma","Metastatic Undifferentiated Pleomorphic Sarcoma","Myxofibrosarcoma","Stage III Soft Tissue Sarcoma AJCC v7","Stage IV Soft Tissue Sarcoma AJCC v7","Undifferentiated (Embryonal) Sarcoma","Unresectable Leiomyosarcoma","Unresectable Liposarcoma","Unresectable Malignant Peripheral Nerve Sheath Tumor","Unresectable Soft Tissue Sarcoma","Unresectable Synovial Sarcoma","Unresectable Undifferentiated Pleomorphic Sarcoma",[217,3495],"Ribociclib",{"trials":3497,"activeCount":100},[3498],{"nctId":328,"briefTitle":329,"status":286,"phases":3499,"primaryCompletion":331,"completion":332,"start":333,"enrollment":235,"conditions":3500,"interventions":3501},[89],[18],[269,270,271,336,326,273,337,338,339],{"trials":3503,"activeCount":100},[],{"trials":3505,"activeCount":100},[],{"trials":3507,"activeCount":100},[],{"intervention":219,"totalTrials":387,"cells":3509},{"EARLY_PHASE1":3510,"PHASE1":3512,"PHASE2":3522,"PHASE3":3528,"PHASE4":3530,"NA":3532},{"trials":3511,"activeCount":100},[],{"trials":3513,"activeCount":100},[3514,3518],{"nctId":203,"briefTitle":204,"status":205,"phases":3515,"primaryCompletion":207,"completion":208,"start":209,"enrollment":210,"conditions":3516,"interventions":3517},[88],[212,213],[215,196,216,70,217,218,219,220,221,222,223,224,225,226,227,228],{"nctId":425,"briefTitle":426,"status":286,"phases":3519,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":3520,"interventions":3521},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":3523,"activeCount":100},[3524],{"nctId":2515,"briefTitle":2516,"status":286,"phases":3525,"primaryCompletion":2518,"completion":2519,"start":2520,"enrollment":22,"conditions":3526,"interventions":3527},[89],[2522,2523,449,450,460,461],[216,219,2525,514,223,516,518,226,519,227],{"trials":3529,"activeCount":100},[],{"trials":3531,"activeCount":100},[],{"trials":3533,"activeCount":100},[],{"intervention":227,"totalTrials":387,"cells":3535},{"EARLY_PHASE1":3536,"PHASE1":3538,"PHASE2":3544,"PHASE3":3560,"PHASE4":3562,"NA":3564},{"trials":3537,"activeCount":100},[],{"trials":3539,"activeCount":100},[3540],{"nctId":203,"briefTitle":204,"status":205,"phases":3541,"primaryCompletion":207,"completion":208,"start":209,"enrollment":210,"conditions":3542,"interventions":3543},[88],[212,213],[215,196,216,70,217,218,219,220,221,222,223,224,225,226,227,228],{"trials":3545,"activeCount":100},[3546,3556],{"nctId":3547,"briefTitle":3548,"status":205,"phases":3549,"primaryCompletion":3550,"completion":3551,"start":595,"enrollment":1351,"conditions":3552,"interventions":3553},"NCT00425386","Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer",[89],"2010-08","2014-03",[2550],[3554,3555],"erlotinib hydrochloride","sunitinib malate",{"nctId":2515,"briefTitle":2516,"status":286,"phases":3557,"primaryCompletion":2518,"completion":2519,"start":2520,"enrollment":22,"conditions":3558,"interventions":3559},[89],[2522,2523,449,450,460,461],[216,219,2525,514,223,516,518,226,519,227],{"trials":3561,"activeCount":100},[],{"trials":3563,"activeCount":100},[],{"trials":3565,"activeCount":100},[],{"intervention":359,"totalTrials":387,"cells":3567},{"EARLY_PHASE1":3568,"PHASE1":3570,"PHASE2":3572,"PHASE3":3586,"PHASE4":3588,"NA":3590},{"trials":3569,"activeCount":100},[],{"trials":3571,"activeCount":100},[],{"trials":3573,"activeCount":100},[3574,3578,3582],{"nctId":2545,"briefTitle":2546,"status":286,"phases":3575,"primaryCompletion":2548,"completion":2548,"start":872,"enrollment":96,"conditions":3576,"interventions":3577},[89],[2550],[357,359,361],{"nctId":868,"briefTitle":869,"status":205,"phases":3579,"primaryCompletion":871,"completion":871,"start":872,"enrollment":873,"conditions":3580,"interventions":3581},[88,89],[349,18,24,350,33,351,875],[877,355,357,359,361,878,879,221],{"nctId":341,"briefTitle":342,"status":286,"phases":3583,"primaryCompletion":344,"completion":345,"start":346,"enrollment":347,"conditions":3584,"interventions":3585},[89],[349,18,24,350,33,351,352],[354,267,355,356,269,357,270,358,359,360,273,337,361,362],{"trials":3587,"activeCount":100},[],{"trials":3589,"activeCount":100},[],{"trials":3591,"activeCount":100},[],{"intervention":484,"totalTrials":387,"cells":3593},{"EARLY_PHASE1":3594,"PHASE1":3596,"PHASE2":3602,"PHASE3":3619,"PHASE4":3621,"NA":3623},{"trials":3595,"activeCount":100},[],{"trials":3597,"activeCount":100},[3598],{"nctId":425,"briefTitle":426,"status":286,"phases":3599,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":3600,"interventions":3601},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":3603,"activeCount":100},[3604,3608],{"nctId":1085,"briefTitle":1086,"status":883,"phases":3605,"primaryCompletion":84,"completion":1088,"start":1089,"enrollment":100,"conditions":3606,"interventions":3607},[89],[1091,1092,1093,1094,1095],[1097,484,512],{"nctId":3609,"briefTitle":3610,"status":883,"phases":3611,"primaryCompletion":3612,"completion":3612,"start":3613,"enrollment":100,"conditions":3614,"interventions":3615},"NCT00244920","Hormone Therapy With or Without Squalamine Lactate in Treating Patients Who Are Undergoing a Radical Prostatectomy for Locally Advanced Prostate Cancer",[89],"2007-06","2002-01",[15],[3616,3617,3618],"bicalutamide","leuprolide acetate","squalamine lactate",{"trials":3620,"activeCount":100},[],{"trials":3622,"activeCount":100},[],{"trials":3624,"activeCount":100},[],{"intervention":1193,"totalTrials":387,"cells":3626},{"EARLY_PHASE1":3627,"PHASE1":3633,"PHASE2":3643,"PHASE3":3649,"PHASE4":3651,"NA":3653},{"trials":3628,"activeCount":100},[3629],{"nctId":1247,"briefTitle":1248,"status":883,"phases":3630,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":100,"conditions":3631,"interventions":3632},[87],[1183,175,1184,1185,1186,1187,1188,432,1228,1253,1254,574,474,1189,475,1190,476],[1256,1257,1258,1259,483,65,299,85,495,1260,1261,1262,678,1193,505,1263,508,1242,510,513,1264,521,523,1265,524],{"trials":3634,"activeCount":100},[3635],{"nctId":3636,"briefTitle":3637,"status":286,"phases":3638,"primaryCompletion":3344,"completion":289,"start":3612,"enrollment":1181,"conditions":3639,"interventions":3640},"NCT00516542","Dehydroepiandrosterone (DHEA) and Letrozole in Treating Patients With Metastatic Breast Cancer",[88],[21],[3641,3642],"letrozole","DHEA",{"trials":3644,"activeCount":100},[3645],{"nctId":1176,"briefTitle":1177,"status":286,"phases":3646,"primaryCompletion":1179,"completion":1179,"start":1180,"enrollment":1181,"conditions":3647,"interventions":3648},[89],[1183,175,1184,1185,1186,1187,1188,432,1189,475,1095,1190,476,477],[480,1192,693,1193,1194,1195,1196],{"trials":3650,"activeCount":100},[],{"trials":3652,"activeCount":100},[],{"trials":3654,"activeCount":100},[],{"intervention":480,"totalTrials":387,"cells":3656},{"EARLY_PHASE1":3657,"PHASE1":3659,"PHASE2":3695,"PHASE3":3701,"PHASE4":3703,"NA":3705},{"trials":3658,"activeCount":100},[],{"trials":3660,"activeCount":100},[3661,3691],{"nctId":3662,"briefTitle":3663,"status":205,"phases":3664,"primaryCompletion":3665,"completion":3666,"start":3667,"enrollment":34,"conditions":3668,"interventions":3689},"NCT04481113","Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer",[88],"2023-10-11","2025-06-20","2021-06-07",[3669,3670,3671,3672,3673,3674,3675,3676,3677,3678,3679,3680,3681,3682,3683,3684,3685,3686,3687,3688],"Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage IA Breast Cancer AJCC v8","Anatomic Stage IB Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage IIA Breast Cancer AJCC v8","Anatomic Stage IIB Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","HER2 Negative Breast Adenocarcinoma","Hormone Receptor Positive Breast Adenocarcinoma","Invasive Breast Carcinoma","Multifocal Breast Carcinoma","Prognostic Stage I Breast Cancer AJCC v8","Prognostic Stage IA Breast Cancer AJCC v8","Prognostic Stage IB Breast Cancer AJCC v8","Prognostic Stage II Breast Cancer AJCC v8","Prognostic Stage IIA Breast Cancer AJCC v8","Prognostic Stage IIB Breast Cancer AJCC v8","Prognostic Stage IIIA Breast Cancer AJCC v8","Prognostic Stage IIIB Breast Cancer AJCC v8","Unilateral Breast Carcinoma",[480,3690],"Niraparib Tosylate Monohydrate",{"nctId":425,"briefTitle":426,"status":286,"phases":3692,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":3693,"interventions":3694},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":3696,"activeCount":100},[3697],{"nctId":1176,"briefTitle":1177,"status":286,"phases":3698,"primaryCompletion":1179,"completion":1179,"start":1180,"enrollment":1181,"conditions":3699,"interventions":3700},[89],[1183,175,1184,1185,1186,1187,1188,432,1189,475,1095,1190,476,477],[480,1192,693,1193,1194,1195,1196],{"trials":3702,"activeCount":100},[],{"trials":3704,"activeCount":100},[],{"trials":3706,"activeCount":100},[],{"intervention":483,"totalTrials":387,"cells":3708},{"EARLY_PHASE1":3709,"PHASE1":3715,"PHASE2":3721,"PHASE3":3732,"PHASE4":3734,"NA":3736},{"trials":3710,"activeCount":100},[3711],{"nctId":1247,"briefTitle":1248,"status":883,"phases":3712,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":100,"conditions":3713,"interventions":3714},[87],[1183,175,1184,1185,1186,1187,1188,432,1228,1253,1254,574,474,1189,475,1190,476],[1256,1257,1258,1259,483,65,299,85,495,1260,1261,1262,678,1193,505,1263,508,1242,510,513,1264,521,523,1265,524],{"trials":3716,"activeCount":100},[3717],{"nctId":425,"briefTitle":426,"status":286,"phases":3718,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":3719,"interventions":3720},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":3722,"activeCount":100},[3723],{"nctId":3724,"briefTitle":3725,"status":286,"phases":3726,"primaryCompletion":3727,"completion":3727,"start":3153,"enrollment":395,"conditions":3728,"interventions":3730},"NCT01821859","Abraxane\u002FBevacizumab",[89],"2011-11",[3020,3729],"Peritoneal Cancer",[3731,483],"Abraxane",{"trials":3733,"activeCount":100},[],{"trials":3735,"activeCount":100},[],{"trials":3737,"activeCount":100},[],{"intervention":3274,"totalTrials":9,"cells":3739},{"EARLY_PHASE1":3740,"PHASE1":3746,"PHASE2":3748,"PHASE3":3754,"PHASE4":3756,"NA":3758},{"trials":3741,"activeCount":100},[3742],{"nctId":1247,"briefTitle":1248,"status":883,"phases":3743,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":100,"conditions":3744,"interventions":3745},[87],[1183,175,1184,1185,1186,1187,1188,432,1228,1253,1254,574,474,1189,475,1190,476],[1256,1257,1258,1259,483,65,299,85,495,1260,1261,1262,678,1193,505,1263,508,1242,510,513,1264,521,523,1265,524],{"trials":3747,"activeCount":100},[],{"trials":3749,"activeCount":100},[3750],{"nctId":3267,"briefTitle":3268,"status":286,"phases":3751,"primaryCompletion":3270,"completion":3271,"start":656,"enrollment":22,"conditions":3752,"interventions":3753},[89],[21],[3274,3263],{"trials":3755,"activeCount":100},[],{"trials":3757,"activeCount":100},[],{"trials":3759,"activeCount":100},[],{"intervention":497,"totalTrials":9,"cells":3761},{"EARLY_PHASE1":3762,"PHASE1":3764,"PHASE2":3770,"PHASE3":3776,"PHASE4":3778,"NA":3780},{"trials":3763,"activeCount":100},[],{"trials":3765,"activeCount":100},[3766],{"nctId":425,"briefTitle":426,"status":286,"phases":3767,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":3768,"interventions":3769},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":3771,"activeCount":100},[3772],{"nctId":3150,"briefTitle":3151,"status":205,"phases":3773,"primaryCompletion":3153,"completion":3153,"start":3154,"enrollment":1286,"conditions":3774,"interventions":3775},[89],[2550],[497,326],{"trials":3777,"activeCount":100},[],{"trials":3779,"activeCount":100},[],{"trials":3781,"activeCount":100},[],{"intervention":223,"totalTrials":9,"cells":3783},{"EARLY_PHASE1":3784,"PHASE1":3786,"PHASE2":3792,"PHASE3":3798,"PHASE4":3800,"NA":3802},{"trials":3785,"activeCount":100},[],{"trials":3787,"activeCount":100},[3788],{"nctId":203,"briefTitle":204,"status":205,"phases":3789,"primaryCompletion":207,"completion":208,"start":209,"enrollment":210,"conditions":3790,"interventions":3791},[88],[212,213],[215,196,216,70,217,218,219,220,221,222,223,224,225,226,227,228],{"trials":3793,"activeCount":100},[3794],{"nctId":2515,"briefTitle":2516,"status":286,"phases":3795,"primaryCompletion":2518,"completion":2519,"start":2520,"enrollment":22,"conditions":3796,"interventions":3797},[89],[2522,2523,449,450,460,461],[216,219,2525,514,223,516,518,226,519,227],{"trials":3799,"activeCount":100},[],{"trials":3801,"activeCount":100},[],{"trials":3803,"activeCount":100},[],{"intervention":225,"totalTrials":9,"cells":3805},{"EARLY_PHASE1":3806,"PHASE1":3808,"PHASE2":3814,"PHASE3":3827,"PHASE4":3829,"NA":3831},{"trials":3807,"activeCount":100},[],{"trials":3809,"activeCount":100},[3810],{"nctId":203,"briefTitle":204,"status":205,"phases":3811,"primaryCompletion":207,"completion":208,"start":209,"enrollment":210,"conditions":3812,"interventions":3813},[88],[212,213],[215,196,216,70,217,218,219,220,221,222,223,224,225,226,227,228],{"trials":3815,"activeCount":100},[3816],{"nctId":3817,"briefTitle":3818,"status":205,"phases":3819,"primaryCompletion":3820,"completion":3821,"start":3822,"enrollment":3823,"conditions":3824,"interventions":3826},"NCT02092324","Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia",[89],"2019-11-22","2020-01-24","2014-07-08",51,[438,3825],"Chronic Neutrophilic Leukemia",[225],{"trials":3828,"activeCount":100},[],{"trials":3830,"activeCount":100},[],{"trials":3832,"activeCount":100},[],{"intervention":228,"totalTrials":9,"cells":3834},{"EARLY_PHASE1":3835,"PHASE1":3837,"PHASE2":3843,"PHASE3":3849,"PHASE4":3851,"NA":3853},{"trials":3836,"activeCount":100},[],{"trials":3838,"activeCount":100},[3839],{"nctId":203,"briefTitle":204,"status":205,"phases":3840,"primaryCompletion":207,"completion":208,"start":209,"enrollment":210,"conditions":3841,"interventions":3842},[88],[212,213],[215,196,216,70,217,218,219,220,221,222,223,224,225,226,227,228],{"trials":3844,"activeCount":100},[3845],{"nctId":328,"briefTitle":329,"status":286,"phases":3846,"primaryCompletion":331,"completion":332,"start":333,"enrollment":235,"conditions":3847,"interventions":3848},[89],[18],[269,270,271,336,326,273,337,338,339],{"trials":3850,"activeCount":100},[],{"trials":3852,"activeCount":100},[],{"trials":3854,"activeCount":100},[],{"intervention":668,"totalTrials":9,"cells":3856},{"EARLY_PHASE1":3857,"PHASE1":3859,"PHASE2":3861,"PHASE3":3880,"PHASE4":3882,"NA":3884},{"trials":3858,"activeCount":100},[],{"trials":3860,"activeCount":100},[],{"trials":3862,"activeCount":100},[3863,3867],{"nctId":653,"briefTitle":654,"status":205,"phases":3864,"primaryCompletion":345,"completion":656,"start":657,"enrollment":658,"conditions":3865,"interventions":3866},[89],[660,661],[663,271,664,665,666,667,668],{"nctId":3868,"briefTitle":3869,"status":205,"phases":3870,"primaryCompletion":3871,"completion":3872,"start":3873,"enrollment":3874,"conditions":3875,"interventions":3877},"NCT03097588","Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant",[89],"2020-02-20","2020-03-20","2017-04-27",43,[3876],"Malignant Neoplasm",[3878,3879],"Netupitant","Palonosetron Hydrochloride",{"trials":3881,"activeCount":100},[],{"trials":3883,"activeCount":100},[],{"trials":3885,"activeCount":100},[],{"intervention":3554,"totalTrials":9,"cells":3887},{"EARLY_PHASE1":3888,"PHASE1":3890,"PHASE2":3892,"PHASE3":3912,"PHASE4":3914,"NA":3916},{"trials":3889,"activeCount":100},[],{"trials":3891,"activeCount":100},[],{"trials":3893,"activeCount":100},[3894,3898],{"nctId":3547,"briefTitle":3548,"status":205,"phases":3895,"primaryCompletion":3550,"completion":3551,"start":595,"enrollment":1351,"conditions":3896,"interventions":3897},[89],[2550],[3554,3555],{"nctId":3899,"briefTitle":3900,"status":883,"phases":3901,"primaryCompletion":3902,"completion":3902,"start":673,"enrollment":100,"conditions":3903,"interventions":3910},"NCT01465815","Phase I\u002FII Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)",[88,89],"2013-09",[3904,3905,3906,3907,3908,3909],"Recurrent Skin Cancer","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Squamous Cell Carcinoma of the Skin","Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity",[3554,3911],"linsitinib",{"trials":3913,"activeCount":100},[],{"trials":3915,"activeCount":100},[],{"trials":3917,"activeCount":100},[],{"intervention":2270,"totalTrials":9,"cells":3919},{"EARLY_PHASE1":3920,"PHASE1":3922,"PHASE2":3924,"PHASE3":3934,"PHASE4":3936,"NA":3938},{"trials":3921,"activeCount":100},[],{"trials":3923,"activeCount":100},[],{"trials":3925,"activeCount":100},[3926,3930],{"nctId":2264,"briefTitle":2265,"status":286,"phases":3927,"primaryCompletion":346,"completion":346,"start":2267,"enrollment":9,"conditions":3928,"interventions":3929},[89],[350],[2270,271,2271],{"nctId":3158,"briefTitle":3159,"status":205,"phases":3931,"primaryCompletion":872,"completion":872,"start":3161,"enrollment":674,"conditions":3932,"interventions":3933},[88,89],[18],[2270,326],{"trials":3935,"activeCount":100},[],{"trials":3937,"activeCount":100},[],{"trials":3939,"activeCount":100},[],{"intervention":1259,"totalTrials":9,"cells":3941},{"EARLY_PHASE1":3942,"PHASE1":3948,"PHASE2":3950,"PHASE3":3964,"PHASE4":3966,"NA":3968},{"trials":3943,"activeCount":100},[3944],{"nctId":1247,"briefTitle":1248,"status":883,"phases":3945,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":100,"conditions":3946,"interventions":3947},[87],[1183,175,1184,1185,1186,1187,1188,432,1228,1253,1254,574,474,1189,475,1190,476],[1256,1257,1258,1259,483,65,299,85,495,1260,1261,1262,678,1193,505,1263,508,1242,510,513,1264,521,523,1265,524],{"trials":3949,"activeCount":100},[],{"trials":3951,"activeCount":100},[3952],{"nctId":3953,"briefTitle":3954,"status":883,"phases":3955,"primaryCompletion":3956,"completion":3956,"start":3957,"enrollment":100,"conditions":3958,"interventions":3962},"NCT05327738","Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma",[89],"2027-12-04","2022-12-10",[3959,3960,793,3961,794],"BCLC Stage B Hepatocellular Carcinoma","BCLC Stage C Hepatocellular Carcinoma","Recurrent Hepatocellular Carcinoma",[1259,3963],"Cabozantinib S-malate",{"trials":3965,"activeCount":100},[],{"trials":3967,"activeCount":100},[],{"trials":3969,"activeCount":100},[],{"intervention":3285,"totalTrials":9,"cells":3971},{"EARLY_PHASE1":3972,"PHASE1":3974,"PHASE2":3980,"PHASE3":3986,"PHASE4":3988,"NA":3990},{"trials":3973,"activeCount":100},[],{"trials":3975,"activeCount":100},[3976],{"nctId":3254,"briefTitle":3255,"status":205,"phases":3977,"primaryCompletion":950,"completion":3257,"start":3258,"enrollment":951,"conditions":3978,"interventions":3979},[88],[921],[3261,3262,3263],{"trials":3981,"activeCount":100},[3982],{"nctId":3276,"briefTitle":3277,"status":205,"phases":3983,"primaryCompletion":3279,"completion":2167,"start":3280,"enrollment":414,"conditions":3984,"interventions":3985},[89],[3282,3283,1229,1230],[3285,3286,226],{"trials":3987,"activeCount":100},[],{"trials":3989,"activeCount":100},[],{"trials":3991,"activeCount":100},[],{"intervention":3286,"totalTrials":9,"cells":3993},{"EARLY_PHASE1":3994,"PHASE1":3996,"PHASE2":4002,"PHASE3":4008,"PHASE4":4010,"NA":4012},{"trials":3995,"activeCount":100},[],{"trials":3997,"activeCount":100},[3998],{"nctId":3254,"briefTitle":3255,"status":205,"phases":3999,"primaryCompletion":950,"completion":3257,"start":3258,"enrollment":951,"conditions":4000,"interventions":4001},[88],[921],[3261,3262,3263],{"trials":4003,"activeCount":100},[4004],{"nctId":3276,"briefTitle":3277,"status":205,"phases":4005,"primaryCompletion":3279,"completion":2167,"start":3280,"enrollment":414,"conditions":4006,"interventions":4007},[89],[3282,3283,1229,1230],[3285,3286,226],{"trials":4009,"activeCount":100},[],{"trials":4011,"activeCount":100},[],{"trials":4013,"activeCount":100},[],{"intervention":4015,"totalTrials":9,"cells":4016},"ipilimumab",{"EARLY_PHASE1":4017,"PHASE1":4019,"PHASE2":4025,"PHASE3":4036,"PHASE4":4038,"NA":4040},{"trials":4018,"activeCount":100},[],{"trials":4020,"activeCount":100},[4021],{"nctId":425,"briefTitle":426,"status":286,"phases":4022,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":4023,"interventions":4024},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":4026,"activeCount":100},[4027],{"nctId":4028,"briefTitle":4029,"status":205,"phases":4030,"primaryCompletion":4031,"completion":4032,"start":4033,"enrollment":740,"conditions":4034,"interventions":4035},"NCT01498978","Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer",[89],"2017-02-28","2019-01-19","2012-02-06",[1642,1643,1644,1059],[4015],{"trials":4037,"activeCount":100},[],{"trials":4039,"activeCount":100},[],{"trials":4041,"activeCount":100},[],{"intervention":496,"totalTrials":9,"cells":4043},{"EARLY_PHASE1":4044,"PHASE1":4046,"PHASE2":4052,"PHASE3":4058,"PHASE4":4060,"NA":4062},{"trials":4045,"activeCount":100},[],{"trials":4047,"activeCount":100},[4048],{"nctId":425,"briefTitle":426,"status":286,"phases":4049,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":4050,"interventions":4051},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":4053,"activeCount":100},[4054],{"nctId":670,"briefTitle":671,"status":286,"phases":4055,"primaryCompletion":673,"completion":673,"start":345,"enrollment":674,"conditions":4056,"interventions":4057},[89],[676],[496,498,502,509,678],{"trials":4059,"activeCount":100},[],{"trials":4061,"activeCount":100},[],{"trials":4063,"activeCount":100},[],{"intervention":525,"totalTrials":9,"cells":4065},{"EARLY_PHASE1":4066,"PHASE1":4068,"PHASE2":4074,"PHASE3":4080,"PHASE4":4082,"NA":4084},{"trials":4067,"activeCount":100},[],{"trials":4069,"activeCount":100},[4070],{"nctId":425,"briefTitle":426,"status":286,"phases":4071,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":4072,"interventions":4073},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":4075,"activeCount":100},[4076],{"nctId":1607,"briefTitle":1608,"status":205,"phases":4077,"primaryCompletion":1610,"completion":1611,"start":1612,"enrollment":1613,"conditions":4078,"interventions":4079},[89],[1615,451,1616,1617],[314,224,525],{"trials":4081,"activeCount":100},[],{"trials":4083,"activeCount":100},[],{"trials":4085,"activeCount":100},[],{"intervention":1264,"totalTrials":9,"cells":4087},{"EARLY_PHASE1":4088,"PHASE1":4094,"PHASE2":4096,"PHASE3":4102,"PHASE4":4104,"NA":4106},{"trials":4089,"activeCount":100},[4090],{"nctId":1247,"briefTitle":1248,"status":883,"phases":4091,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":100,"conditions":4092,"interventions":4093},[87],[1183,175,1184,1185,1186,1187,1188,432,1228,1253,1254,574,474,1189,475,1190,476],[1256,1257,1258,1259,483,65,299,85,495,1260,1261,1262,678,1193,505,1263,508,1242,510,513,1264,521,523,1265,524],{"trials":4095,"activeCount":100},[],{"trials":4097,"activeCount":100},[4098],{"nctId":881,"briefTitle":882,"status":883,"phases":4099,"primaryCompletion":885,"completion":885,"start":885,"enrollment":100,"conditions":4100,"interventions":4101},[88,89],[293,21,887,294,888],[890,891,273,892],{"trials":4103,"activeCount":100},[],{"trials":4105,"activeCount":100},[],{"trials":4107,"activeCount":100},[],{"intervention":485,"totalTrials":9,"cells":4109},{"EARLY_PHASE1":4110,"PHASE1":4112,"PHASE2":4118,"PHASE3":4132,"PHASE4":4134,"NA":4136},{"trials":4111,"activeCount":100},[],{"trials":4113,"activeCount":100},[4114],{"nctId":425,"briefTitle":426,"status":286,"phases":4115,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":4116,"interventions":4117},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":4119,"activeCount":100},[4120],{"nctId":4121,"briefTitle":4122,"status":286,"phases":4123,"primaryCompletion":4124,"completion":1640,"start":2507,"enrollment":387,"conditions":4125,"interventions":4130},"NCT01397591","Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma",[89],"2013-05",[4126,4127,4128,4129,742],"Recurrent Adult Diffuse Large Cell Lymphoma","Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Grade 3 Follicular Lymphoma",[4131,485],"Ofatumumab",{"trials":4133,"activeCount":100},[],{"trials":4135,"activeCount":100},[],{"trials":4137,"activeCount":100},[],{"intervention":487,"totalTrials":9,"cells":4139},{"EARLY_PHASE1":4140,"PHASE1":4142,"PHASE2":4148,"PHASE3":4159,"PHASE4":4161,"NA":4163},{"trials":4141,"activeCount":100},[],{"trials":4143,"activeCount":100},[4144],{"nctId":425,"briefTitle":426,"status":286,"phases":4145,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":4146,"interventions":4147},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":4149,"activeCount":100},[4150],{"nctId":4151,"briefTitle":4152,"status":286,"phases":4153,"primaryCompletion":4154,"completion":320,"start":4155,"enrollment":4156,"conditions":4157,"interventions":4158},"NCT02840162","Pre-Prostatectomy Celecoxib or Placebo",[89],"2005-01","2001-05",34,[1642,15],[487],{"trials":4160,"activeCount":100},[],{"trials":4162,"activeCount":100},[],{"trials":4164,"activeCount":100},[],{"intervention":337,"totalTrials":9,"cells":4166},{"EARLY_PHASE1":4167,"PHASE1":4169,"PHASE2":4171,"PHASE3":4181,"PHASE4":4183,"NA":4185},{"trials":4168,"activeCount":100},[],{"trials":4170,"activeCount":100},[],{"trials":4172,"activeCount":100},[4173,4177],{"nctId":328,"briefTitle":329,"status":286,"phases":4174,"primaryCompletion":331,"completion":332,"start":333,"enrollment":235,"conditions":4175,"interventions":4176},[89],[18],[269,270,271,336,326,273,337,338,339],{"nctId":341,"briefTitle":342,"status":286,"phases":4178,"primaryCompletion":344,"completion":345,"start":346,"enrollment":347,"conditions":4179,"interventions":4180},[89],[349,18,24,350,33,351,352],[354,267,355,356,269,357,270,358,359,360,273,337,361,362],{"trials":4182,"activeCount":100},[],{"trials":4184,"activeCount":100},[],{"trials":4186,"activeCount":100},[],{"intervention":600,"totalTrials":9,"cells":4188},{"EARLY_PHASE1":4189,"PHASE1":4191,"PHASE2":4193,"PHASE3":4203,"PHASE4":4205,"NA":4207},{"trials":4190,"activeCount":100},[],{"trials":4192,"activeCount":100},[],{"trials":4194,"activeCount":100},[4195,4199],{"nctId":3365,"briefTitle":3366,"status":205,"phases":4196,"primaryCompletion":3368,"start":3369,"enrollment":1613,"conditions":4197,"interventions":4198},[89],[15],[3332,600],{"nctId":592,"briefTitle":593,"status":205,"phases":4200,"primaryCompletion":595,"completion":595,"start":596,"enrollment":597,"conditions":4201,"interventions":4202},[89],[15],[600,601],{"trials":4204,"activeCount":100},[],{"trials":4206,"activeCount":100},[],{"trials":4208,"activeCount":100},[],{"intervention":356,"totalTrials":9,"cells":4210},{"EARLY_PHASE1":4211,"PHASE1":4213,"PHASE2":4219,"PHASE3":4225,"PHASE4":4227,"NA":4229},{"trials":4212,"activeCount":100},[],{"trials":4214,"activeCount":100},[4215],{"nctId":230,"briefTitle":231,"status":205,"phases":4216,"primaryCompletion":233,"completion":233,"start":234,"enrollment":235,"conditions":4217,"interventions":4218},[88],[237,238],[240,196,241,242,243,221,244],{"trials":4220,"activeCount":100},[4221],{"nctId":341,"briefTitle":342,"status":286,"phases":4222,"primaryCompletion":344,"completion":345,"start":346,"enrollment":347,"conditions":4223,"interventions":4224},[89],[349,18,24,350,33,351,352],[354,267,355,356,269,357,270,358,359,360,273,337,361,362],{"trials":4226,"activeCount":100},[],{"trials":4228,"activeCount":100},[],{"trials":4230,"activeCount":100},[],{"intervention":518,"totalTrials":9,"cells":4232},{"EARLY_PHASE1":4233,"PHASE1":4235,"PHASE2":4241,"PHASE3":4247,"PHASE4":4249,"NA":4251},{"trials":4234,"activeCount":100},[],{"trials":4236,"activeCount":100},[4237],{"nctId":425,"briefTitle":426,"status":286,"phases":4238,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":4239,"interventions":4240},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":4242,"activeCount":100},[4243],{"nctId":2515,"briefTitle":2516,"status":286,"phases":4244,"primaryCompletion":2518,"completion":2519,"start":2520,"enrollment":22,"conditions":4245,"interventions":4246},[89],[2522,2523,449,450,460,461],[216,219,2525,514,223,516,518,226,519,227],{"trials":4248,"activeCount":100},[],{"trials":4250,"activeCount":100},[],{"trials":4252,"activeCount":100},[],{"intervention":519,"totalTrials":9,"cells":4254},{"EARLY_PHASE1":4255,"PHASE1":4257,"PHASE2":4263,"PHASE3":4269,"PHASE4":4271,"NA":4273},{"trials":4256,"activeCount":100},[],{"trials":4258,"activeCount":100},[4259],{"nctId":425,"briefTitle":426,"status":286,"phases":4260,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":4261,"interventions":4262},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":4264,"activeCount":100},[4265],{"nctId":2515,"briefTitle":2516,"status":286,"phases":4266,"primaryCompletion":2518,"completion":2519,"start":2520,"enrollment":22,"conditions":4267,"interventions":4268},[89],[2522,2523,449,450,460,461],[216,219,2525,514,223,516,518,226,519,227],{"trials":4270,"activeCount":100},[],{"trials":4272,"activeCount":100},[],{"trials":4274,"activeCount":100},[],{"intervention":268,"totalTrials":96,"cells":4276},{"EARLY_PHASE1":4277,"PHASE1":4279,"PHASE2":4281,"PHASE3":4287,"PHASE4":4289,"NA":4291},{"trials":4278,"activeCount":100},[],{"trials":4280,"activeCount":100},[],{"trials":4282,"activeCount":100},[4283],{"nctId":259,"briefTitle":260,"status":205,"phases":4284,"primaryCompletion":262,"completion":262,"start":263,"enrollment":264,"conditions":4285,"interventions":4286},[89],[24],[267,268,269,270,271,272,273],{"trials":4288,"activeCount":100},[],{"trials":4290,"activeCount":100},[],{"trials":4292,"activeCount":100},[],{"intervention":4294,"totalTrials":96,"cells":4295},"Docetaxel+IMRT",{"EARLY_PHASE1":4296,"PHASE1":4298,"PHASE2":4300,"PHASE3":4311,"PHASE4":4313,"NA":4315},{"trials":4297,"activeCount":100},[],{"trials":4299,"activeCount":100},[],{"trials":4301,"activeCount":100},[4302],{"nctId":4303,"briefTitle":4304,"status":286,"phases":4305,"primaryCompletion":4306,"completion":4307,"start":4308,"enrollment":3177,"conditions":4309,"interventions":4310},"NCT00321698","Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer",[88,89],"2009-10-01","2023-08-18","2006-04-21",[15],[4294],{"trials":4312,"activeCount":100},[],{"trials":4314,"activeCount":100},[],{"trials":4316,"activeCount":100},[],{"intervention":281,"totalTrials":96,"cells":4318},{"EARLY_PHASE1":4319,"PHASE1":4321,"PHASE2":4323,"PHASE3":4329,"PHASE4":4331,"NA":4333},{"trials":4320,"activeCount":100},[],{"trials":4322,"activeCount":100},[],{"trials":4324,"activeCount":100},[4325],{"nctId":275,"briefTitle":276,"status":205,"phases":4326,"primaryCompletion":278,"completion":278,"start":263,"enrollment":96,"conditions":4327,"interventions":4328},[89],[24],[270,271,281,273,282],{"trials":4330,"activeCount":100},[],{"trials":4332,"activeCount":100},[],{"trials":4334,"activeCount":100},[],{"intervention":282,"totalTrials":96,"cells":4336},{"EARLY_PHASE1":4337,"PHASE1":4339,"PHASE2":4341,"PHASE3":4347,"PHASE4":4349,"NA":4351},{"trials":4338,"activeCount":100},[],{"trials":4340,"activeCount":100},[],{"trials":4342,"activeCount":100},[4343],{"nctId":275,"briefTitle":276,"status":205,"phases":4344,"primaryCompletion":278,"completion":278,"start":263,"enrollment":96,"conditions":4345,"interventions":4346},[89],[24],[270,271,281,273,282],{"trials":4348,"activeCount":100},[],{"trials":4350,"activeCount":100},[],{"trials":4352,"activeCount":100},[],{"intervention":4354,"totalTrials":96,"cells":4355},"Fluocinonide Cream",{"EARLY_PHASE1":4356,"PHASE1":4358,"PHASE2":4360,"PHASE3":4370,"PHASE4":4372,"NA":4374},{"trials":4357,"activeCount":100},[],{"trials":4359,"activeCount":100},[],{"trials":4361,"activeCount":100},[4362],{"nctId":4363,"briefTitle":4364,"status":205,"phases":4365,"primaryCompletion":4366,"completion":4366,"start":4367,"enrollment":4156,"conditions":4368,"interventions":4369},"NCT01422408","Fluocinonide Cream in Treating Symptoms of Vaginal Dryness and Painful Sexual Intercourse In Patients With Breast Cancer Undergoing Hormone Therapy",[89],"2015-10","2011-09",[30],[4354],{"trials":4371,"activeCount":100},[],{"trials":4373,"activeCount":100},[],{"trials":4375,"activeCount":100},[],{"intervention":4377,"totalTrials":96,"cells":4378},"Ferumoxtran-10",{"EARLY_PHASE1":4379,"PHASE1":4381,"PHASE2":4383,"PHASE3":4394,"PHASE4":4396,"NA":4398},{"trials":4380,"activeCount":100},[],{"trials":4382,"activeCount":100},[],{"trials":4384,"activeCount":100},[4385],{"nctId":4386,"briefTitle":4387,"status":286,"phases":4388,"primaryCompletion":4389,"completion":4389,"start":4390,"enrollment":4391,"conditions":4392,"interventions":4393},"NCT00659334","Imaging of Intravenous (IV) Combidex to Brain, Intra-cerebral Tumors and in Central Nervous System (CNS) Inflammation",[89],"2010-03","2000-08",116,[2154],[4377],{"trials":4395,"activeCount":100},[],{"trials":4397,"activeCount":100},[],{"trials":4399,"activeCount":100},[],{"intervention":2271,"totalTrials":96,"cells":4401},{"EARLY_PHASE1":4402,"PHASE1":4404,"PHASE2":4406,"PHASE3":4412,"PHASE4":4414,"NA":4416},{"trials":4403,"activeCount":100},[],{"trials":4405,"activeCount":100},[],{"trials":4407,"activeCount":100},[4408],{"nctId":2264,"briefTitle":2265,"status":286,"phases":4409,"primaryCompletion":346,"completion":346,"start":2267,"enrollment":9,"conditions":4410,"interventions":4411},[89],[350],[2270,271,2271],{"trials":4413,"activeCount":100},[],{"trials":4415,"activeCount":100},[],{"trials":4417,"activeCount":100},[],{"intervention":1355,"totalTrials":96,"cells":4419},{"EARLY_PHASE1":4420,"PHASE1":4422,"PHASE2":4424,"PHASE3":4430,"PHASE4":4432,"NA":4434},{"trials":4421,"activeCount":100},[],{"trials":4423,"activeCount":100},[],{"trials":4425,"activeCount":100},[4426],{"nctId":1347,"briefTitle":1348,"status":205,"phases":4427,"primaryCompletion":1350,"completion":1350,"start":872,"enrollment":1351,"conditions":4428,"interventions":4429},[88,89],[18,33],[1354,1355],{"trials":4431,"activeCount":100},[],{"trials":4433,"activeCount":100},[],{"trials":4435,"activeCount":100},[],{"intervention":3963,"totalTrials":96,"cells":4437},{"EARLY_PHASE1":4438,"PHASE1":4440,"PHASE2":4442,"PHASE3":4448,"PHASE4":4450,"NA":4452},{"trials":4439,"activeCount":100},[],{"trials":4441,"activeCount":100},[],{"trials":4443,"activeCount":100},[4444],{"nctId":3953,"briefTitle":3954,"status":883,"phases":4445,"primaryCompletion":3956,"completion":3956,"start":3957,"enrollment":100,"conditions":4446,"interventions":4447},[89],[3959,3960,793,3961,794],[1259,3963],{"trials":4449,"activeCount":100},[],{"trials":4451,"activeCount":100},[],{"trials":4453,"activeCount":100},[],{"intervention":4455,"totalTrials":96,"cells":4456},"Xisomab 3G3",{"EARLY_PHASE1":4457,"PHASE1":4459,"PHASE2":4461,"PHASE3":4473,"PHASE4":4475,"NA":4477},{"trials":4458,"activeCount":100},[],{"trials":4460,"activeCount":100},[],{"trials":4462,"activeCount":100},[4463],{"nctId":4464,"briefTitle":4465,"status":286,"phases":4466,"primaryCompletion":4467,"completion":4468,"start":4469,"enrollment":31,"conditions":4470,"interventions":4472},"NCT04465760","Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy",[89],"2021-10-05","2021-11-05","2021-02-25",[24,28,4471],"Plasma Cell Myeloma",[4455],{"trials":4474,"activeCount":100},[],{"trials":4476,"activeCount":100},[],{"trials":4478,"activeCount":100},[],{"intervention":1097,"totalTrials":96,"cells":4480},{"EARLY_PHASE1":4481,"PHASE1":4483,"PHASE2":4485,"PHASE3":4491,"PHASE4":4493,"NA":4495},{"trials":4482,"activeCount":100},[],{"trials":4484,"activeCount":100},[],{"trials":4486,"activeCount":100},[4487],{"nctId":1085,"briefTitle":1086,"status":883,"phases":4488,"primaryCompletion":84,"completion":1088,"start":1089,"enrollment":100,"conditions":4489,"interventions":4490},[89],[1091,1092,1093,1094,1095],[1097,484,512],{"trials":4492,"activeCount":100},[],{"trials":4494,"activeCount":100},[],{"trials":4496,"activeCount":100},[],{"intervention":4498,"totalTrials":96,"cells":4499},"transdermal estradiol",{"EARLY_PHASE1":4500,"PHASE1":4502,"PHASE2":4504,"PHASE3":4514,"PHASE4":4516,"NA":4518},{"trials":4501,"activeCount":100},[],{"trials":4503,"activeCount":100},[],{"trials":4505,"activeCount":100},[4506],{"nctId":4507,"briefTitle":4508,"status":286,"phases":4509,"primaryCompletion":3344,"completion":3344,"start":4510,"enrollment":3207,"conditions":4511,"interventions":4512},"NCT00459810","Paclitaxel Poliglumex and Estradiol in Treating Patients With Stage IV Prostate Cancer",[89],"2007-02",[15],[4498,4513],"paclitaxel poliglumex",{"trials":4515,"activeCount":100},[],{"trials":4517,"activeCount":100},[],{"trials":4519,"activeCount":100},[],{"intervention":4513,"totalTrials":96,"cells":4521},{"EARLY_PHASE1":4522,"PHASE1":4524,"PHASE2":4526,"PHASE3":4532,"PHASE4":4534,"NA":4536},{"trials":4523,"activeCount":100},[],{"trials":4525,"activeCount":100},[],{"trials":4527,"activeCount":100},[4528],{"nctId":4507,"briefTitle":4508,"status":286,"phases":4529,"primaryCompletion":3344,"completion":3344,"start":4510,"enrollment":3207,"conditions":4530,"interventions":4531},[89],[15],[4498,4513],{"trials":4533,"activeCount":100},[],{"trials":4535,"activeCount":100},[],{"trials":4537,"activeCount":100},[],{"intervention":4539,"totalTrials":96,"cells":4540},"fosaprepitant dimeglumine",{"EARLY_PHASE1":4541,"PHASE1":4543,"PHASE2":4545,"PHASE3":4557,"PHASE4":4559,"NA":4561},{"trials":4542,"activeCount":100},[],{"trials":4544,"activeCount":100},[],{"trials":4546,"activeCount":100},[4547],{"nctId":4548,"briefTitle":4549,"status":286,"phases":4550,"primaryCompletion":4551,"completion":4551,"start":1612,"enrollment":4156,"conditions":4552,"interventions":4555},"NCT01031953","Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy",[88,89],"2013-02",[4553,4554],"Breakthrough Nausea and Vomiting","Unspecified Adult Solid Tumor, Protocol Specific",[4539,4556],"systemic chemotherapy",{"trials":4558,"activeCount":100},[],{"trials":4560,"activeCount":100},[],{"trials":4562,"activeCount":100},[],{"intervention":4556,"totalTrials":96,"cells":4564},{"EARLY_PHASE1":4565,"PHASE1":4567,"PHASE2":4569,"PHASE3":4575,"PHASE4":4577,"NA":4579},{"trials":4566,"activeCount":100},[],{"trials":4568,"activeCount":100},[],{"trials":4570,"activeCount":100},[4571],{"nctId":4548,"briefTitle":4549,"status":286,"phases":4572,"primaryCompletion":4551,"completion":4551,"start":1612,"enrollment":4156,"conditions":4573,"interventions":4574},[88,89],[4553,4554],[4539,4556],{"trials":4576,"activeCount":100},[],{"trials":4578,"activeCount":100},[],{"trials":4580,"activeCount":100},[],{"intervention":4582,"totalTrials":96,"cells":4583},"Sulforaphane",{"EARLY_PHASE1":4584,"PHASE1":4586,"PHASE2":4588,"PHASE3":4598,"PHASE4":4600,"NA":4602},{"trials":4585,"activeCount":100},[],{"trials":4587,"activeCount":100},[],{"trials":4589,"activeCount":100},[4590],{"nctId":4591,"briefTitle":4592,"status":205,"phases":4593,"primaryCompletion":4594,"completion":4124,"start":4595,"enrollment":414,"conditions":4596,"interventions":4597},"NCT01228084","Sulforaphane in Treating Patients With Recurrent Prostate Cancer",[89],"2012-05","2010-11",[1642,1644],[4582],{"trials":4599,"activeCount":100},[],{"trials":4601,"activeCount":100},[],{"trials":4603,"activeCount":100},[],{"intervention":2466,"totalTrials":96,"cells":4605},{"EARLY_PHASE1":4606,"PHASE1":4608,"PHASE2":4610,"PHASE3":4616,"PHASE4":4618,"NA":4620},{"trials":4607,"activeCount":100},[],{"trials":4609,"activeCount":100},[],{"trials":4611,"activeCount":100},[4612],{"nctId":2458,"briefTitle":2459,"status":286,"phases":4613,"primaryCompletion":2290,"completion":2461,"start":2462,"enrollment":9,"conditions":4614,"interventions":4615},[88,89],[24],[2465,2466,2467,2468,2469,2470],{"trials":4617,"activeCount":100},[],{"trials":4619,"activeCount":100},[],{"trials":4621,"activeCount":100},[],{"intervention":2467,"totalTrials":96,"cells":4623},{"EARLY_PHASE1":4624,"PHASE1":4626,"PHASE2":4628,"PHASE3":4634,"PHASE4":4636,"NA":4638},{"trials":4625,"activeCount":100},[],{"trials":4627,"activeCount":100},[],{"trials":4629,"activeCount":100},[4630],{"nctId":2458,"briefTitle":2459,"status":286,"phases":4631,"primaryCompletion":2290,"completion":2461,"start":2462,"enrollment":9,"conditions":4632,"interventions":4633},[88,89],[24],[2465,2466,2467,2468,2469,2470],{"trials":4635,"activeCount":100},[],{"trials":4637,"activeCount":100},[],{"trials":4639,"activeCount":100},[],{"intervention":2468,"totalTrials":96,"cells":4641},{"EARLY_PHASE1":4642,"PHASE1":4644,"PHASE2":4646,"PHASE3":4652,"PHASE4":4654,"NA":4656},{"trials":4643,"activeCount":100},[],{"trials":4645,"activeCount":100},[],{"trials":4647,"activeCount":100},[4648],{"nctId":2458,"briefTitle":2459,"status":286,"phases":4649,"primaryCompletion":2290,"completion":2461,"start":2462,"enrollment":9,"conditions":4650,"interventions":4651},[88,89],[24],[2465,2466,2467,2468,2469,2470],{"trials":4653,"activeCount":100},[],{"trials":4655,"activeCount":100},[],{"trials":4657,"activeCount":100},[],{"intervention":1192,"totalTrials":96,"cells":4659},{"EARLY_PHASE1":4660,"PHASE1":4662,"PHASE2":4664,"PHASE3":4670,"PHASE4":4672,"NA":4674},{"trials":4661,"activeCount":100},[],{"trials":4663,"activeCount":100},[],{"trials":4665,"activeCount":100},[4666],{"nctId":1176,"briefTitle":1177,"status":286,"phases":4667,"primaryCompletion":1179,"completion":1179,"start":1180,"enrollment":1181,"conditions":4668,"interventions":4669},[89],[1183,175,1184,1185,1186,1187,1188,432,1189,475,1095,1190,476,477],[480,1192,693,1193,1194,1195,1196],{"trials":4671,"activeCount":100},[],{"trials":4673,"activeCount":100},[],{"trials":4675,"activeCount":100},[],{"intervention":1194,"totalTrials":96,"cells":4677},{"EARLY_PHASE1":4678,"PHASE1":4680,"PHASE2":4682,"PHASE3":4688,"PHASE4":4690,"NA":4692},{"trials":4679,"activeCount":100},[],{"trials":4681,"activeCount":100},[],{"trials":4683,"activeCount":100},[4684],{"nctId":1176,"briefTitle":1177,"status":286,"phases":4685,"primaryCompletion":1179,"completion":1179,"start":1180,"enrollment":1181,"conditions":4686,"interventions":4687},[89],[1183,175,1184,1185,1186,1187,1188,432,1189,475,1095,1190,476,477],[480,1192,693,1193,1194,1195,1196],{"trials":4689,"activeCount":100},[],{"trials":4691,"activeCount":100},[],{"trials":4693,"activeCount":100},[],{"intervention":1195,"totalTrials":96,"cells":4695},{"EARLY_PHASE1":4696,"PHASE1":4698,"PHASE2":4700,"PHASE3":4706,"PHASE4":4708,"NA":4710},{"trials":4697,"activeCount":100},[],{"trials":4699,"activeCount":100},[],{"trials":4701,"activeCount":100},[4702],{"nctId":1176,"briefTitle":1177,"status":286,"phases":4703,"primaryCompletion":1179,"completion":1179,"start":1180,"enrollment":1181,"conditions":4704,"interventions":4705},[89],[1183,175,1184,1185,1186,1187,1188,432,1189,475,1095,1190,476,477],[480,1192,693,1193,1194,1195,1196],{"trials":4707,"activeCount":100},[],{"trials":4709,"activeCount":100},[],{"trials":4711,"activeCount":100},[],{"intervention":1196,"totalTrials":96,"cells":4713},{"EARLY_PHASE1":4714,"PHASE1":4716,"PHASE2":4718,"PHASE3":4724,"PHASE4":4726,"NA":4728},{"trials":4715,"activeCount":100},[],{"trials":4717,"activeCount":100},[],{"trials":4719,"activeCount":100},[4720],{"nctId":1176,"briefTitle":1177,"status":286,"phases":4721,"primaryCompletion":1179,"completion":1179,"start":1180,"enrollment":1181,"conditions":4722,"interventions":4723},[89],[1183,175,1184,1185,1186,1187,1188,432,1189,475,1095,1190,476,477],[480,1192,693,1193,1194,1195,1196],{"trials":4725,"activeCount":100},[],{"trials":4727,"activeCount":100},[],{"trials":4729,"activeCount":100},[],{"intervention":3232,"totalTrials":96,"cells":4731},{"EARLY_PHASE1":4732,"PHASE1":4734,"PHASE2":4736,"PHASE3":4742,"PHASE4":4744,"NA":4746},{"trials":4733,"activeCount":100},[],{"trials":4735,"activeCount":100},[],{"trials":4737,"activeCount":100},[4738],{"nctId":3226,"briefTitle":3227,"status":205,"phases":4739,"primaryCompletion":871,"completion":3205,"start":3229,"enrollment":571,"conditions":4740,"interventions":4741},[89],[24],[267,355,360,3232],{"trials":4743,"activeCount":100},[],{"trials":4745,"activeCount":100},[],{"trials":4747,"activeCount":100},[],{"intervention":3911,"totalTrials":96,"cells":4749},{"EARLY_PHASE1":4750,"PHASE1":4752,"PHASE2":4754,"PHASE3":4760,"PHASE4":4762,"NA":4764},{"trials":4751,"activeCount":100},[],{"trials":4753,"activeCount":100},[],{"trials":4755,"activeCount":100},[4756],{"nctId":3899,"briefTitle":3900,"status":883,"phases":4757,"primaryCompletion":3902,"completion":3902,"start":673,"enrollment":100,"conditions":4758,"interventions":4759},[88,89],[3904,3905,3906,3907,3908,3909],[3554,3911],{"trials":4761,"activeCount":100},[],{"trials":4763,"activeCount":100},[],{"trials":4765,"activeCount":100},[],{"intervention":297,"totalTrials":96,"cells":4767},{"EARLY_PHASE1":4768,"PHASE1":4770,"PHASE2":4772,"PHASE3":4778,"PHASE4":4780,"NA":4782},{"trials":4769,"activeCount":100},[],{"trials":4771,"activeCount":100},[],{"trials":4773,"activeCount":100},[4774],{"nctId":284,"briefTitle":285,"status":286,"phases":4775,"primaryCompletion":288,"completion":289,"start":290,"enrollment":291,"conditions":4776,"interventions":4777},[89],[293,294,24,295],[297,215,241,298,299,300,301,302,196],{"trials":4779,"activeCount":100},[],{"trials":4781,"activeCount":100},[],{"trials":4783,"activeCount":100},[],{"intervention":301,"totalTrials":96,"cells":4785},{"EARLY_PHASE1":4786,"PHASE1":4788,"PHASE2":4790,"PHASE3":4796,"PHASE4":4798,"NA":4800},{"trials":4787,"activeCount":100},[],{"trials":4789,"activeCount":100},[],{"trials":4791,"activeCount":100},[4792],{"nctId":284,"briefTitle":285,"status":286,"phases":4793,"primaryCompletion":288,"completion":289,"start":290,"enrollment":291,"conditions":4794,"interventions":4795},[89],[293,294,24,295],[297,215,241,298,299,300,301,302,196],{"trials":4797,"activeCount":100},[],{"trials":4799,"activeCount":100},[],{"trials":4801,"activeCount":100},[],{"intervention":302,"totalTrials":96,"cells":4803},{"EARLY_PHASE1":4804,"PHASE1":4806,"PHASE2":4808,"PHASE3":4814,"PHASE4":4816,"NA":4818},{"trials":4805,"activeCount":100},[],{"trials":4807,"activeCount":100},[],{"trials":4809,"activeCount":100},[4810],{"nctId":284,"briefTitle":285,"status":286,"phases":4811,"primaryCompletion":288,"completion":289,"start":290,"enrollment":291,"conditions":4812,"interventions":4813},[89],[293,294,24,295],[297,215,241,298,299,300,301,302,196],{"trials":4815,"activeCount":100},[],{"trials":4817,"activeCount":100},[],{"trials":4819,"activeCount":100},[],{"intervention":877,"totalTrials":96,"cells":4821},{"EARLY_PHASE1":4822,"PHASE1":4824,"PHASE2":4826,"PHASE3":4832,"PHASE4":4834,"NA":4836},{"trials":4823,"activeCount":100},[],{"trials":4825,"activeCount":100},[],{"trials":4827,"activeCount":100},[4828],{"nctId":868,"briefTitle":869,"status":205,"phases":4829,"primaryCompletion":871,"completion":871,"start":872,"enrollment":873,"conditions":4830,"interventions":4831},[88,89],[349,18,24,350,33,351,875],[877,355,357,359,361,878,879,221],{"trials":4833,"activeCount":100},[],{"trials":4835,"activeCount":100},[],{"trials":4837,"activeCount":100},[],{"intervention":878,"totalTrials":96,"cells":4839},{"EARLY_PHASE1":4840,"PHASE1":4842,"PHASE2":4844,"PHASE3":4850,"PHASE4":4852,"NA":4854},{"trials":4841,"activeCount":100},[],{"trials":4843,"activeCount":100},[],{"trials":4845,"activeCount":100},[4846],{"nctId":868,"briefTitle":869,"status":205,"phases":4847,"primaryCompletion":871,"completion":871,"start":872,"enrollment":873,"conditions":4848,"interventions":4849},[88,89],[349,18,24,350,33,351,875],[877,355,357,359,361,878,879,221],{"trials":4851,"activeCount":100},[],{"trials":4853,"activeCount":100},[],{"trials":4855,"activeCount":100},[],{"intervention":879,"totalTrials":96,"cells":4857},{"EARLY_PHASE1":4858,"PHASE1":4860,"PHASE2":4862,"PHASE3":4868,"PHASE4":4870,"NA":4872},{"trials":4859,"activeCount":100},[],{"trials":4861,"activeCount":100},[],{"trials":4863,"activeCount":100},[4864],{"nctId":868,"briefTitle":869,"status":205,"phases":4865,"primaryCompletion":871,"completion":871,"start":872,"enrollment":873,"conditions":4866,"interventions":4867},[88,89],[349,18,24,350,33,351,875],[877,355,357,359,361,878,879,221],{"trials":4869,"activeCount":100},[],{"trials":4871,"activeCount":100},[],{"trials":4873,"activeCount":100},[],{"intervention":4875,"totalTrials":96,"cells":4876},"Daptomycin",{"EARLY_PHASE1":4877,"PHASE1":4879,"PHASE2":4881,"PHASE3":4893,"PHASE4":4895,"NA":4897},{"trials":4878,"activeCount":100},[],{"trials":4880,"activeCount":100},[],{"trials":4882,"activeCount":100},[4883],{"nctId":4884,"briefTitle":4885,"status":205,"phases":4886,"primaryCompletion":2152,"completion":2152,"start":2395,"enrollment":658,"conditions":4887,"interventions":4892},"NCT00335478","Daptomycin in Treating Neutropenia and Fever in Patients With Cancer",[89],[4888,4889,4890,3018,4891,4554],"Fever","Sweating","Hot Flashes","Neutropenia",[4875],{"trials":4894,"activeCount":100},[],{"trials":4896,"activeCount":100},[],{"trials":4898,"activeCount":100},[],{"intervention":4131,"totalTrials":96,"cells":4900},{"EARLY_PHASE1":4901,"PHASE1":4903,"PHASE2":4905,"PHASE3":4911,"PHASE4":4913,"NA":4915},{"trials":4902,"activeCount":100},[],{"trials":4904,"activeCount":100},[],{"trials":4906,"activeCount":100},[4907],{"nctId":4121,"briefTitle":4122,"status":286,"phases":4908,"primaryCompletion":4124,"completion":1640,"start":2507,"enrollment":387,"conditions":4909,"interventions":4910},[89],[4126,4127,4128,4129,742],[4131,485],{"trials":4912,"activeCount":100},[],{"trials":4914,"activeCount":100},[],{"trials":4916,"activeCount":100},[],{"intervention":338,"totalTrials":96,"cells":4918},{"EARLY_PHASE1":4919,"PHASE1":4921,"PHASE2":4923,"PHASE3":4929,"PHASE4":4931,"NA":4933},{"trials":4920,"activeCount":100},[],{"trials":4922,"activeCount":100},[],{"trials":4924,"activeCount":100},[4925],{"nctId":328,"briefTitle":329,"status":286,"phases":4926,"primaryCompletion":331,"completion":332,"start":333,"enrollment":235,"conditions":4927,"interventions":4928},[89],[18],[269,270,271,336,326,273,337,338,339],{"trials":4930,"activeCount":100},[],{"trials":4932,"activeCount":100},[],{"trials":4934,"activeCount":100},[],{"intervention":3731,"totalTrials":96,"cells":4936},{"EARLY_PHASE1":4937,"PHASE1":4939,"PHASE2":4941,"PHASE3":4947,"PHASE4":4949,"NA":4951},{"trials":4938,"activeCount":100},[],{"trials":4940,"activeCount":100},[],{"trials":4942,"activeCount":100},[4943],{"nctId":3724,"briefTitle":3725,"status":286,"phases":4944,"primaryCompletion":3727,"completion":3727,"start":3153,"enrollment":395,"conditions":4945,"interventions":4946},[89],[3020,3729],[3731,483],{"trials":4948,"activeCount":100},[],{"trials":4950,"activeCount":100},[],{"trials":4952,"activeCount":100},[],{"intervention":3180,"totalTrials":96,"cells":4954},{"EARLY_PHASE1":4955,"PHASE1":4957,"PHASE2":4959,"PHASE3":4965,"PHASE4":4967,"NA":4969},{"trials":4956,"activeCount":100},[],{"trials":4958,"activeCount":100},[],{"trials":4960,"activeCount":100},[4961],{"nctId":3173,"briefTitle":3174,"status":286,"phases":4962,"primaryCompletion":320,"completion":320,"start":3176,"enrollment":3177,"conditions":4963,"interventions":4964},[89],[18],[3180,326],{"trials":4966,"activeCount":100},[],{"trials":4968,"activeCount":100},[],{"trials":4970,"activeCount":100},[],{"intervention":4972,"totalTrials":96,"cells":4973},"caspofungin acetate",{"EARLY_PHASE1":4974,"PHASE1":4976,"PHASE2":4978,"PHASE3":4989,"PHASE4":4991,"NA":4993},{"trials":4975,"activeCount":100},[],{"trials":4977,"activeCount":100},[],{"trials":4979,"activeCount":100},[4980],{"nctId":4981,"briefTitle":4982,"status":286,"phases":4983,"primaryCompletion":4984,"completion":4984,"start":4985,"enrollment":19,"conditions":4986,"interventions":4987},"NCT00238355","Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems",[89],"2008-06","2003-08",[3018,4554],[4972,4988],"voriconazole",{"trials":4990,"activeCount":100},[],{"trials":4992,"activeCount":100},[],{"trials":4994,"activeCount":100},[],{"intervention":4988,"totalTrials":96,"cells":4996},{"EARLY_PHASE1":4997,"PHASE1":4999,"PHASE2":5001,"PHASE3":5007,"PHASE4":5009,"NA":5011},{"trials":4998,"activeCount":100},[],{"trials":5000,"activeCount":100},[],{"trials":5002,"activeCount":100},[5003],{"nctId":4981,"briefTitle":4982,"status":286,"phases":5004,"primaryCompletion":4984,"completion":4984,"start":4985,"enrollment":19,"conditions":5005,"interventions":5006},[89],[3018,4554],[4972,4988],{"trials":5008,"activeCount":100},[],{"trials":5010,"activeCount":100},[],{"trials":5012,"activeCount":100},[],{"intervention":1232,"totalTrials":96,"cells":5014},{"EARLY_PHASE1":5015,"PHASE1":5017,"PHASE2":5019,"PHASE3":5025,"PHASE4":5027,"NA":5029},{"trials":5016,"activeCount":100},[],{"trials":5018,"activeCount":100},[],{"trials":5020,"activeCount":100},[5021],{"nctId":1207,"briefTitle":1208,"status":205,"phases":5022,"primaryCompletion":1210,"completion":1210,"start":1211,"enrollment":658,"conditions":5023,"interventions":5024},[89],[1213,1214,1215,1216,1217,1218,1219,1220,1221,1222,1223,1224,1225,1226,1227,1228,921,1229,1230],[693,1232,1233,1234],{"trials":5026,"activeCount":100},[],{"trials":5028,"activeCount":100},[],{"trials":5030,"activeCount":100},[],{"intervention":1233,"totalTrials":96,"cells":5032},{"EARLY_PHASE1":5033,"PHASE1":5035,"PHASE2":5037,"PHASE3":5043,"PHASE4":5045,"NA":5047},{"trials":5034,"activeCount":100},[],{"trials":5036,"activeCount":100},[],{"trials":5038,"activeCount":100},[5039],{"nctId":1207,"briefTitle":1208,"status":205,"phases":5040,"primaryCompletion":1210,"completion":1210,"start":1211,"enrollment":658,"conditions":5041,"interventions":5042},[89],[1213,1214,1215,1216,1217,1218,1219,1220,1221,1222,1223,1224,1225,1226,1227,1228,921,1229,1230],[693,1232,1233,1234],{"trials":5044,"activeCount":100},[],{"trials":5046,"activeCount":100},[],{"trials":5048,"activeCount":100},[],{"intervention":1234,"totalTrials":96,"cells":5050},{"EARLY_PHASE1":5051,"PHASE1":5053,"PHASE2":5055,"PHASE3":5061,"PHASE4":5063,"NA":5065},{"trials":5052,"activeCount":100},[],{"trials":5054,"activeCount":100},[],{"trials":5056,"activeCount":100},[5057],{"nctId":1207,"briefTitle":1208,"status":205,"phases":5058,"primaryCompletion":1210,"completion":1210,"start":1211,"enrollment":658,"conditions":5059,"interventions":5060},[89],[1213,1214,1215,1216,1217,1218,1219,1220,1221,1222,1223,1224,1225,1226,1227,1228,921,1229,1230],[693,1232,1233,1234],{"trials":5062,"activeCount":100},[],{"trials":5064,"activeCount":100},[],{"trials":5066,"activeCount":100},[],{"intervention":3617,"totalTrials":96,"cells":5068},{"EARLY_PHASE1":5069,"PHASE1":5071,"PHASE2":5073,"PHASE3":5079,"PHASE4":5081,"NA":5083},{"trials":5070,"activeCount":100},[],{"trials":5072,"activeCount":100},[],{"trials":5074,"activeCount":100},[5075],{"nctId":3609,"briefTitle":3610,"status":883,"phases":5076,"primaryCompletion":3612,"completion":3612,"start":3613,"enrollment":100,"conditions":5077,"interventions":5078},[89],[15],[3616,3617,3618],{"trials":5080,"activeCount":100},[],{"trials":5082,"activeCount":100},[],{"trials":5084,"activeCount":100},[],{"intervention":3618,"totalTrials":96,"cells":5086},{"EARLY_PHASE1":5087,"PHASE1":5089,"PHASE2":5091,"PHASE3":5097,"PHASE4":5099,"NA":5101},{"trials":5088,"activeCount":100},[],{"trials":5090,"activeCount":100},[],{"trials":5092,"activeCount":100},[5093],{"nctId":3609,"briefTitle":3610,"status":883,"phases":5094,"primaryCompletion":3612,"completion":3612,"start":3613,"enrollment":100,"conditions":5095,"interventions":5096},[89],[15],[3616,3617,3618],{"trials":5098,"activeCount":100},[],{"trials":5100,"activeCount":100},[],{"trials":5102,"activeCount":100},[],{"intervention":5104,"totalTrials":96,"cells":5105},"Botulinum Toxin Type A",{"EARLY_PHASE1":5106,"PHASE1":5108,"PHASE2":5110,"PHASE3":5121,"PHASE4":5123,"NA":5125},{"trials":5107,"activeCount":100},[],{"trials":5109,"activeCount":100},[],{"trials":5111,"activeCount":100},[5112],{"nctId":5113,"briefTitle":5114,"status":286,"phases":5115,"primaryCompletion":5116,"completion":5116,"start":5117,"enrollment":917,"conditions":5118,"interventions":5120},"NCT04965311","Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy",[89],"2024-07-10","2023-03-01",[5119],"Pancreatic Carcinoma",[5104],{"trials":5122,"activeCount":100},[],{"trials":5124,"activeCount":100},[],{"trials":5126,"activeCount":100},[],{"intervention":5128,"totalTrials":96,"cells":5129},"Edicotinib",{"EARLY_PHASE1":5130,"PHASE1":5132,"PHASE2":5134,"PHASE3":5144,"PHASE4":5146,"NA":5148},{"trials":5131,"activeCount":100},[],{"trials":5133,"activeCount":100},[],{"trials":5135,"activeCount":100},[5136],{"nctId":5137,"briefTitle":5138,"status":286,"phases":5139,"primaryCompletion":5140,"completion":5140,"start":5141,"enrollment":387,"conditions":5142,"interventions":5143},"NCT03557970","JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia",[89],"2020-09-28","2018-10-05",[450,461],[5128],{"trials":5145,"activeCount":100},[],{"trials":5147,"activeCount":100},[],{"trials":5149,"activeCount":100},[],{"intervention":354,"totalTrials":96,"cells":5151},{"EARLY_PHASE1":5152,"PHASE1":5154,"PHASE2":5156,"PHASE3":5162,"PHASE4":5164,"NA":5166},{"trials":5153,"activeCount":100},[],{"trials":5155,"activeCount":100},[],{"trials":5157,"activeCount":100},[5158],{"nctId":341,"briefTitle":342,"status":286,"phases":5159,"primaryCompletion":344,"completion":345,"start":346,"enrollment":347,"conditions":5160,"interventions":5161},[89],[349,18,24,350,33,351,352],[354,267,355,356,269,357,270,358,359,360,273,337,361,362],{"trials":5163,"activeCount":100},[],{"trials":5165,"activeCount":100},[],{"trials":5167,"activeCount":100},[],{"intervention":5169,"totalTrials":96,"cells":5170},"Lopinavir\u002FRitonavir",{"EARLY_PHASE1":5171,"PHASE1":5173,"PHASE2":5175,"PHASE3":5187,"PHASE4":5189,"NA":5191},{"trials":5172,"activeCount":100},[],{"trials":5174,"activeCount":100},[],{"trials":5176,"activeCount":100},[5177],{"nctId":5178,"briefTitle":5179,"status":883,"phases":5180,"primaryCompletion":5181,"completion":5181,"start":5182,"enrollment":100,"conditions":5183,"interventions":5186},"NCT04455958","Lopinavir\u002FRitonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year",[89],"2021-11-01","2021-05-01",[5184,28,5185],"Hematopoietic and Lymphoid Cell Neoplasm","Symptomatic COVID-19 Infection Laboratory-Confirmed",[5169],{"trials":5188,"activeCount":100},[],{"trials":5190,"activeCount":100},[],{"trials":5192,"activeCount":100},[],{"intervention":2525,"totalTrials":96,"cells":5194},{"EARLY_PHASE1":5195,"PHASE1":5197,"PHASE2":5199,"PHASE3":5205,"PHASE4":5207,"NA":5209},{"trials":5196,"activeCount":100},[],{"trials":5198,"activeCount":100},[],{"trials":5200,"activeCount":100},[5201],{"nctId":2515,"briefTitle":2516,"status":286,"phases":5202,"primaryCompletion":2518,"completion":2519,"start":2520,"enrollment":22,"conditions":5203,"interventions":5204},[89],[2522,2523,449,450,460,461],[216,219,2525,514,223,516,518,226,519,227],{"trials":5206,"activeCount":100},[],{"trials":5208,"activeCount":100},[],{"trials":5210,"activeCount":100},[],{"intervention":3383,"totalTrials":96,"cells":5212},{"EARLY_PHASE1":5213,"PHASE1":5215,"PHASE2":5217,"PHASE3":5223,"PHASE4":5225,"NA":5227},{"trials":5214,"activeCount":100},[],{"trials":5216,"activeCount":100},[],{"trials":5218,"activeCount":100},[5219],{"nctId":3373,"briefTitle":3374,"status":286,"phases":5220,"primaryCompletion":3376,"completion":3377,"start":3378,"enrollment":235,"conditions":5221,"interventions":5222},[89],[1040,3380,121,574],[3382,3383],{"trials":5224,"activeCount":100},[],{"trials":5226,"activeCount":100},[],{"trials":5228,"activeCount":100},[],{"intervention":3878,"totalTrials":96,"cells":5230},{"EARLY_PHASE1":5231,"PHASE1":5233,"PHASE2":5235,"PHASE3":5241,"PHASE4":5243,"NA":5245},{"trials":5232,"activeCount":100},[],{"trials":5234,"activeCount":100},[],{"trials":5236,"activeCount":100},[5237],{"nctId":3868,"briefTitle":3869,"status":205,"phases":5238,"primaryCompletion":3871,"completion":3872,"start":3873,"enrollment":3874,"conditions":5239,"interventions":5240},[89],[3876],[3878,3879],{"trials":5242,"activeCount":100},[],{"trials":5244,"activeCount":100},[],{"trials":5246,"activeCount":100},[],{"intervention":1367,"totalTrials":96,"cells":5248},{"EARLY_PHASE1":5249,"PHASE1":5251,"PHASE2":5253,"PHASE3":5259,"PHASE4":5261,"NA":5263},{"trials":5250,"activeCount":100},[],{"trials":5252,"activeCount":100},[],{"trials":5254,"activeCount":100},[5255],{"nctId":1361,"briefTitle":1362,"status":286,"phases":5256,"primaryCompletion":345,"completion":345,"start":1364,"enrollment":96,"conditions":5257,"interventions":5258},[89],[18],[1367,374],{"trials":5260,"activeCount":100},[],{"trials":5262,"activeCount":100},[],{"trials":5264,"activeCount":100},[],{"intervention":5266,"totalTrials":96,"cells":5267},"bcr-abl peptide vaccine",{"EARLY_PHASE1":5268,"PHASE1":5270,"PHASE2":5272,"PHASE3":5282,"PHASE4":5284,"NA":5286},{"trials":5269,"activeCount":100},[],{"trials":5271,"activeCount":100},[],{"trials":5273,"activeCount":100},[5274],{"nctId":5275,"briefTitle":5276,"status":286,"phases":5277,"primaryCompletion":2461,"completion":2461,"start":5278,"enrollment":917,"conditions":5279,"interventions":5280},"NCT00428077","Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia",[89],"2005-10",[18],[5266,5281],"reverse transcriptase-polymerase chain reaction",{"trials":5283,"activeCount":100},[],{"trials":5285,"activeCount":100},[],{"trials":5287,"activeCount":100},[],{"intervention":510,"totalTrials":9,"cells":5289},{"EARLY_PHASE1":5290,"PHASE1":5296,"PHASE2":5302,"PHASE3":5304,"PHASE4":5306,"NA":5308},{"trials":5291,"activeCount":100},[5292],{"nctId":1247,"briefTitle":1248,"status":883,"phases":5293,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":100,"conditions":5294,"interventions":5295},[87],[1183,175,1184,1185,1186,1187,1188,432,1228,1253,1254,574,474,1189,475,1190,476],[1256,1257,1258,1259,483,65,299,85,495,1260,1261,1262,678,1193,505,1263,508,1242,510,513,1264,521,523,1265,524],{"trials":5297,"activeCount":100},[5298],{"nctId":425,"briefTitle":426,"status":286,"phases":5299,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":5300,"interventions":5301},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":5303,"activeCount":100},[],{"trials":5305,"activeCount":100},[],{"trials":5307,"activeCount":100},[],{"trials":5309,"activeCount":100},[],{"intervention":513,"totalTrials":9,"cells":5311},{"EARLY_PHASE1":5312,"PHASE1":5318,"PHASE2":5324,"PHASE3":5326,"PHASE4":5328,"NA":5330},{"trials":5313,"activeCount":100},[5314],{"nctId":1247,"briefTitle":1248,"status":883,"phases":5315,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":100,"conditions":5316,"interventions":5317},[87],[1183,175,1184,1185,1186,1187,1188,432,1228,1253,1254,574,474,1189,475,1190,476],[1256,1257,1258,1259,483,65,299,85,495,1260,1261,1262,678,1193,505,1263,508,1242,510,513,1264,521,523,1265,524],{"trials":5319,"activeCount":100},[5320],{"nctId":425,"briefTitle":426,"status":286,"phases":5321,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":5322,"interventions":5323},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":5325,"activeCount":100},[],{"trials":5327,"activeCount":100},[],{"trials":5329,"activeCount":100},[],{"trials":5331,"activeCount":100},[],{"intervention":521,"totalTrials":9,"cells":5333},{"EARLY_PHASE1":5334,"PHASE1":5340,"PHASE2":5346,"PHASE3":5348,"PHASE4":5350,"NA":5352},{"trials":5335,"activeCount":100},[5336],{"nctId":1247,"briefTitle":1248,"status":883,"phases":5337,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":100,"conditions":5338,"interventions":5339},[87],[1183,175,1184,1185,1186,1187,1188,432,1228,1253,1254,574,474,1189,475,1190,476],[1256,1257,1258,1259,483,65,299,85,495,1260,1261,1262,678,1193,505,1263,508,1242,510,513,1264,521,523,1265,524],{"trials":5341,"activeCount":100},[5342],{"nctId":425,"briefTitle":426,"status":286,"phases":5343,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":5344,"interventions":5345},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":5347,"activeCount":100},[],{"trials":5349,"activeCount":100},[],{"trials":5351,"activeCount":100},[],{"trials":5353,"activeCount":100},[],{"intervention":523,"totalTrials":9,"cells":5355},{"EARLY_PHASE1":5356,"PHASE1":5362,"PHASE2":5368,"PHASE3":5370,"PHASE4":5372,"NA":5374},{"trials":5357,"activeCount":100},[5358],{"nctId":1247,"briefTitle":1248,"status":883,"phases":5359,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":100,"conditions":5360,"interventions":5361},[87],[1183,175,1184,1185,1186,1187,1188,432,1228,1253,1254,574,474,1189,475,1190,476],[1256,1257,1258,1259,483,65,299,85,495,1260,1261,1262,678,1193,505,1263,508,1242,510,513,1264,521,523,1265,524],{"trials":5363,"activeCount":100},[5364],{"nctId":425,"briefTitle":426,"status":286,"phases":5365,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":5366,"interventions":5367},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":5369,"activeCount":100},[],{"trials":5371,"activeCount":100},[],{"trials":5373,"activeCount":100},[],{"trials":5375,"activeCount":100},[],{"intervention":524,"totalTrials":9,"cells":5377},{"EARLY_PHASE1":5378,"PHASE1":5384,"PHASE2":5390,"PHASE3":5392,"PHASE4":5394,"NA":5396},{"trials":5379,"activeCount":100},[5380],{"nctId":1247,"briefTitle":1248,"status":883,"phases":5381,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":100,"conditions":5382,"interventions":5383},[87],[1183,175,1184,1185,1186,1187,1188,432,1228,1253,1254,574,474,1189,475,1190,476],[1256,1257,1258,1259,483,65,299,85,495,1260,1261,1262,678,1193,505,1263,508,1242,510,513,1264,521,523,1265,524],{"trials":5385,"activeCount":100},[5386],{"nctId":425,"briefTitle":426,"status":286,"phases":5387,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":5388,"interventions":5389},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":5391,"activeCount":100},[],{"trials":5393,"activeCount":100},[],{"trials":5395,"activeCount":100},[],{"trials":5397,"activeCount":100},[],{"intervention":517,"totalTrials":9,"cells":5399},{"EARLY_PHASE1":5400,"PHASE1":5402,"PHASE2":5412,"PHASE3":5414,"PHASE4":5416,"NA":5418},{"trials":5401,"activeCount":100},[],{"trials":5403,"activeCount":100},[5404,5408],{"nctId":946,"briefTitle":947,"status":205,"phases":5405,"primaryCompletion":949,"start":950,"enrollment":951,"conditions":5406,"interventions":5407},[88],[238,471],[215,70,954,517],{"nctId":425,"briefTitle":426,"status":286,"phases":5409,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":5410,"interventions":5411},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":5413,"activeCount":100},[],{"trials":5415,"activeCount":100},[],{"trials":5417,"activeCount":100},[],{"trials":5419,"activeCount":100},[],{"intervention":222,"totalTrials":96,"cells":5421},{"EARLY_PHASE1":5422,"PHASE1":5424,"PHASE2":5430,"PHASE3":5432,"PHASE4":5434,"NA":5436},{"trials":5423,"activeCount":100},[],{"trials":5425,"activeCount":100},[5426],{"nctId":203,"briefTitle":204,"status":205,"phases":5427,"primaryCompletion":207,"completion":208,"start":209,"enrollment":210,"conditions":5428,"interventions":5429},[88],[212,213],[215,196,216,70,217,218,219,220,221,222,223,224,225,226,227,228],{"trials":5431,"activeCount":100},[],{"trials":5433,"activeCount":100},[],{"trials":5435,"activeCount":100},[],{"trials":5437,"activeCount":100},[],{"intervention":1278,"totalTrials":96,"cells":5439},{"EARLY_PHASE1":5440,"PHASE1":5442,"PHASE2":5448,"PHASE3":5450,"PHASE4":5452,"NA":5454},{"trials":5441,"activeCount":100},[],{"trials":5443,"activeCount":100},[5444],{"nctId":1269,"briefTitle":1270,"status":883,"phases":5445,"primaryCompletion":1272,"completion":1272,"start":288,"enrollment":100,"conditions":5446,"interventions":5447},[88],[1274,1275,1276],[1242,1278,1279],{"trials":5449,"activeCount":100},[],{"trials":5451,"activeCount":100},[],{"trials":5453,"activeCount":100},[],{"trials":5455,"activeCount":100},[],{"intervention":1279,"totalTrials":96,"cells":5457},{"EARLY_PHASE1":5458,"PHASE1":5460,"PHASE2":5466,"PHASE3":5468,"PHASE4":5470,"NA":5472},{"trials":5459,"activeCount":100},[],{"trials":5461,"activeCount":100},[5462],{"nctId":1269,"briefTitle":1270,"status":883,"phases":5463,"primaryCompletion":1272,"completion":1272,"start":288,"enrollment":100,"conditions":5464,"interventions":5465},[88],[1274,1275,1276],[1242,1278,1279],{"trials":5467,"activeCount":100},[],{"trials":5469,"activeCount":100},[],{"trials":5471,"activeCount":100},[],{"trials":5473,"activeCount":100},[],{"intervention":3642,"totalTrials":96,"cells":5475},{"EARLY_PHASE1":5476,"PHASE1":5478,"PHASE2":5484,"PHASE3":5486,"PHASE4":5488,"NA":5490},{"trials":5477,"activeCount":100},[],{"trials":5479,"activeCount":100},[5480],{"nctId":3636,"briefTitle":3637,"status":286,"phases":5481,"primaryCompletion":3344,"completion":289,"start":3612,"enrollment":1181,"conditions":5482,"interventions":5483},[88],[21],[3641,3642],{"trials":5485,"activeCount":100},[],{"trials":5487,"activeCount":100},[],{"trials":5489,"activeCount":100},[],{"trials":5491,"activeCount":100},[],{"intervention":3495,"totalTrials":96,"cells":5493},{"EARLY_PHASE1":5494,"PHASE1":5496,"PHASE2":5502,"PHASE3":5504,"PHASE4":5506,"NA":5508},{"trials":5495,"activeCount":100},[],{"trials":5497,"activeCount":100},[5498],{"nctId":3461,"briefTitle":3462,"status":205,"phases":5499,"primaryCompletion":3464,"completion":3465,"start":3466,"enrollment":674,"conditions":5500,"interventions":5501},[88],[3468,3469,3470,3471,3472,3473,3474,3475,3476,3477,3478,3479,3480,3481,3482,3483,3484,3282,3485,3486,3487,3488,3489,3490,3491,3492,3493],[217,3495],{"trials":5503,"activeCount":100},[],{"trials":5505,"activeCount":100},[],{"trials":5507,"activeCount":100},[],{"trials":5509,"activeCount":100},[],{"intervention":943,"totalTrials":96,"cells":5511},{"EARLY_PHASE1":5512,"PHASE1":5514,"PHASE2":5520,"PHASE3":5522,"PHASE4":5524,"NA":5526},{"trials":5513,"activeCount":100},[],{"trials":5515,"activeCount":100},[5516],{"nctId":934,"briefTitle":935,"status":286,"phases":5517,"primaryCompletion":937,"completion":937,"start":938,"enrollment":9,"conditions":5518,"interventions":5519},[88],[940,293,294,941],[267,943,891,269,272,944,892],{"trials":5521,"activeCount":100},[],{"trials":5523,"activeCount":100},[],{"trials":5525,"activeCount":100},[],{"trials":5527,"activeCount":100},[],{"intervention":3690,"totalTrials":96,"cells":5529},{"EARLY_PHASE1":5530,"PHASE1":5532,"PHASE2":5538,"PHASE3":5540,"PHASE4":5542,"NA":5544},{"trials":5531,"activeCount":100},[],{"trials":5533,"activeCount":100},[5534],{"nctId":3662,"briefTitle":3663,"status":205,"phases":5535,"primaryCompletion":3665,"completion":3666,"start":3667,"enrollment":34,"conditions":5536,"interventions":5537},[88],[3669,3670,3671,3672,3673,3674,3675,3676,3677,3678,3679,3680,3681,3682,3683,3684,3685,3686,3687,3688],[480,3690],{"trials":5539,"activeCount":100},[],{"trials":5541,"activeCount":100},[],{"trials":5543,"activeCount":100},[],{"trials":5545,"activeCount":100},[],{"intervention":1291,"totalTrials":96,"cells":5547},{"EARLY_PHASE1":5548,"PHASE1":5550,"PHASE2":5556,"PHASE3":5558,"PHASE4":5560,"NA":5562},{"trials":5549,"activeCount":100},[],{"trials":5551,"activeCount":100},[5552],{"nctId":1281,"briefTitle":1282,"status":205,"phases":5553,"primaryCompletion":1284,"completion":1284,"start":1285,"enrollment":1286,"conditions":5554,"interventions":5555},[88],[1288,1289],[1242,1291],{"trials":5557,"activeCount":100},[],{"trials":5559,"activeCount":100},[],{"trials":5561,"activeCount":100},[],{"trials":5563,"activeCount":100},[],{"intervention":954,"totalTrials":96,"cells":5565},{"EARLY_PHASE1":5566,"PHASE1":5568,"PHASE2":5574,"PHASE3":5576,"PHASE4":5578,"NA":5580},{"trials":5567,"activeCount":100},[],{"trials":5569,"activeCount":100},[5570],{"nctId":946,"briefTitle":947,"status":205,"phases":5571,"primaryCompletion":949,"start":950,"enrollment":951,"conditions":5572,"interventions":5573},[88],[238,471],[215,70,954,517],{"trials":5575,"activeCount":100},[],{"trials":5577,"activeCount":100},[],{"trials":5579,"activeCount":100},[],{"trials":5581,"activeCount":100},[],{"intervention":242,"totalTrials":96,"cells":5583},{"EARLY_PHASE1":5584,"PHASE1":5586,"PHASE2":5592,"PHASE3":5594,"PHASE4":5596,"NA":5598},{"trials":5585,"activeCount":100},[],{"trials":5587,"activeCount":100},[5588],{"nctId":230,"briefTitle":231,"status":205,"phases":5589,"primaryCompletion":233,"completion":233,"start":234,"enrollment":235,"conditions":5590,"interventions":5591},[88],[237,238],[240,196,241,242,243,221,244],{"trials":5593,"activeCount":100},[],{"trials":5595,"activeCount":100},[],{"trials":5597,"activeCount":100},[],{"trials":5599,"activeCount":100},[],{"intervention":481,"totalTrials":96,"cells":5601},{"EARLY_PHASE1":5602,"PHASE1":5604,"PHASE2":5610,"PHASE3":5612,"PHASE4":5614,"NA":5616},{"trials":5603,"activeCount":100},[],{"trials":5605,"activeCount":100},[5606],{"nctId":425,"briefTitle":426,"status":286,"phases":5607,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":5608,"interventions":5609},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":5611,"activeCount":100},[],{"trials":5613,"activeCount":100},[],{"trials":5615,"activeCount":100},[],{"trials":5617,"activeCount":100},[],{"intervention":482,"totalTrials":96,"cells":5619},{"EARLY_PHASE1":5620,"PHASE1":5622,"PHASE2":5628,"PHASE3":5630,"PHASE4":5632,"NA":5634},{"trials":5621,"activeCount":100},[],{"trials":5623,"activeCount":100},[5624],{"nctId":425,"briefTitle":426,"status":286,"phases":5625,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":5626,"interventions":5627},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":5629,"activeCount":100},[],{"trials":5631,"activeCount":100},[],{"trials":5633,"activeCount":100},[],{"trials":5635,"activeCount":100},[],{"intervention":486,"totalTrials":96,"cells":5637},{"EARLY_PHASE1":5638,"PHASE1":5640,"PHASE2":5646,"PHASE3":5648,"PHASE4":5650,"NA":5652},{"trials":5639,"activeCount":100},[],{"trials":5641,"activeCount":100},[5642],{"nctId":425,"briefTitle":426,"status":286,"phases":5643,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":5644,"interventions":5645},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":5647,"activeCount":100},[],{"trials":5649,"activeCount":100},[],{"trials":5651,"activeCount":100},[],{"trials":5653,"activeCount":100},[],{"intervention":488,"totalTrials":96,"cells":5655},{"EARLY_PHASE1":5656,"PHASE1":5658,"PHASE2":5664,"PHASE3":5666,"PHASE4":5668,"NA":5670},{"trials":5657,"activeCount":100},[],{"trials":5659,"activeCount":100},[5660],{"nctId":425,"briefTitle":426,"status":286,"phases":5661,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":5662,"interventions":5663},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":5665,"activeCount":100},[],{"trials":5667,"activeCount":100},[],{"trials":5669,"activeCount":100},[],{"trials":5671,"activeCount":100},[],{"intervention":489,"totalTrials":96,"cells":5673},{"EARLY_PHASE1":5674,"PHASE1":5676,"PHASE2":5682,"PHASE3":5684,"PHASE4":5686,"NA":5688},{"trials":5675,"activeCount":100},[],{"trials":5677,"activeCount":100},[5678],{"nctId":425,"briefTitle":426,"status":286,"phases":5679,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":5680,"interventions":5681},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":5683,"activeCount":100},[],{"trials":5685,"activeCount":100},[],{"trials":5687,"activeCount":100},[],{"trials":5689,"activeCount":100},[],{"intervention":490,"totalTrials":96,"cells":5691},{"EARLY_PHASE1":5692,"PHASE1":5694,"PHASE2":5700,"PHASE3":5702,"PHASE4":5704,"NA":5706},{"trials":5693,"activeCount":100},[],{"trials":5695,"activeCount":100},[5696],{"nctId":425,"briefTitle":426,"status":286,"phases":5697,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":5698,"interventions":5699},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":5701,"activeCount":100},[],{"trials":5703,"activeCount":100},[],{"trials":5705,"activeCount":100},[],{"trials":5707,"activeCount":100},[],{"intervention":491,"totalTrials":96,"cells":5709},{"EARLY_PHASE1":5710,"PHASE1":5712,"PHASE2":5718,"PHASE3":5720,"PHASE4":5722,"NA":5724},{"trials":5711,"activeCount":100},[],{"trials":5713,"activeCount":100},[5714],{"nctId":425,"briefTitle":426,"status":286,"phases":5715,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":5716,"interventions":5717},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":5719,"activeCount":100},[],{"trials":5721,"activeCount":100},[],{"trials":5723,"activeCount":100},[],{"trials":5725,"activeCount":100},[],{"intervention":494,"totalTrials":96,"cells":5727},{"EARLY_PHASE1":5728,"PHASE1":5730,"PHASE2":5736,"PHASE3":5738,"PHASE4":5740,"NA":5742},{"trials":5729,"activeCount":100},[],{"trials":5731,"activeCount":100},[5732],{"nctId":425,"briefTitle":426,"status":286,"phases":5733,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":5734,"interventions":5735},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":5737,"activeCount":100},[],{"trials":5739,"activeCount":100},[],{"trials":5741,"activeCount":100},[],{"trials":5743,"activeCount":100},[],{"intervention":499,"totalTrials":96,"cells":5745},{"EARLY_PHASE1":5746,"PHASE1":5748,"PHASE2":5754,"PHASE3":5756,"PHASE4":5758,"NA":5760},{"trials":5747,"activeCount":100},[],{"trials":5749,"activeCount":100},[5750],{"nctId":425,"briefTitle":426,"status":286,"phases":5751,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":5752,"interventions":5753},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":5755,"activeCount":100},[],{"trials":5757,"activeCount":100},[],{"trials":5759,"activeCount":100},[],{"trials":5761,"activeCount":100},[],{"intervention":501,"totalTrials":96,"cells":5763},{"EARLY_PHASE1":5764,"PHASE1":5766,"PHASE2":5772,"PHASE3":5774,"PHASE4":5776,"NA":5778},{"trials":5765,"activeCount":100},[],{"trials":5767,"activeCount":100},[5768],{"nctId":425,"briefTitle":426,"status":286,"phases":5769,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":5770,"interventions":5771},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":5773,"activeCount":100},[],{"trials":5775,"activeCount":100},[],{"trials":5777,"activeCount":100},[],{"trials":5779,"activeCount":100},[],{"intervention":503,"totalTrials":96,"cells":5781},{"EARLY_PHASE1":5782,"PHASE1":5784,"PHASE2":5790,"PHASE3":5792,"PHASE4":5794,"NA":5796},{"trials":5783,"activeCount":100},[],{"trials":5785,"activeCount":100},[5786],{"nctId":425,"briefTitle":426,"status":286,"phases":5787,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":5788,"interventions":5789},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":5791,"activeCount":100},[],{"trials":5793,"activeCount":100},[],{"trials":5795,"activeCount":100},[],{"trials":5797,"activeCount":100},[],{"intervention":504,"totalTrials":96,"cells":5799},{"EARLY_PHASE1":5800,"PHASE1":5802,"PHASE2":5808,"PHASE3":5810,"PHASE4":5812,"NA":5814},{"trials":5801,"activeCount":100},[],{"trials":5803,"activeCount":100},[5804],{"nctId":425,"briefTitle":426,"status":286,"phases":5805,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":5806,"interventions":5807},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":5809,"activeCount":100},[],{"trials":5811,"activeCount":100},[],{"trials":5813,"activeCount":100},[],{"trials":5815,"activeCount":100},[],{"intervention":506,"totalTrials":96,"cells":5817},{"EARLY_PHASE1":5818,"PHASE1":5820,"PHASE2":5826,"PHASE3":5828,"PHASE4":5830,"NA":5832},{"trials":5819,"activeCount":100},[],{"trials":5821,"activeCount":100},[5822],{"nctId":425,"briefTitle":426,"status":286,"phases":5823,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":5824,"interventions":5825},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":5827,"activeCount":100},[],{"trials":5829,"activeCount":100},[],{"trials":5831,"activeCount":100},[],{"trials":5833,"activeCount":100},[],{"intervention":507,"totalTrials":96,"cells":5835},{"EARLY_PHASE1":5836,"PHASE1":5838,"PHASE2":5844,"PHASE3":5846,"PHASE4":5848,"NA":5850},{"trials":5837,"activeCount":100},[],{"trials":5839,"activeCount":100},[5840],{"nctId":425,"briefTitle":426,"status":286,"phases":5841,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":5842,"interventions":5843},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":5845,"activeCount":100},[],{"trials":5847,"activeCount":100},[],{"trials":5849,"activeCount":100},[],{"trials":5851,"activeCount":100},[],{"intervention":511,"totalTrials":96,"cells":5853},{"EARLY_PHASE1":5854,"PHASE1":5856,"PHASE2":5862,"PHASE3":5864,"PHASE4":5866,"NA":5868},{"trials":5855,"activeCount":100},[],{"trials":5857,"activeCount":100},[5858],{"nctId":425,"briefTitle":426,"status":286,"phases":5859,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":5860,"interventions":5861},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":5863,"activeCount":100},[],{"trials":5865,"activeCount":100},[],{"trials":5867,"activeCount":100},[],{"trials":5869,"activeCount":100},[],{"intervention":515,"totalTrials":96,"cells":5871},{"EARLY_PHASE1":5872,"PHASE1":5874,"PHASE2":5880,"PHASE3":5882,"PHASE4":5884,"NA":5886},{"trials":5873,"activeCount":100},[],{"trials":5875,"activeCount":100},[5876],{"nctId":425,"briefTitle":426,"status":286,"phases":5877,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":5878,"interventions":5879},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":5881,"activeCount":100},[],{"trials":5883,"activeCount":100},[],{"trials":5885,"activeCount":100},[],{"trials":5887,"activeCount":100},[],{"intervention":520,"totalTrials":96,"cells":5889},{"EARLY_PHASE1":5890,"PHASE1":5892,"PHASE2":5898,"PHASE3":5900,"PHASE4":5902,"NA":5904},{"trials":5891,"activeCount":100},[],{"trials":5893,"activeCount":100},[5894],{"nctId":425,"briefTitle":426,"status":286,"phases":5895,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":5896,"interventions":5897},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":5899,"activeCount":100},[],{"trials":5901,"activeCount":100},[],{"trials":5903,"activeCount":100},[],{"trials":5905,"activeCount":100},[],{"intervention":522,"totalTrials":96,"cells":5907},{"EARLY_PHASE1":5908,"PHASE1":5910,"PHASE2":5916,"PHASE3":5918,"PHASE4":5920,"NA":5922},{"trials":5909,"activeCount":100},[],{"trials":5911,"activeCount":100},[5912],{"nctId":425,"briefTitle":426,"status":286,"phases":5913,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":5914,"interventions":5915},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":5917,"activeCount":100},[],{"trials":5919,"activeCount":100},[],{"trials":5921,"activeCount":100},[],{"trials":5923,"activeCount":100},[],{"intervention":5925,"totalTrials":96,"cells":5926},"Fluorothymidine F-18",{"EARLY_PHASE1":5927,"PHASE1":5943,"PHASE2":5945,"PHASE3":5947,"PHASE4":5949,"NA":5951},{"trials":5928,"activeCount":100},[5929],{"nctId":5930,"briefTitle":5931,"status":883,"phases":5932,"primaryCompletion":5933,"completion":5933,"start":5934,"enrollment":100,"conditions":5935,"interventions":5942},"NCT03613259","Fluorothymidine F-18 PET in Diagnosing Patients With Intermediate or High Grade Soft Tissue Sarcoma",[87],"2022-06-01","2020-06-01",[5936,5937,5938,5939,5940,5941],"Stage II Adult Soft Tissue Sarcoma","Stage IIA Adult Soft Tissue Sarcoma","Stage IIB Adult Soft Tissue Sarcoma","Stage IIC Adult Soft Tissue Sarcoma","Stage III Adult Soft Tissue Sarcoma","Stage IV Adult Soft Tissue Sarcoma",[5925],{"trials":5944,"activeCount":100},[],{"trials":5946,"activeCount":100},[],{"trials":5948,"activeCount":100},[],{"trials":5950,"activeCount":100},[],{"trials":5952,"activeCount":100},[],{"intervention":5954,"totalTrials":96,"cells":5955},"Wee1 Inhibitor ZN-c3",{"EARLY_PHASE1":5956,"PHASE1":5974,"PHASE2":5976,"PHASE3":5978,"PHASE4":5980,"NA":5982},{"trials":5957,"activeCount":100},[5958],{"nctId":5959,"briefTitle":5960,"status":883,"phases":5961,"primaryCompletion":5962,"completion":5963,"start":5964,"enrollment":100,"conditions":5965,"interventions":5973},"NCT05368506","ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer",[87],"2024-09-30","2025-07-31","2023-07-30",[5966,1184,5967,432,5968,5969,1189,5970,5971,1190,5972],"Advanced Fallopian Tube Carcinoma","Advanced Primary Peritoneal Carcinoma","Metastatic Triple-Negative Breast Carcinoma","Stage III Fallopian Tube Cancer AJCC v8","Stage III Primary Peritoneal Cancer AJCC v8","Stage IV Fallopian Tube Cancer AJCC v8","Stage IV Primary Peritoneal Cancer AJCC v8",[5954],{"trials":5975,"activeCount":100},[],{"trials":5977,"activeCount":100},[],{"trials":5979,"activeCount":100},[],{"trials":5981,"activeCount":100},[],{"trials":5983,"activeCount":100},[],{"intervention":1256,"totalTrials":96,"cells":5985},{"EARLY_PHASE1":5986,"PHASE1":5992,"PHASE2":5994,"PHASE3":5996,"PHASE4":5998,"NA":6000},{"trials":5987,"activeCount":100},[5988],{"nctId":1247,"briefTitle":1248,"status":883,"phases":5989,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":100,"conditions":5990,"interventions":5991},[87],[1183,175,1184,1185,1186,1187,1188,432,1228,1253,1254,574,474,1189,475,1190,476],[1256,1257,1258,1259,483,65,299,85,495,1260,1261,1262,678,1193,505,1263,508,1242,510,513,1264,521,523,1265,524],{"trials":5993,"activeCount":100},[],{"trials":5995,"activeCount":100},[],{"trials":5997,"activeCount":100},[],{"trials":5999,"activeCount":100},[],{"trials":6001,"activeCount":100},[],{"intervention":1257,"totalTrials":96,"cells":6003},{"EARLY_PHASE1":6004,"PHASE1":6010,"PHASE2":6012,"PHASE3":6014,"PHASE4":6016,"NA":6018},{"trials":6005,"activeCount":100},[6006],{"nctId":1247,"briefTitle":1248,"status":883,"phases":6007,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":100,"conditions":6008,"interventions":6009},[87],[1183,175,1184,1185,1186,1187,1188,432,1228,1253,1254,574,474,1189,475,1190,476],[1256,1257,1258,1259,483,65,299,85,495,1260,1261,1262,678,1193,505,1263,508,1242,510,513,1264,521,523,1265,524],{"trials":6011,"activeCount":100},[],{"trials":6013,"activeCount":100},[],{"trials":6015,"activeCount":100},[],{"trials":6017,"activeCount":100},[],{"trials":6019,"activeCount":100},[],{"intervention":1258,"totalTrials":96,"cells":6021},{"EARLY_PHASE1":6022,"PHASE1":6028,"PHASE2":6030,"PHASE3":6032,"PHASE4":6034,"NA":6036},{"trials":6023,"activeCount":100},[6024],{"nctId":1247,"briefTitle":1248,"status":883,"phases":6025,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":100,"conditions":6026,"interventions":6027},[87],[1183,175,1184,1185,1186,1187,1188,432,1228,1253,1254,574,474,1189,475,1190,476],[1256,1257,1258,1259,483,65,299,85,495,1260,1261,1262,678,1193,505,1263,508,1242,510,513,1264,521,523,1265,524],{"trials":6029,"activeCount":100},[],{"trials":6031,"activeCount":100},[],{"trials":6033,"activeCount":100},[],{"trials":6035,"activeCount":100},[],{"trials":6037,"activeCount":100},[],{"intervention":1260,"totalTrials":96,"cells":6039},{"EARLY_PHASE1":6040,"PHASE1":6046,"PHASE2":6048,"PHASE3":6050,"PHASE4":6052,"NA":6054},{"trials":6041,"activeCount":100},[6042],{"nctId":1247,"briefTitle":1248,"status":883,"phases":6043,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":100,"conditions":6044,"interventions":6045},[87],[1183,175,1184,1185,1186,1187,1188,432,1228,1253,1254,574,474,1189,475,1190,476],[1256,1257,1258,1259,483,65,299,85,495,1260,1261,1262,678,1193,505,1263,508,1242,510,513,1264,521,523,1265,524],{"trials":6047,"activeCount":100},[],{"trials":6049,"activeCount":100},[],{"trials":6051,"activeCount":100},[],{"trials":6053,"activeCount":100},[],{"trials":6055,"activeCount":100},[],{"intervention":1262,"totalTrials":96,"cells":6057},{"EARLY_PHASE1":6058,"PHASE1":6064,"PHASE2":6066,"PHASE3":6068,"PHASE4":6070,"NA":6072},{"trials":6059,"activeCount":100},[6060],{"nctId":1247,"briefTitle":1248,"status":883,"phases":6061,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":100,"conditions":6062,"interventions":6063},[87],[1183,175,1184,1185,1186,1187,1188,432,1228,1253,1254,574,474,1189,475,1190,476],[1256,1257,1258,1259,483,65,299,85,495,1260,1261,1262,678,1193,505,1263,508,1242,510,513,1264,521,523,1265,524],{"trials":6065,"activeCount":100},[],{"trials":6067,"activeCount":100},[],{"trials":6069,"activeCount":100},[],{"trials":6071,"activeCount":100},[],{"trials":6073,"activeCount":100},[],{"intervention":1263,"totalTrials":96,"cells":6075},{"EARLY_PHASE1":6076,"PHASE1":6082,"PHASE2":6084,"PHASE3":6086,"PHASE4":6088,"NA":6090},{"trials":6077,"activeCount":100},[6078],{"nctId":1247,"briefTitle":1248,"status":883,"phases":6079,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":100,"conditions":6080,"interventions":6081},[87],[1183,175,1184,1185,1186,1187,1188,432,1228,1253,1254,574,474,1189,475,1190,476],[1256,1257,1258,1259,483,65,299,85,495,1260,1261,1262,678,1193,505,1263,508,1242,510,513,1264,521,523,1265,524],{"trials":6083,"activeCount":100},[],{"trials":6085,"activeCount":100},[],{"trials":6087,"activeCount":100},[],{"trials":6089,"activeCount":100},[],{"trials":6091,"activeCount":100},[],{"intervention":1265,"totalTrials":96,"cells":6093},{"EARLY_PHASE1":6094,"PHASE1":6100,"PHASE2":6102,"PHASE3":6104,"PHASE4":6106,"NA":6108},{"trials":6095,"activeCount":100},[6096],{"nctId":1247,"briefTitle":1248,"status":883,"phases":6097,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":100,"conditions":6098,"interventions":6099},[87],[1183,175,1184,1185,1186,1187,1188,432,1228,1253,1254,574,474,1189,475,1190,476],[1256,1257,1258,1259,483,65,299,85,495,1260,1261,1262,678,1193,505,1263,508,1242,510,513,1264,521,523,1265,524],{"trials":6101,"activeCount":100},[],{"trials":6103,"activeCount":100},[],{"trials":6105,"activeCount":100},[],{"trials":6107,"activeCount":100},[],{"trials":6109,"activeCount":100},[],{"intervention":267,"totalTrials":395,"cells":6111},{"EARLY_PHASE1":6112,"PHASE1":6114,"PHASE2":6120,"PHASE3":6134,"PHASE4":6136,"NA":6138},{"trials":6113,"activeCount":100},[],{"trials":6115,"activeCount":100},[6116],{"nctId":934,"briefTitle":935,"status":286,"phases":6117,"primaryCompletion":937,"completion":937,"start":938,"enrollment":9,"conditions":6118,"interventions":6119},[88],[940,293,294,941],[267,943,891,269,272,944,892],{"trials":6121,"activeCount":100},[6122,6126,6130],{"nctId":259,"briefTitle":260,"status":205,"phases":6123,"primaryCompletion":262,"completion":262,"start":263,"enrollment":264,"conditions":6124,"interventions":6125},[89],[24],[267,268,269,270,271,272,273],{"nctId":3226,"briefTitle":3227,"status":205,"phases":6127,"primaryCompletion":871,"completion":3205,"start":3229,"enrollment":571,"conditions":6128,"interventions":6129},[89],[24],[267,355,360,3232],{"nctId":341,"briefTitle":342,"status":286,"phases":6131,"primaryCompletion":344,"completion":345,"start":346,"enrollment":347,"conditions":6132,"interventions":6133},[89],[349,18,24,350,33,351,352],[354,267,355,356,269,357,270,358,359,360,273,337,361,362],{"trials":6135,"activeCount":100},[],{"trials":6137,"activeCount":100},[],{"trials":6139,"activeCount":100},[6140],{"nctId":912,"briefTitle":913,"status":286,"phases":6141,"primaryCompletion":915,"completion":915,"start":916,"enrollment":917,"conditions":6142,"interventions":6143},[92],[349,919,18,24,350,33,920,921],[267,355,269,357,358,273],{"intervention":357,"totalTrials":917,"cells":6145},{"EARLY_PHASE1":6146,"PHASE1":6148,"PHASE2":6150,"PHASE3":6164,"PHASE4":6166,"NA":6168},{"trials":6147,"activeCount":100},[],{"trials":6149,"activeCount":100},[],{"trials":6151,"activeCount":100},[6152,6156,6160],{"nctId":2545,"briefTitle":2546,"status":286,"phases":6153,"primaryCompletion":2548,"completion":2548,"start":872,"enrollment":96,"conditions":6154,"interventions":6155},[89],[2550],[357,359,361],{"nctId":868,"briefTitle":869,"status":205,"phases":6157,"primaryCompletion":871,"completion":871,"start":872,"enrollment":873,"conditions":6158,"interventions":6159},[88,89],[349,18,24,350,33,351,875],[877,355,357,359,361,878,879,221],{"nctId":341,"briefTitle":342,"status":286,"phases":6161,"primaryCompletion":344,"completion":345,"start":346,"enrollment":347,"conditions":6162,"interventions":6163},[89],[349,18,24,350,33,351,352],[354,267,355,356,269,357,270,358,359,360,273,337,361,362],{"trials":6165,"activeCount":100},[],{"trials":6167,"activeCount":100},[],{"trials":6169,"activeCount":100},[6170],{"nctId":912,"briefTitle":913,"status":286,"phases":6171,"primaryCompletion":915,"completion":915,"start":916,"enrollment":917,"conditions":6172,"interventions":6173},[92],[349,919,18,24,350,33,920,921],[267,355,269,357,358,273],{"intervention":355,"totalTrials":917,"cells":6175},{"EARLY_PHASE1":6176,"PHASE1":6178,"PHASE2":6180,"PHASE3":6194,"PHASE4":6196,"NA":6198},{"trials":6177,"activeCount":100},[],{"trials":6179,"activeCount":100},[],{"trials":6181,"activeCount":100},[6182,6186,6190],{"nctId":3226,"briefTitle":3227,"status":205,"phases":6183,"primaryCompletion":871,"completion":3205,"start":3229,"enrollment":571,"conditions":6184,"interventions":6185},[89],[24],[267,355,360,3232],{"nctId":868,"briefTitle":869,"status":205,"phases":6187,"primaryCompletion":871,"completion":871,"start":872,"enrollment":873,"conditions":6188,"interventions":6189},[88,89],[349,18,24,350,33,351,875],[877,355,357,359,361,878,879,221],{"nctId":341,"briefTitle":342,"status":286,"phases":6191,"primaryCompletion":344,"completion":345,"start":346,"enrollment":347,"conditions":6192,"interventions":6193},[89],[349,18,24,350,33,351,352],[354,267,355,356,269,357,270,358,359,360,273,337,361,362],{"trials":6195,"activeCount":100},[],{"trials":6197,"activeCount":100},[],{"trials":6199,"activeCount":100},[6200],{"nctId":912,"briefTitle":913,"status":286,"phases":6201,"primaryCompletion":915,"completion":915,"start":916,"enrollment":917,"conditions":6202,"interventions":6203},[92],[349,919,18,24,350,33,920,921],[267,355,269,357,358,273],{"intervention":2469,"totalTrials":387,"cells":6205},{"EARLY_PHASE1":6206,"PHASE1":6208,"PHASE2":6210,"PHASE3":6216,"PHASE4":6218,"NA":6220},{"trials":6207,"activeCount":100},[],{"trials":6209,"activeCount":100},[],{"trials":6211,"activeCount":100},[6212],{"nctId":2458,"briefTitle":2459,"status":286,"phases":6213,"primaryCompletion":2290,"completion":2461,"start":2462,"enrollment":9,"conditions":6214,"interventions":6215},[88,89],[24],[2465,2466,2467,2468,2469,2470],{"trials":6217,"activeCount":100},[],{"trials":6219,"activeCount":100},[],{"trials":6221,"activeCount":100},[6222,6235],{"nctId":6223,"briefTitle":6224,"status":205,"phases":6225,"primaryCompletion":6226,"completion":6226,"start":6227,"enrollment":6228,"conditions":6229,"interventions":6231},"NCT00900055","Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma",[],"2016-08-23","1975-06",213,[349,6230,350,351],"Fanconi Anemia",[2469,6232,2470,6233,5281,6234],"polyacrylamide gel electrophoresis","protein expression analysis","western blotting",{"nctId":6236,"briefTitle":6237,"status":286,"phases":6238,"primaryCompletion":6239,"completion":6239,"start":6240,"enrollment":12,"conditions":6241,"interventions":6242},"NCT00896740","Gene Function in Bone Marrow Cells From Patients With Fanconi Anemia and From Healthy Participants",[],"2007-09","2002-03",[6230],[2469],{"intervention":514,"totalTrials":387,"cells":6244},{"EARLY_PHASE1":6245,"PHASE1":6247,"PHASE2":6253,"PHASE3":6259,"PHASE4":6261,"NA":6263},{"trials":6246,"activeCount":100},[],{"trials":6248,"activeCount":100},[6249],{"nctId":425,"briefTitle":426,"status":286,"phases":6250,"primaryCompletion":428,"completion":428,"start":429,"enrollment":9,"conditions":6251,"interventions":6252},[88],[431,432,433,434,435,436,437,438,439,440,441,442,443,444,182,445,446,447,448,449,450,451,452,453,454,455,456,457,458,238,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],[480,481,482,483,484,485,40,486,65,299,487,85,488,489,490,491,216,492,493,494,495,55,496,497,498,219,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,315,524,525],{"trials":6254,"activeCount":100},[6255],{"nctId":2515,"briefTitle":2516,"status":286,"phases":6256,"primaryCompletion":2518,"completion":2519,"start":2520,"enrollment":22,"conditions":6257,"interventions":6258},[89],[2522,2523,449,450,460,461],[216,219,2525,514,223,516,518,226,519,227],{"trials":6260,"activeCount":100},[],{"trials":6262,"activeCount":100},[],{"trials":6264,"activeCount":100},[6265],{"nctId":6266,"briefTitle":6267,"status":6268,"phases":6269,"conditions":6270,"interventions":6273},"NCT01549548","Compassionate Use Ponatinib","NO_LONGER_AVAILABLE",[],[6271,6272],"Philadelphia Chromosome Positive (Ph+) Leukemias","Chronic Myeloid Leukemia",[514],{"intervention":2470,"totalTrials":9,"cells":6275},{"EARLY_PHASE1":6276,"PHASE1":6278,"PHASE2":6280,"PHASE3":6286,"PHASE4":6288,"NA":6290},{"trials":6277,"activeCount":100},[],{"trials":6279,"activeCount":100},[],{"trials":6281,"activeCount":100},[6282],{"nctId":2458,"briefTitle":2459,"status":286,"phases":6283,"primaryCompletion":2290,"completion":2461,"start":2462,"enrollment":9,"conditions":6284,"interventions":6285},[88,89],[24],[2465,2466,2467,2468,2469,2470],{"trials":6287,"activeCount":100},[],{"trials":6289,"activeCount":100},[],{"trials":6291,"activeCount":100},[6292],{"nctId":6223,"briefTitle":6224,"status":205,"phases":6293,"primaryCompletion":6226,"completion":6226,"start":6227,"enrollment":6228,"conditions":6294,"interventions":6295},[],[349,6230,350,351],[2469,6232,2470,6233,5281,6234],{"intervention":6233,"totalTrials":9,"cells":6297},{"EARLY_PHASE1":6298,"PHASE1":6300,"PHASE2":6302,"PHASE3":6304,"PHASE4":6306,"NA":6308},{"trials":6299,"activeCount":100},[],{"trials":6301,"activeCount":100},[],{"trials":6303,"activeCount":100},[],{"trials":6305,"activeCount":100},[],{"trials":6307,"activeCount":100},[],{"trials":6309,"activeCount":100},[6310,6314],{"nctId":6223,"briefTitle":6224,"status":205,"phases":6311,"primaryCompletion":6226,"completion":6226,"start":6227,"enrollment":6228,"conditions":6312,"interventions":6313},[],[349,6230,350,351],[2469,6232,2470,6233,5281,6234],{"nctId":6315,"briefTitle":6316,"status":205,"phases":6317,"primaryCompletion":6318,"completion":6318,"start":6319,"enrollment":6320,"conditions":6321,"interventions":6322},"NCT00900302","OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer",[],"2011-03","2005-04",98,[2292],[6233],{"intervention":5281,"totalTrials":9,"cells":6324},{"EARLY_PHASE1":6325,"PHASE1":6327,"PHASE2":6329,"PHASE3":6335,"PHASE4":6337,"NA":6339},{"trials":6326,"activeCount":100},[],{"trials":6328,"activeCount":100},[],{"trials":6330,"activeCount":100},[6331],{"nctId":5275,"briefTitle":5276,"status":286,"phases":6332,"primaryCompletion":2461,"completion":2461,"start":5278,"enrollment":917,"conditions":6333,"interventions":6334},[89],[18],[5266,5281],{"trials":6336,"activeCount":100},[],{"trials":6338,"activeCount":100},[],{"trials":6340,"activeCount":100},[6341],{"nctId":6223,"briefTitle":6224,"status":205,"phases":6342,"primaryCompletion":6226,"completion":6226,"start":6227,"enrollment":6228,"conditions":6343,"interventions":6344},[],[349,6230,350,351],[2469,6232,2470,6233,5281,6234],{"intervention":663,"totalTrials":9,"cells":6346},{"EARLY_PHASE1":6347,"PHASE1":6349,"PHASE2":6351,"PHASE3":6357,"PHASE4":6359,"NA":6361},{"trials":6348,"activeCount":100},[],{"trials":6350,"activeCount":100},[],{"trials":6352,"activeCount":100},[6353],{"nctId":653,"briefTitle":654,"status":205,"phases":6354,"primaryCompletion":345,"completion":656,"start":657,"enrollment":658,"conditions":6355,"interventions":6356},[89],[660,661],[663,271,664,665,666,667,668],{"trials":6358,"activeCount":100},[],{"trials":6360,"activeCount":100},[],{"trials":6362,"activeCount":100},[6363],{"nctId":2287,"briefTitle":2288,"status":205,"phases":6364,"primaryCompletion":2290,"completion":2290,"start":916,"enrollment":310,"conditions":6365,"interventions":6366},[92],[2292],[663,271,2294],{"intervention":2372,"totalTrials":9,"cells":6368},{"EARLY_PHASE1":6369,"PHASE1":6375,"PHASE2":6377,"PHASE3":6379,"PHASE4":6381,"NA":6383},{"trials":6370,"activeCount":100},[6371],{"nctId":2361,"briefTitle":2362,"status":205,"phases":6372,"primaryCompletion":2364,"completion":2365,"start":2366,"enrollment":2367,"conditions":6373,"interventions":6374},[87],[2369,2370],[2372,2173],{"trials":6376,"activeCount":100},[],{"trials":6378,"activeCount":100},[],{"trials":6380,"activeCount":100},[],{"trials":6382,"activeCount":100},[],{"trials":6384,"activeCount":100},[6385],{"nctId":2392,"briefTitle":2393,"status":205,"phases":6386,"primaryCompletion":1639,"completion":1639,"start":2395,"enrollment":2367,"conditions":6387,"interventions":6388},[92],[2397],[2173,2372],{"intervention":6232,"totalTrials":96,"cells":6390},{"EARLY_PHASE1":6391,"PHASE1":6393,"PHASE2":6395,"PHASE3":6397,"PHASE4":6399,"NA":6401},{"trials":6392,"activeCount":100},[],{"trials":6394,"activeCount":100},[],{"trials":6396,"activeCount":100},[],{"trials":6398,"activeCount":100},[],{"trials":6400,"activeCount":100},[],{"trials":6402,"activeCount":100},[6403],{"nctId":6223,"briefTitle":6224,"status":205,"phases":6404,"primaryCompletion":6226,"completion":6226,"start":6227,"enrollment":6228,"conditions":6405,"interventions":6406},[],[349,6230,350,351],[2469,6232,2470,6233,5281,6234],{"intervention":6234,"totalTrials":96,"cells":6408},{"EARLY_PHASE1":6409,"PHASE1":6411,"PHASE2":6413,"PHASE3":6415,"PHASE4":6417,"NA":6419},{"trials":6410,"activeCount":100},[],{"trials":6412,"activeCount":100},[],{"trials":6414,"activeCount":100},[],{"trials":6416,"activeCount":100},[],{"trials":6418,"activeCount":100},[],{"trials":6420,"activeCount":100},[6421],{"nctId":6223,"briefTitle":6224,"status":205,"phases":6422,"primaryCompletion":6226,"completion":6226,"start":6227,"enrollment":6228,"conditions":6423,"interventions":6424},[],[349,6230,350,351],[2469,6232,2470,6233,5281,6234],{"intervention":2294,"totalTrials":96,"cells":6426},{"EARLY_PHASE1":6427,"PHASE1":6429,"PHASE2":6431,"PHASE3":6433,"PHASE4":6435,"NA":6437},{"trials":6428,"activeCount":100},[],{"trials":6430,"activeCount":100},[],{"trials":6432,"activeCount":100},[],{"trials":6434,"activeCount":100},[],{"trials":6436,"activeCount":100},[],{"trials":6438,"activeCount":100},[6439],{"nctId":2287,"briefTitle":2288,"status":205,"phases":6440,"primaryCompletion":2290,"completion":2290,"start":916,"enrollment":310,"conditions":6441,"interventions":6442},[92],[2292],[663,271,2294],{"intervention":2213,"totalTrials":96,"cells":6444},{"EARLY_PHASE1":6445,"PHASE1":6447,"PHASE2":6449,"PHASE3":6451,"PHASE4":6453,"NA":6455},{"trials":6446,"activeCount":100},[],{"trials":6448,"activeCount":100},[],{"trials":6450,"activeCount":100},[],{"trials":6452,"activeCount":100},[],{"trials":6454,"activeCount":100},[],{"trials":6456,"activeCount":100},[6457],{"nctId":2205,"briefTitle":2206,"status":205,"phases":6458,"primaryCompletion":2208,"completion":2208,"start":2209,"enrollment":2210,"conditions":6459,"interventions":6460},[92],[1111],[1083,2213],{"intervention":6462,"totalTrials":96,"cells":6463},"Lidocaine",{"EARLY_PHASE1":6464,"PHASE1":6466,"PHASE2":6468,"PHASE3":6470,"PHASE4":6472,"NA":6474},{"trials":6465,"activeCount":100},[],{"trials":6467,"activeCount":100},[],{"trials":6469,"activeCount":100},[],{"trials":6471,"activeCount":100},[],{"trials":6473,"activeCount":100},[],{"trials":6475,"activeCount":100},[6476],{"nctId":6477,"briefTitle":6478,"status":286,"phases":6479,"primaryCompletion":6480,"completion":6480,"start":6481,"enrollment":291,"conditions":6482,"interventions":6486},"NCT03699995","MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma",[92],"2025-12-31","2018-05-18",[6483,6484,6485],"Cutaneous Melanoma","Melanocytic Nevus","Skin Carcinoma",[6462],{"intervention":6488,"totalTrials":96,"cells":6489},"fibrin sealant",{"EARLY_PHASE1":6490,"PHASE1":6492,"PHASE2":6494,"PHASE3":6496,"PHASE4":6498,"NA":6500},{"trials":6491,"activeCount":100},[],{"trials":6493,"activeCount":100},[],{"trials":6495,"activeCount":100},[],{"trials":6497,"activeCount":100},[],{"trials":6499,"activeCount":100},[],{"trials":6501,"activeCount":100},[6502],{"nctId":6503,"briefTitle":6504,"status":286,"phases":6505,"primaryCompletion":6506,"completion":6506,"start":6507,"enrollment":9,"conditions":6508,"interventions":6510},"NCT01649505","Fibrin Sealant in Preventing Fluid Build Up During Surgery in Patients Undergoing Breast Reconstruction",[92],"2012-01","2011-01",[21,6509],"Perioperative\u002FPostoperative Complications",[6488],{"intervention":6512,"totalTrials":96,"cells":6513},"Calendula Ointment",{"EARLY_PHASE1":6514,"PHASE1":6516,"PHASE2":6518,"PHASE3":6520,"PHASE4":6522,"NA":6524},{"trials":6515,"activeCount":100},[],{"trials":6517,"activeCount":100},[],{"trials":6519,"activeCount":100},[],{"trials":6521,"activeCount":100},[],{"trials":6523,"activeCount":100},[],{"trials":6525,"activeCount":100},[6526],{"nctId":6527,"briefTitle":6528,"status":883,"phases":6529,"primaryCompletion":6530,"completion":6531,"start":6532,"enrollment":100,"conditions":6533,"interventions":6536},"NCT05073172","StrataXRT for the Prevention and Treatment of Radiation Dermatitis in Breast Cancer or Head and Neck Cancer Patients",[92],"2024-12-31","2025-07-01","2024-01-01",[30,6534,6535],"Head and Neck Carcinoma","Radiation-Induced Dermatitis",[6512,6537,6538,6539],"Silicone-based Film Forming Topical Gel","Silver Sulfadiazine","Topical Hydrocortisone",{"intervention":6537,"totalTrials":96,"cells":6541},{"EARLY_PHASE1":6542,"PHASE1":6544,"PHASE2":6546,"PHASE3":6548,"PHASE4":6550,"NA":6552},{"trials":6543,"activeCount":100},[],{"trials":6545,"activeCount":100},[],{"trials":6547,"activeCount":100},[],{"trials":6549,"activeCount":100},[],{"trials":6551,"activeCount":100},[],{"trials":6553,"activeCount":100},[6554],{"nctId":6527,"briefTitle":6528,"status":883,"phases":6555,"primaryCompletion":6530,"completion":6531,"start":6532,"enrollment":100,"conditions":6556,"interventions":6557},[92],[30,6534,6535],[6512,6537,6538,6539],{"intervention":6538,"totalTrials":96,"cells":6559},{"EARLY_PHASE1":6560,"PHASE1":6562,"PHASE2":6564,"PHASE3":6566,"PHASE4":6568,"NA":6570},{"trials":6561,"activeCount":100},[],{"trials":6563,"activeCount":100},[],{"trials":6565,"activeCount":100},[],{"trials":6567,"activeCount":100},[],{"trials":6569,"activeCount":100},[],{"trials":6571,"activeCount":100},[6572],{"nctId":6527,"briefTitle":6528,"status":883,"phases":6573,"primaryCompletion":6530,"completion":6531,"start":6532,"enrollment":100,"conditions":6574,"interventions":6575},[92],[30,6534,6535],[6512,6537,6538,6539],{"intervention":6539,"totalTrials":96,"cells":6577},{"EARLY_PHASE1":6578,"PHASE1":6580,"PHASE2":6582,"PHASE3":6584,"PHASE4":6586,"NA":6588},{"trials":6579,"activeCount":100},[],{"trials":6581,"activeCount":100},[],{"trials":6583,"activeCount":100},[],{"trials":6585,"activeCount":100},[],{"trials":6587,"activeCount":100},[],{"trials":6589,"activeCount":100},[6590],{"nctId":6527,"briefTitle":6528,"status":883,"phases":6591,"primaryCompletion":6530,"completion":6531,"start":6532,"enrollment":100,"conditions":6592,"interventions":6593},[92],[30,6534,6535],[6512,6537,6538,6539],{"intervention":6595,"totalTrials":96,"cells":6596},"raloxifene",{"EARLY_PHASE1":6597,"PHASE1":6599,"PHASE2":6601,"PHASE3":6603,"PHASE4":6605,"NA":6607},{"trials":6598,"activeCount":100},[],{"trials":6600,"activeCount":100},[],{"trials":6602,"activeCount":100},[],{"trials":6604,"activeCount":100},[],{"trials":6606,"activeCount":100},[],{"trials":6608,"activeCount":100},[6609],{"nctId":6610,"briefTitle":6611,"status":205,"phases":6612,"primaryCompletion":6613,"completion":6613,"start":6614,"enrollment":117,"conditions":6615,"interventions":6618},"NCT00031811","Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer",[92],"2003-04","2001-03",[21,6616,6617],"Menopausal Symptoms","Osteoporosis",[6595],{"intervention":6620,"totalTrials":96,"cells":6621},"cytogenetic analysis",{"EARLY_PHASE1":6622,"PHASE1":6624,"PHASE2":6626,"PHASE3":6628,"PHASE4":6630,"NA":6632},{"trials":6623,"activeCount":100},[],{"trials":6625,"activeCount":100},[],{"trials":6627,"activeCount":100},[],{"trials":6629,"activeCount":100},[],{"trials":6631,"activeCount":100},[],{"trials":6633,"activeCount":100},[6634],{"nctId":6635,"briefTitle":6636,"status":205,"phases":6637,"primaryCompletion":6638,"completion":6638,"start":3360,"enrollment":6639,"conditions":6640,"interventions":6641},"NCT00899795","Evaluating Cell Damage in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Fanconi Anemia; in Patients Who Were Exposed to Alkylating Agents; and in Healthy Volunteers",[],"2010-10",35,[18,33],[6620,6642],"fluorescence in situ hybridization",{"intervention":6642,"totalTrials":96,"cells":6644},{"EARLY_PHASE1":6645,"PHASE1":6647,"PHASE2":6649,"PHASE3":6651,"PHASE4":6653,"NA":6655},{"trials":6646,"activeCount":100},[],{"trials":6648,"activeCount":100},[],{"trials":6650,"activeCount":100},[],{"trials":6652,"activeCount":100},[],{"trials":6654,"activeCount":100},[],{"trials":6656,"activeCount":100},[6657],{"nctId":6635,"briefTitle":6636,"status":205,"phases":6658,"primaryCompletion":6638,"completion":6638,"start":3360,"enrollment":6639,"conditions":6659,"interventions":6660},[],[18,33],[6620,6642],{"intervention":6662,"totalTrials":96,"cells":6663},"Weekly procrit dosing",{"EARLY_PHASE1":6664,"PHASE1":6666,"PHASE2":6668,"PHASE3":6670,"PHASE4":6672,"NA":6674},{"trials":6665,"activeCount":100},[],{"trials":6667,"activeCount":100},[],{"trials":6669,"activeCount":100},[],{"trials":6671,"activeCount":100},[],{"trials":6673,"activeCount":100},[],{"trials":6675,"activeCount":100},[6676],{"nctId":6677,"briefTitle":6678,"status":286,"phases":6679,"primaryCompletion":6680,"completion":6680,"start":1364,"enrollment":210,"conditions":6681,"interventions":6683},"NCT00258440","Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer",[92],"2008-09",[433,6682,4554],"Fatigue",[6662,6684],"Interval Dosing",{"intervention":6684,"totalTrials":96,"cells":6686},{"EARLY_PHASE1":6687,"PHASE1":6689,"PHASE2":6691,"PHASE3":6693,"PHASE4":6695,"NA":6697},{"trials":6688,"activeCount":100},[],{"trials":6690,"activeCount":100},[],{"trials":6692,"activeCount":100},[],{"trials":6694,"activeCount":100},[],{"trials":6696,"activeCount":100},[],{"trials":6698,"activeCount":100},[6699],{"nctId":6677,"briefTitle":6678,"status":286,"phases":6700,"primaryCompletion":6680,"completion":6680,"start":1364,"enrollment":210,"conditions":6701,"interventions":6702},[92],[433,6682,4554],[6662,6684]]